WO2023201338A1 - Combination therapy comprising a mat2a inhibitor and a parp inhibitor - Google Patents
Combination therapy comprising a mat2a inhibitor and a parp inhibitor Download PDFInfo
- Publication number
- WO2023201338A1 WO2023201338A1 PCT/US2023/065780 US2023065780W WO2023201338A1 WO 2023201338 A1 WO2023201338 A1 WO 2023201338A1 US 2023065780 W US2023065780 W US 2023065780W WO 2023201338 A1 WO2023201338 A1 WO 2023201338A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- compound
- pharmaceutically acceptable
- acceptable salt
- inhibitor
- cancer
- Prior art date
Links
- 239000012661 PARP inhibitor Substances 0.000 title claims abstract description 211
- 229940121906 Poly ADP ribose polymerase inhibitor Drugs 0.000 title claims abstract description 211
- ZTNQNZDNHUAVEI-UHFFFAOYSA-N CC=1SC2=C(N=1)C=CC(=C2)C1=C(NC=2N(C1=O)N=C(C=2C1=CC=CC=C1)C1=CC=CC=C1)NC1=NC=CC=C1 Chemical compound CC=1SC2=C(N=1)C=CC(=C2)C1=C(NC=2N(C1=O)N=C(C=2C1=CC=CC=C1)C1=CC=CC=C1)NC1=NC=CC=C1 ZTNQNZDNHUAVEI-UHFFFAOYSA-N 0.000 title claims abstract description 201
- 229940125535 MAT2A inhibitor Drugs 0.000 title claims abstract description 201
- 238000002648 combination therapy Methods 0.000 title description 8
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 178
- 201000011510 cancer Diseases 0.000 claims abstract description 156
- 238000000034 method Methods 0.000 claims abstract description 130
- 150000003839 salts Chemical class 0.000 claims description 402
- 150000001875 compounds Chemical class 0.000 claims description 275
- 229940126062 Compound A Drugs 0.000 claims description 165
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 claims description 165
- 239000003814 drug Substances 0.000 claims description 45
- WXRCLFFPZXJCLS-UHFFFAOYSA-N 6-fluoro-5-[4-[(5-fluoro-2-methyl-3-oxo-4H-quinoxalin-6-yl)methyl]piperazin-1-yl]-N-methylpyridine-2-carboxamide Chemical compound CC1=NC2=CC=C(CN(CC3)CCN3C(C=CC(C(NC)=O)=N3)=C3F)C(F)=C2NC1=O WXRCLFFPZXJCLS-UHFFFAOYSA-N 0.000 claims description 43
- WQAVGRAETZEADU-UHFFFAOYSA-N 5-[4-[(7-ethyl-6-oxo-5H-1,5-naphthyridin-3-yl)methyl]piperazin-1-yl]-N-methylpyridine-2-carboxamide Chemical compound C(C)C=1C(NC=2C=C(C=NC=2C=1)CN1CCN(CC1)C=1C=CC(=NC=1)C(=O)NC)=O WQAVGRAETZEADU-UHFFFAOYSA-N 0.000 claims description 42
- 229940126195 AZD5305 Drugs 0.000 claims description 42
- JNGZXGGOCLZBFB-IVCQMTBJSA-N compound E Chemical group N([C@@H](C)C(=O)N[C@@H]1C(N(C)C2=CC=CC=C2C(C=2C=CC=CC=2)=N1)=O)C(=O)CC1=CC(F)=CC(F)=C1 JNGZXGGOCLZBFB-IVCQMTBJSA-N 0.000 claims description 41
- LVTJOONKWUXEFR-FZRMHRINSA-N protoneodioscin Natural products O(C[C@@H](CC[C@]1(O)[C@H](C)[C@@H]2[C@]3(C)[C@H]([C@H]4[C@@H]([C@]5(C)C(=CC4)C[C@@H](O[C@@H]4[C@H](O[C@H]6[C@@H](O)[C@@H](O)[C@@H](O)[C@H](C)O6)[C@@H](O)[C@H](O[C@H]6[C@@H](O)[C@@H](O)[C@@H](O)[C@H](C)O6)[C@H](CO)O4)CC5)CC3)C[C@@H]2O1)C)[C@H]1[C@H](O)[C@H](O)[C@H](O)[C@@H](CO)O1 LVTJOONKWUXEFR-FZRMHRINSA-N 0.000 claims description 37
- 239000002552 dosage form Substances 0.000 claims description 33
- 238000004519 manufacturing process Methods 0.000 claims description 31
- 125000005843 halogen group Chemical group 0.000 claims description 19
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 18
- 229910052739 hydrogen Inorganic materials 0.000 claims description 16
- 239000001257 hydrogen Substances 0.000 claims description 16
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 16
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims description 15
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims description 15
- 206010033128 Ovarian cancer Diseases 0.000 claims description 14
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims description 13
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 11
- 125000001309 chloro group Chemical group Cl* 0.000 claims description 11
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 10
- 206010006187 Breast cancer Diseases 0.000 claims description 10
- 208000026310 Breast neoplasm Diseases 0.000 claims description 10
- 208000032839 leukemia Diseases 0.000 claims description 10
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 9
- 101150102751 mtap gene Proteins 0.000 claims description 9
- 206010005003 Bladder cancer Diseases 0.000 claims description 8
- 208000031839 Peripheral nerve sheath tumour malignant Diseases 0.000 claims description 8
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 8
- 201000009020 malignant peripheral nerve sheath tumor Diseases 0.000 claims description 8
- 208000029974 neurofibrosarcoma Diseases 0.000 claims description 8
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 8
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 claims description 7
- 239000007787 solid Substances 0.000 claims description 6
- 208000032612 Glial tumor Diseases 0.000 claims description 5
- 206010018338 Glioma Diseases 0.000 claims description 5
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims description 5
- 206010039491 Sarcoma Diseases 0.000 claims description 5
- 201000001441 melanoma Diseases 0.000 claims description 5
- 206010003571 Astrocytoma Diseases 0.000 claims description 4
- 206010014733 Endometrial cancer Diseases 0.000 claims description 4
- 206010014759 Endometrial neoplasm Diseases 0.000 claims description 4
- 208000021712 Soft tissue sarcoma Diseases 0.000 claims description 4
- 238000012224 gene deletion Methods 0.000 claims description 4
- 201000010536 head and neck cancer Diseases 0.000 claims description 4
- 208000014829 head and neck neoplasm Diseases 0.000 claims description 4
- 208000006178 malignant mesothelioma Diseases 0.000 claims description 4
- 201000009500 myxoid chondrosarcoma Diseases 0.000 claims description 4
- 201000008968 osteosarcoma Diseases 0.000 claims description 4
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 3
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims description 2
- 125000006583 (C1-C3) haloalkyl group Chemical group 0.000 claims description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 43
- 201000010099 disease Diseases 0.000 abstract description 24
- 208000035475 disorder Diseases 0.000 abstract description 19
- 239000008194 pharmaceutical composition Substances 0.000 description 84
- 210000004027 cell Anatomy 0.000 description 66
- 238000011282 treatment Methods 0.000 description 66
- 239000013066 combination product Substances 0.000 description 62
- 229940127555 combination product Drugs 0.000 description 62
- 239000000203 mixture Substances 0.000 description 55
- 108010034457 5'-methylthioadenosine phosphorylase Proteins 0.000 description 44
- 102100034187 S-methyl-5'-thioadenosine phosphorylase Human genes 0.000 description 44
- 238000009472 formulation Methods 0.000 description 36
- 102100035947 S-adenosylmethionine synthase isoform type-2 Human genes 0.000 description 31
- 101000947881 Homo sapiens S-adenosylmethionine synthase isoform type-2 Proteins 0.000 description 27
- 239000003112 inhibitor Substances 0.000 description 26
- 108010061844 Poly(ADP-ribose) Polymerases Proteins 0.000 description 25
- 102000012338 Poly(ADP-ribose) Polymerases Human genes 0.000 description 25
- 229920000776 Poly(Adenosine diphosphate-ribose) polymerase Polymers 0.000 description 25
- 239000003795 chemical substances by application Substances 0.000 description 24
- 239000003937 drug carrier Substances 0.000 description 22
- PCHKPVIQAHNQLW-CQSZACIVSA-N niraparib Chemical compound N1=C2C(C(=O)N)=CC=CC2=CN1C(C=C1)=CC=C1[C@@H]1CCCNC1 PCHKPVIQAHNQLW-CQSZACIVSA-N 0.000 description 22
- 229950011068 niraparib Drugs 0.000 description 22
- 230000000694 effects Effects 0.000 description 20
- HWGQMRYQVZSGDQ-HZPDHXFCSA-N chembl3137320 Chemical compound CN1N=CN=C1[C@H]([C@H](N1)C=2C=CC(F)=CC=2)C2=NNC(=O)C3=C2C1=CC(F)=C3 HWGQMRYQVZSGDQ-HZPDHXFCSA-N 0.000 description 17
- FDLYAMZZIXQODN-UHFFFAOYSA-N olaparib Chemical compound FC1=CC=C(CC=2C3=CC=CC=C3C(=O)NN=2)C=C1C(=O)N(CC1)CCN1C(=O)C1CC1 FDLYAMZZIXQODN-UHFFFAOYSA-N 0.000 description 17
- 229960000572 olaparib Drugs 0.000 description 16
- 229950004550 talazoparib Drugs 0.000 description 16
- 230000002950 deficient Effects 0.000 description 15
- 239000000047 product Substances 0.000 description 14
- HMABYWSNWIZPAG-UHFFFAOYSA-N rucaparib Chemical compound C1=CC(CNC)=CC=C1C(N1)=C2CCNC(=O)C3=C2C1=CC(F)=C3 HMABYWSNWIZPAG-UHFFFAOYSA-N 0.000 description 14
- 229950004707 rucaparib Drugs 0.000 description 14
- 239000003826 tablet Substances 0.000 description 14
- -1 organic acid salts Chemical class 0.000 description 13
- 239000002775 capsule Substances 0.000 description 12
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 11
- 230000002401 inhibitory effect Effects 0.000 description 11
- 239000004480 active ingredient Substances 0.000 description 10
- 230000002939 deleterious effect Effects 0.000 description 10
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 10
- 201000002528 pancreatic cancer Diseases 0.000 description 10
- 208000008443 pancreatic carcinoma Diseases 0.000 description 10
- WUUGFSXJNOTRMR-IOSLPCCCSA-N 5'-S-methyl-5'-thioadenosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CSC)O[C@H]1N1C2=NC=NC(N)=C2N=C1 WUUGFSXJNOTRMR-IOSLPCCCSA-N 0.000 description 9
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 9
- 230000009036 growth inhibition Effects 0.000 description 9
- 239000000126 substance Substances 0.000 description 9
- MEFKEPWMEQBLKI-AIRLBKTGSA-N S-adenosyl-L-methioninate Chemical compound O[C@@H]1[C@H](O)[C@@H](C[S+](CC[C@H](N)C([O-])=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 MEFKEPWMEQBLKI-AIRLBKTGSA-N 0.000 description 8
- 229960001570 ademetionine Drugs 0.000 description 8
- 239000000546 pharmaceutical excipient Substances 0.000 description 8
- 230000002829 reductive effect Effects 0.000 description 8
- 230000001225 therapeutic effect Effects 0.000 description 8
- 238000012054 celltiter-glo Methods 0.000 description 7
- 239000003085 diluting agent Substances 0.000 description 7
- 230000012010 growth Effects 0.000 description 7
- 230000005764 inhibitory process Effects 0.000 description 7
- 239000000463 material Substances 0.000 description 7
- 230000002195 synergetic effect Effects 0.000 description 7
- 238000009825 accumulation Methods 0.000 description 6
- 125000000217 alkyl group Chemical group 0.000 description 6
- 239000004615 ingredient Substances 0.000 description 6
- 231100000252 nontoxic Toxicity 0.000 description 6
- 230000003000 nontoxic effect Effects 0.000 description 6
- 238000010899 nucleation Methods 0.000 description 6
- 229940124597 therapeutic agent Drugs 0.000 description 6
- 238000004448 titration Methods 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 5
- 101000914035 Homo sapiens Pre-mRNA-splicing regulator WTAP Proteins 0.000 description 5
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 5
- 206010025323 Lymphomas Diseases 0.000 description 5
- 102100026431 Pre-mRNA-splicing regulator WTAP Human genes 0.000 description 5
- 125000000753 cycloalkyl group Chemical group 0.000 description 5
- 125000001153 fluoro group Chemical group F* 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 230000014509 gene expression Effects 0.000 description 5
- 201000005202 lung cancer Diseases 0.000 description 5
- 208000020816 lung neoplasm Diseases 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 230000009467 reduction Effects 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 239000003981 vehicle Substances 0.000 description 5
- 108091033409 CRISPR Proteins 0.000 description 4
- 238000010354 CRISPR gene editing Methods 0.000 description 4
- 201000001342 Fallopian tube cancer Diseases 0.000 description 4
- 208000013452 Fallopian tube neoplasm Diseases 0.000 description 4
- 208000026149 Primary peritoneal carcinoma Diseases 0.000 description 4
- 102100034607 Protein arginine N-methyltransferase 5 Human genes 0.000 description 4
- 101710084427 Protein arginine N-methyltransferase 5 Proteins 0.000 description 4
- 101710167557 S-adenosylmethionine synthase isoform type-2 Proteins 0.000 description 4
- 208000005718 Stomach Neoplasms Diseases 0.000 description 4
- 230000009286 beneficial effect Effects 0.000 description 4
- 208000029742 colonic neoplasm Diseases 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 206010017758 gastric cancer Diseases 0.000 description 4
- 230000006801 homologous recombination Effects 0.000 description 4
- 238000002744 homologous recombination Methods 0.000 description 4
- 210000003101 oviduct Anatomy 0.000 description 4
- 230000007170 pathology Effects 0.000 description 4
- 230000037361 pathway Effects 0.000 description 4
- 238000011518 platinum-based chemotherapy Methods 0.000 description 4
- 230000035755 proliferation Effects 0.000 description 4
- 230000004044 response Effects 0.000 description 4
- 230000005783 single-strand break Effects 0.000 description 4
- 239000012453 solvate Substances 0.000 description 4
- 201000011549 stomach cancer Diseases 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- ZKHQWZAMYRWXGA-KQYNXXCUSA-J ATP(4-) Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-J 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- ZKHQWZAMYRWXGA-UHFFFAOYSA-N Adenosine triphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)C(O)C1O ZKHQWZAMYRWXGA-UHFFFAOYSA-N 0.000 description 3
- 239000004215 Carbon black (E152) Substances 0.000 description 3
- 206010009944 Colon cancer Diseases 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- 206010029260 Neuroblastoma Diseases 0.000 description 3
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 3
- 208000007571 Ovarian Epithelial Carcinoma Diseases 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 206010060862 Prostate cancer Diseases 0.000 description 3
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 230000000996 additive effect Effects 0.000 description 3
- 239000002585 base Substances 0.000 description 3
- 230000033590 base-excision repair Effects 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 230000004071 biological effect Effects 0.000 description 3
- 125000004432 carbon atom Chemical group C* 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 201000004101 esophageal cancer Diseases 0.000 description 3
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 3
- 210000004602 germ cell Anatomy 0.000 description 3
- 229930195733 hydrocarbon Natural products 0.000 description 3
- 238000001802 infusion Methods 0.000 description 3
- 238000001990 intravenous administration Methods 0.000 description 3
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 238000011418 maintenance treatment Methods 0.000 description 3
- 230000036961 partial effect Effects 0.000 description 3
- 238000002203 pretreatment Methods 0.000 description 3
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 3
- 229920006395 saturated elastomer Polymers 0.000 description 3
- 239000000829 suppository Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- JNAHVYVRKWKWKQ-CYBMUJFWSA-N veliparib Chemical group N=1C2=CC=CC(C(N)=O)=C2NC=1[C@@]1(C)CCCN1 JNAHVYVRKWKWKQ-CYBMUJFWSA-N 0.000 description 3
- 229950011257 veliparib Drugs 0.000 description 3
- 229920002261 Corn starch Polymers 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 2
- 230000005971 DNA damage repair Effects 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 101001113440 Homo sapiens Poly [ADP-ribose] polymerase 2 Proteins 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 206010027406 Mesothelioma Diseases 0.000 description 2
- 108010064218 Poly (ADP-Ribose) Polymerase-1 Proteins 0.000 description 2
- 102100023712 Poly [ADP-ribose] polymerase 1 Human genes 0.000 description 2
- 102100023652 Poly [ADP-ribose] polymerase 2 Human genes 0.000 description 2
- 208000015634 Rectal Neoplasms Diseases 0.000 description 2
- 206010038389 Renal cancer Diseases 0.000 description 2
- 208000000453 Skin Neoplasms Diseases 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 125000001246 bromo group Chemical group Br* 0.000 description 2
- 239000007894 caplet Substances 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- QUQKKHBYEFLEHK-QNBGGDODSA-N chembl3137318 Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1.CN1N=CN=C1[C@H]([C@H](N1)C=2C=CC(F)=CC=2)C2=NNC(=O)C3=C2C1=CC(F)=C3 QUQKKHBYEFLEHK-QNBGGDODSA-N 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- 238000011260 co-administration Methods 0.000 description 2
- 210000001072 colon Anatomy 0.000 description 2
- 239000008120 corn starch Substances 0.000 description 2
- 229940099112 cornstarch Drugs 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 239000002270 dispersing agent Substances 0.000 description 2
- 230000005782 double-strand break Effects 0.000 description 2
- 239000000890 drug combination Substances 0.000 description 2
- 235000019441 ethanol Nutrition 0.000 description 2
- MMXKVMNBHPAILY-UHFFFAOYSA-N ethyl laurate Chemical compound CCCCCCCCCCCC(=O)OCC MMXKVMNBHPAILY-UHFFFAOYSA-N 0.000 description 2
- 239000007897 gelcap Substances 0.000 description 2
- 125000001188 haloalkyl group Chemical group 0.000 description 2
- 239000007902 hard capsule Substances 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 239000003701 inert diluent Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 230000001394 metastastic effect Effects 0.000 description 2
- 206010061289 metastatic neoplasm Diseases 0.000 description 2
- 229930182817 methionine Natural products 0.000 description 2
- 125000000250 methylamino group Chemical group [H]N(*)C([H])([H])[H] 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- 125000002950 monocyclic group Chemical group 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 230000002611 ovarian Effects 0.000 description 2
- 238000004806 packaging method and process Methods 0.000 description 2
- 201000008129 pancreatic ductal adenocarcinoma Diseases 0.000 description 2
- 125000006340 pentafluoro ethyl group Chemical group FC(F)(F)C(F)(F)* 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- 229940127557 pharmaceutical product Drugs 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 125000004194 piperazin-1-yl group Chemical group [H]N1C([H])([H])C([H])([H])N(*)C([H])([H])C1([H])[H] 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 210000000664 rectum Anatomy 0.000 description 2
- 230000000306 recurrent effect Effects 0.000 description 2
- 201000000849 skin cancer Diseases 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- 229940124652 talazoparib tosylate Drugs 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 238000011200 topical administration Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- DENYZIUJOTUUNY-MRXNPFEDSA-N (2R)-14-fluoro-2-methyl-6,9,10,19-tetrazapentacyclo[14.2.1.02,6.08,18.012,17]nonadeca-1(18),8,12(17),13,15-pentaen-11-one Chemical compound FC=1C=C2C=3C=4C(CN5[C@@](C4NC3C1)(CCC5)C)=NNC2=O DENYZIUJOTUUNY-MRXNPFEDSA-N 0.000 description 1
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- RYWIWBIJBCNLMR-UHFFFAOYSA-N 10-ethoxy-8-(morpholin-4-ylmethyl)-2,3,4,6-tetrahydro-1h-benzo[h][1,6]naphthyridin-5-one;dihydrate;dihydrochloride Chemical compound O.O.Cl.Cl.C=1C=2NC(=O)C=3CCCNC=3C=2C(OCC)=CC=1CN1CCOCC1 RYWIWBIJBCNLMR-UHFFFAOYSA-N 0.000 description 1
- JNAHVYVRKWKWKQ-UHFFFAOYSA-N 2-(2-methyl-2-pyrrolidinyl)-1H-benzimidazole-4-carboxamide Chemical compound N=1C2=C(C(N)=O)C=CC=C2NC=1C1(C)CCCN1 JNAHVYVRKWKWKQ-UHFFFAOYSA-N 0.000 description 1
- PCHKPVIQAHNQLW-UHFFFAOYSA-N 2-[4-(piperidin-3-yl)phenyl]-2H-indazole-7-carboxamide Chemical compound N1=C2C(C(=O)N)=CC=CC2=CN1C(C=C1)=CC=C1C1CCCNC1 PCHKPVIQAHNQLW-UHFFFAOYSA-N 0.000 description 1
- JCZLABDVDPYLRZ-UHFFFAOYSA-N 2-azaniumyl-3-(4-phenylphenyl)propanoate Chemical compound C1=CC(CC(N)C(O)=O)=CC=C1C1=CC=CC=C1 JCZLABDVDPYLRZ-UHFFFAOYSA-N 0.000 description 1
- ZRMNUBSZWKYSME-UHFFFAOYSA-N 3,4-dimethyl-10h-acridin-9-one Chemical compound C1=CC=C2C(=O)C3=CC=C(C)C(C)=C3NC2=C1 ZRMNUBSZWKYSME-UHFFFAOYSA-N 0.000 description 1
- UQZCQKXJAXKZQH-LBPRGKRZSA-N 4-[[(2S)-1-[3-oxo-3-[4-[5-(trifluoromethyl)pyrimidin-2-yl]piperazin-1-yl]propoxy]propan-2-yl]amino]-5-(trifluoromethyl)-1H-pyridazin-6-one Chemical compound O=C(CCOC[C@H](C)NC1=C(C(NN=C1)=O)C(F)(F)F)N1CCN(CC1)C1=NC=C(C=N1)C(F)(F)F UQZCQKXJAXKZQH-LBPRGKRZSA-N 0.000 description 1
- XJGXCBHXFWBOTN-UHFFFAOYSA-N 4-[[4-fluoro-3-[2-(trifluoromethyl)-6,8-dihydro-5h-[1,2,4]triazolo[1,5-a]pyrazine-7-carbonyl]phenyl]methyl]-2h-phthalazin-1-one Chemical compound C1CN2N=C(C(F)(F)F)N=C2CN1C(=O)C1=CC(CC=2C3=CC=CC=C3C(=O)NN=2)=CC=C1F XJGXCBHXFWBOTN-UHFFFAOYSA-N 0.000 description 1
- QNQFPYADHVFRKQ-UHFFFAOYSA-N 4-[[4-fluoro-3-[5-methyl-3-(trifluoromethyl)-6,8-dihydro-5h-[1,2,4]triazolo[4,3-a]pyrazine-7-carbonyl]phenyl]methyl]-2h-phthalazin-1-one Chemical compound C1=CC=C2C(CC=3C=C(C(=CC=3)F)C(=O)N3CC(N4C(=NN=C4C3)C(F)(F)F)C)=NNC(=O)C2=C1 QNQFPYADHVFRKQ-UHFFFAOYSA-N 0.000 description 1
- VBTUJTGLLREMNW-UHFFFAOYSA-N 5-fluoro-1-[[4-fluoro-3-(4-pyrimidin-2-ylpiperazine-1-carbonyl)phenyl]methyl]quinazoline-2,4-dione Chemical compound FC1=CC=C(CN2C(NC(=O)C3=C(F)C=CC=C32)=O)C=C1C(=O)N(CC1)CCN1C1=NC=CC=N1 VBTUJTGLLREMNW-UHFFFAOYSA-N 0.000 description 1
- GRPXLKXGJAGYSD-UHFFFAOYSA-N 6-[4-[(5-oxo-2,3,4,6-tetrahydro-1H-benzo[h][1,6]naphthyridin-8-yl)methyl]piperazin-1-yl]pyridine-3-carbonitrile Chemical compound O=C1C=2CCCNC=2C2=C(N1)C=C(C=C2)CN1CCN(CC1)C1=NC=C(C#N)C=C1 GRPXLKXGJAGYSD-UHFFFAOYSA-N 0.000 description 1
- JLFSBHQQXIAQEC-UHFFFAOYSA-N 9x5a2qia7c Chemical compound C1=CC(C(=O)NN2)=C3C2=NC(CN2CC4=CC=CC=C4C2)=NC3=C1 JLFSBHQQXIAQEC-UHFFFAOYSA-N 0.000 description 1
- 206010052747 Adenocarcinoma pancreas Diseases 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 206010005949 Bone cancer Diseases 0.000 description 1
- 208000018084 Bone neoplasm Diseases 0.000 description 1
- 208000003174 Brain Neoplasms Diseases 0.000 description 1
- 206010055113 Breast cancer metastatic Diseases 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 206010008342 Cervix carcinoma Diseases 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 101000983970 Conus catus Alpha-conotoxin CIB Proteins 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 230000033616 DNA repair Effects 0.000 description 1
- 208000020401 Depressive disease Diseases 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- 206010062878 Gastrooesophageal cancer Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 208000031448 Genomic Instability Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 208000017604 Hodgkin disease Diseases 0.000 description 1
- 208000021519 Hodgkin lymphoma Diseases 0.000 description 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 description 1
- 208000008839 Kidney Neoplasms Diseases 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- GXCLVBGFBYZDAG-UHFFFAOYSA-N N-[2-(1H-indol-3-yl)ethyl]-N-methylprop-2-en-1-amine Chemical compound CN(CCC1=CNC2=C1C=CC=C2)CC=C GXCLVBGFBYZDAG-UHFFFAOYSA-N 0.000 description 1
- 241000282320 Panthera leo Species 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 208000006265 Renal cell carcinoma Diseases 0.000 description 1
- 201000000582 Retinoblastoma Diseases 0.000 description 1
- 235000019485 Safflower oil Nutrition 0.000 description 1
- 206010041067 Small cell lung cancer Diseases 0.000 description 1
- 108091027967 Small hairpin RNA Proteins 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 208000000102 Squamous Cell Carcinoma of Head and Neck Diseases 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 208000024313 Testicular Neoplasms Diseases 0.000 description 1
- 206010057644 Testis cancer Diseases 0.000 description 1
- 208000000728 Thymus Neoplasms Diseases 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 101150110932 US19 gene Proteins 0.000 description 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
- 208000002495 Uterine Neoplasms Diseases 0.000 description 1
- 239000003070 absorption delaying agent Substances 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 208000009956 adenocarcinoma Diseases 0.000 description 1
- 208000002517 adenoid cystic carcinoma Diseases 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 125000002947 alkylene group Chemical group 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- MDFFNEOEWAXZRQ-UHFFFAOYSA-N aminyl Chemical compound [NH2] MDFFNEOEWAXZRQ-UHFFFAOYSA-N 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000008135 aqueous vehicle Substances 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 201000008274 breast adenocarcinoma Diseases 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 238000001516 cell proliferation assay Methods 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 229920002301 cellulose acetate Polymers 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 201000010881 cervical cancer Diseases 0.000 description 1
- 201000010288 cervix melanoma Diseases 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000009104 chemotherapy regimen Methods 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 208000006990 cholangiocarcinoma Diseases 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 239000002385 cottonseed oil Substances 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 206010013663 drug dependence Diseases 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- DCSUGHIXMFUMOQ-UHFFFAOYSA-N ethyl N-[6-[2-fluoro-5-[(4-oxo-3H-phthalazin-1-yl)methyl]phenyl]-1H-benzimidazol-2-yl]carbamate Chemical compound C1=C(CC=2C3=CC=CC=C3C(=O)NN=2)C=C(C2=CC=C3N=C(NC3=C2)NC(=O)OCC)C(F)=C1 DCSUGHIXMFUMOQ-UHFFFAOYSA-N 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 125000003709 fluoroalkyl group Chemical group 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 201000006585 gastric adenocarcinoma Diseases 0.000 description 1
- 201000006974 gastroesophageal cancer Diseases 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 208000005017 glioblastoma Diseases 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 150000002367 halogens Chemical class 0.000 description 1
- 201000000459 head and neck squamous cell carcinoma Diseases 0.000 description 1
- 201000005787 hematologic cancer Diseases 0.000 description 1
- 230000002489 hematologic effect Effects 0.000 description 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000000266 injurious effect Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 125000002346 iodo group Chemical group I* 0.000 description 1
- 201000010982 kidney cancer Diseases 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 230000000527 lymphocytic effect Effects 0.000 description 1
- VTHJTEIRLNZDEV-UHFFFAOYSA-L magnesium dihydroxide Chemical compound [OH-].[OH-].[Mg+2] VTHJTEIRLNZDEV-UHFFFAOYSA-L 0.000 description 1
- 239000000347 magnesium hydroxide Substances 0.000 description 1
- 229910001862 magnesium hydroxide Inorganic materials 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 239000012457 nonaqueous media Substances 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- KJIFKLIQANRMOU-UHFFFAOYSA-N oxidanium;4-methylbenzenesulfonate Chemical compound O.CC1=CC=C(S(O)(=O)=O)C=C1 KJIFKLIQANRMOU-UHFFFAOYSA-N 0.000 description 1
- 229950007072 pamiparib Drugs 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 201000002094 pancreatic adenocarcinoma Diseases 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 206010038038 rectal cancer Diseases 0.000 description 1
- 201000001275 rectum cancer Diseases 0.000 description 1
- 238000005057 refrigeration Methods 0.000 description 1
- 201000010174 renal carcinoma Diseases 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- INBJJAFXHQQSRW-STOWLHSFSA-N rucaparib camsylate Chemical compound CC1(C)[C@@H]2CC[C@@]1(CS(O)(=O)=O)C(=O)C2.CNCc1ccc(cc1)-c1[nH]c2cc(F)cc3C(=O)NCCc1c23 INBJJAFXHQQSRW-STOWLHSFSA-N 0.000 description 1
- 235000005713 safflower oil Nutrition 0.000 description 1
- 239000003813 safflower oil Substances 0.000 description 1
- 201000007416 salivary gland adenoid cystic carcinoma Diseases 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 238000009097 single-agent therapy Methods 0.000 description 1
- 239000004055 small Interfering RNA Substances 0.000 description 1
- 208000000587 small cell lung carcinoma Diseases 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 230000000392 somatic effect Effects 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 206010041823 squamous cell carcinoma Diseases 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 208000011117 substance-related disease Diseases 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 230000002123 temporal effect Effects 0.000 description 1
- 201000003120 testicular cancer Diseases 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000004797 therapeutic response Effects 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- 206010044412 transitional cell carcinoma Diseases 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 208000025444 tumor of salivary gland Diseases 0.000 description 1
- 206010046766 uterine cancer Diseases 0.000 description 1
- YNBQAYKYNYRCCA-UHFFFAOYSA-N venadaparib Chemical compound C1(CC1)NCC1CN(C1)C(=O)C=1C=C(CC2=NNC(C3=CC=CC=C23)=O)C=CC1F YNBQAYKYNYRCCA-UHFFFAOYSA-N 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
Definitions
- Cancer is a leading cause of death throughout the world.
- a limitation of prevailing therapeutic approaches, e.g. chemotherapy and immunotherapy, is that their cytotoxic effects are not restricted to cancer cells and adverse side effects can occur within normal tissues.
- Methionine adenosyltransferase 2A is an enzyme that utilizes methionine (Met) and adenosine triphosphate (ATP) to generate s-adenosyl methionine (SAM).
- SAM is a primary methyl donor in cells used to methylate several substrates including DNA, RNA and proteins.
- One methylase that utilizes SAM as a methyl donor is protein arginine N- methyltransferase 5 (PRMT5). While SAM is required for PRMT5 activity, PRMT5 is competitively inhibited by 5’methylthioadenosine (MTA). Since MTA is part of the methionine salvage pathway, cellular MTA levels stay low in a process initiated by methylthioadenosine phosphorylase (MTAP).
- MTAP methylthioadenosine phosphorylase
- MTAP is in a locus on chromosome 9 that is often deleted in cells of patients with cancers from several tissues of origin including central nervous system, pancreas, esophageal, bladder and lung (cBioPortal database). Loss of MTAP results in the accumulation of MTA making MTAP-deleted cells more dependent on SAM production, and thus MAT2A activity, compared to cells that express MTAP. In an shRNA cell-line screen across approximately 400 cancer cell lines, MAT2A knockdown resulted in the loss of viability in a larger percentage of MTAP-deleted cells compare to MTAP WT cells (see McDonald et. al. 2017 Cell 170, 577-592).
- MAT2A inhibitors may provide a novel therapy for cancer patients including those with MTAP-deleted tumors.
- Poly (ADP-ribose) polymerases are a family of enzymes involved in DNA damage repair (DDR) by resolving single-strand breaks (SSBs) and double-strand breaks (DSBs), and by inducing base excision repair (BER). PARP inhibition leads to accumulation of single-strand breaks (SSBs) and which renders cells more dependent on other DNA repair pathways, namely, the homologous recombination (HR) repair pathway. Cancer cells with HR deficiencies are in turn susceptible to PARP impairment of the BER pathway.
- Poly (ADP- ribose) Polymerase (PARP) inhibitors are a class of compounds that act as inhibitors of Poly (ADP-ribose) polymerase. It is believed that PARP inhibitors are useful in the treatment of cancer by preventing cancer cells from repairing their DNA, leading to cellular death.
- Niraparib is approved as a PARP inhibitor for the maintenance treatment of adult patients with advanced or recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to first-line platinum-based chemotherapy; and for the treatment of adult patients with advanced ovarian, fallopian tube, or primary peritoneal cancer who have been treated with three or more prior chemotherapy regimens and whose cancer is associated with homologous recombination deficiency (HRD) status defined by either a deleterious or suspected deleterious BRCA mutation, or genomic instability and who have progressed more than six months after response to the last platinum-based chemotherapy.
- HRD homologous recombination deficiency
- Olaparib is approved as a PARP inhibitor for use in the treatment of ovarian cancer, breast cancer, pancreatic cancer and prostate cancer in certain patient subgroups.
- ovarian cancer olaparib is used for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy; for the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer, who are in complete or partial response to platinum-based chemotherapy; and for the treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm) advanced ovarian cancer who have been treated with three or more prior lines of chemotherapy.
- gBRCAm deleterious or suspected deleterious germline BRCA-mutated
- Rucaparib is approved as PARP inhibitor for use in the treatment of ovarian and prostate cancer in certain patient subgroups.
- Talazoparib is approved for use in the treatment of breast cancer in adult patients with deleterious or suspected deleterious germline BRCA-mutated HER2-negative locally advanced metastatic breast cancer.
- a combination comprising a methionine adenosyltransferase II alpha (MAT2A) inhibitor and a Poly (ADP-ribose) Polymerase (PARP) inhibitor.
- MAT2A methionine adenosyltransferase II alpha
- PARP Poly (ADP-ribose) Polymerase
- the combination is useful for the treatment of a variety of cancers, including solid tumors.
- the combination is also useful for the treatment of any number of MAT2A-associated diseases.
- the combination is also useful for the treatment of a variety of diseases or disorders treatable by inhibiting MAT2A.
- the combination is useful for treating MTAP-deficient tumors.
- the combination is also useful for the treatment of a variety of diseases or disorders treatable by inhibiting PARP.
- a combination product comprising a methionine adenosyltransferase II alpha (MAT2A) inhibitor and a Poly (ADP-ribose)Polymerase (PARP) inhibitor.
- the combination product is useful for the treatment of a variety of cancers, including solid tumors.
- the combination product is also useful for the treatment of any number of MAT2A-associated diseases.
- the combination product is also useful for the treatment of a variety of diseases or disorders treatable by inhibiting MAT2A.
- the combination product is useful for the treatment of MTAP-deficient tumors.
- the combination product is also useful for the treatment of a variety of diseases or disorders treatable by inhibiting PARP.
- a combination of a MAT2A inhibitor and a PARP inhibitor is provided herein.
- a pharmaceutical composition comprising a therapeutically effective amount of a MAT2A inhibitor and a second pharmaceutical composition comprising a therapeutically effective amount of a PARP inhibitor.
- provided herein are methods of treating cancer in a subject in need thereof, the methods comprising administering to the subject a combination comprising a MAT2A inhibitor and a PARP inhibitor, thereby treating the cancer in the subject.
- provided herein are methods of treating cancer in a subject in need thereof, the methods comprising administering to the subject a combination comprising a MAT2A inhibitor and a PARP inhibitor together with at least a pharmaceutically acceptable carrier, thereby treating the cancer in the subject.
- the cancer is characterized by a reduction or absence of methylthioadenosine phosphorylase (MTAP) gene expression, absence of MTAP gene, reduced function of MTAP protein, reduced level or absence of MTAP protein, MTA accumulation, or combination thereof.
- MTAP methylthioadenosine phosphorylase
- provided herein are methods of treating cancer in a subject in need thereof, the methods comprising administering to the subject a therapeutically effective amount of a pharmaceutical composition comprising a MAT2A inhibitor and a therapeutically effective amount of a pharmaceutical composition comprising a PARP inhibitor, thereby treating the cancer in the subject.
- methods of treating a disease or disorder treatable by inhibiting MAT2A in a subject in need thereof the methods comprising administering to the subject a combination comprising a MAT2A inhibitor and a PARP inhibitor, thereby treating the disease or disorder in the subject.
- the disease or disorder is cancer.
- provided herein are methods of treating a disease or disorder treatable by inhibiting MAT2A in a subject in need thereof, the methods comprising administering to the subject a combination comprising a MAT2A inhibitor and a PARP inhibitor, together with at least a pharmaceutically acceptable carrier, thereby treating the disease or disorder in the subject.
- the PARP inhibitor is niraparib, or a pharmaceutically acceptable salt thereof.
- the disease or disorder is cancer.
- the MAT2A inhibitor is a compound of Formula (I): or a pharmaceutically acceptable salt thereof, wherein the variables of Formula I are defined below.
- the MAT2A inhibitor is Compound A having the following structural formula:
- Compound A or a pharmaceutically acceptable salt thereof.
- Compound A, and methods of making Compound A are disclosed in PCT/US 19/65260 (WO 2020/123395).
- the MAT2A inhibitor is Compound A1 having the following structural formula: Compound A1 or a pharmaceutically acceptable salt thereof.
- Compound A1 and methods of making Compound A1 are disclosed in PCT/US 19/65260 (WO 2020/123395).
- MAT2A inhibitors for use in the combination therapy described herein are described in WO 2020/123395 (PCT/US19/65260), the generic and specific compounds described in this application can be used to treats cancer as described herein.
- the PARP inhibitor is niraparib (Compound B) having the following structural formula:
- the PARP inhibitor is rucaparib (Compound C) having the following structural formula
- Compound C or a pharmaceutically acceptable salt thereof is 8- fluoro-5-(4-((methylamino)methyl)phenyl)-2,3,4,6-tetrahydro-1H-azepino[5,4,3-cd]indol-1- one.
- the PARP inhibitor is olaparib (Compound D):
- Compound D or a pharmaceutically acceptable salt thereof.
- the chemical name for olaparib is 4- (3-(4-(cyclopropanecarbonyl)piperazine-1 -carbonyl )-4-fluorobenzyl)phthalazin-1(2H)-one.
- the PARP inhibitor is talazoparib (Compound E):
- talazoparib 8S,9R)-5-fluoro-8-(4-fluorophenyl)-9-(1-methyl-1 H-1 ,2,4-triazol-5-yl)-2,7,8,9-tetrahydro-3H- pyrido[4,3,2-de]phthalazin-3-one.
- the PARP inhibitor is veliparib (Compound F): Compound F or a pharmaceutically acceptable salt thereof.
- the chemical name for veliparib is (R)-
- the PARP inhibitor is AZD5305: or a pharmaceutically acceptable salt thereof.
- the chemical name for AZD5305 is 5- [4-[(7-ethyl-6-oxo-5H-1 ,5-napthyridine-3-yl)methyl]piperazin-1-yl]-N-methyl-pyridine-2- carboxamide.
- the PARP inhibitor is AZD9574: or a pharmaceutically acceptable salt thereof.
- the chemical name for AZD9574 is 6- fluoro-5-[4-[(5-fluoro-2-methyl-3-oxo-4H-quinoxalin-6-yl)methyl]piperazin-1-yl]-N-methyl- pyridine-2-carboxamide.
- FIG. 1 A-1C depict excess over Bliss synergy of Compound A and PARP inhibitor combinations in NCI-H838 cell line.
- FIG. 2A-2C depict excess over Bliss synergy of Compound A and PARP inhibitor combinations in NCI-H2228 cell line.
- FIG. 3A-3C depict excess over Bliss synergy of Compound A and PARP inhibitor combinations in RT112/84 cell line.
- FIG. 4A-4C depict excess over Bliss synergy of Compound A and PARP inhibitor combinations in UMUC5 cell line.
- FIG. 5A-5C depict excess over Bliss synergy of Compound A and PARP inhibitor combinations in Pane 03.27 MTAP CRISPR knock-out cell line (Clone 31).
- FIG. 6A-6C depict excess over Bliss synergy of Compound A and PARP inhibitor combinations in Pane 03.27 MTAP wild type cell line.
- FIG. 7A-7C depict excess over Bliss synergy of Compound A and PARP inhibitor combinations in NCI-H520 MTAP wild type cell line.
- FIG. 8A-8C depict excess over Bliss synergy of Compound A and PARP inhibitor combinations in TCCSUP MTAP wild type cell line.
- a combination therapy comprising a MAT2A inhibitor, or a pharmaceutically acceptable salt thereof, and a PARP inhibitor, or a pharmaceutically acceptable salt thereof.
- the combination therapy is useful for the treatment of a variety of cancers, including, for example, pancreatic cancer and lung cancer.
- the combination therapy is useful for the treatment of any number of MAT2A-associated diseases.
- Administering a combination of a MAT2A inhibitor and a PARP inhibitor can provide beneficial effects for treating cancer, e.g., solid tumors, in a subject.
- Such an approach - combination or co-administration of the two types of agents - may offer an uninterrupted treatment to a subject in need over a clinically relevant treatment period.
- the articles “a” and “an” refer to one or to more than one (i.e., to at least one) of the grammatical object of the article.
- an element means one element or more than one element.
- use of the term “including” as well as other forms, such as “include,” “includes,” and “included,” is not limiting.
- the term “about” will be understood by persons of ordinary skill in the art and will vary to some extent on the context in which it is used. As used herein when referring to a measurable value such as an amount, a temporal duration, and the like, the term “about” is meant to encompass variations of ⁇ 20% or ⁇ 10%, including ⁇ 5%, ⁇ 1%, and ⁇ 0.1% from the specified value, as such variations are appropriate to perform the disclosed methods.
- the term “comprising” may include the embodiments “consisting of’ and “consisting essentially of.”
- the terms “comprise(s),” “include(s),” “having,” “has,” “may,” “contain(s),” and variants thereof, as used herein, are intended to be open-ended transitional phrases, terms, or words that require the presence of the named ingredients/steps and permit the presence of other ingredients/steps.
- ratios, concentrations, amounts, and other numerical data may be expressed herein in a range format. It is to be understood that such a range format is used for convenience and brevity, and thus, should be interpreted in a flexible manner to include not only the numerical values explicitly recited as the limits of the range, but also to include all the individual numerical values or sub-ranges encompassed within that range as if each numerical value and sub-range is explicitly recited.
- the phrase “about ‘x’ to ‘y’” includes “about ‘x’ to about ‘y’”.
- combination refers to either a fixed combination in one dosage unit form, or non-fixed combination in separate dosage forms, or a kit of parts for the combined administration where two or more therapeutic agents may be administered independently, at the same time or separately within time intervals.
- combination therapy refers to the administration of two or more therapeutic agents to treat a therapeutic condition or disorder described in the present disclosure.
- administration encompasses co-administration of these therapeutic agents in a substantially simultaneous manner, such as in a single formulation having a fixed ratio of active ingredients or in separate formulations (e.g., capsules and/or intravenous formulations) for each active ingredient.
- administration also encompasses use of each type of therapeutic agent in a sequential or separate manner, either at approximately the same time or at different times.
- the active ingredients are administered as a single formulation or in separate formulations
- the drugs are administered to the same patient as part of the same course of therapy.
- the treatment regimen will provide beneficial effects in treating the conditions or disorders described herein.
- treating refers to inhibiting a disease; for example, inhibiting a disease, condition, or disorder in an individual who is experiencing or displaying the pathology or symptomology of the disease, condition, or disorder (j.e. , arresting further development of the pathology and/or symptomology) or ameliorating the disease; for example, ameliorating a disease, condition, or disorder in an individual who is experiencing or displaying the pathology or symptomology of the disease, condition, or disorder (i.e., reversing the pathology and/or symptomology) such as decreasing the severity of the disease.
- the term “patient,” “individual,” or “subject” refers to a human.
- the terms “effective amount,” “pharmaceutically effective amount,” and “therapeutically effective amount” refer to a nontoxic but sufficient amount of an agent to provide the desired biological result. That result may be reduction or alleviation of the signs, symptoms, or causes of a disease, or any other desired alteration of a biological system. An appropriate therapeutic amount in any individual case may be determined by one of ordinary skill in the art using routine experimentation.
- the term “pharmaceutically acceptable” refers to a material, such as a carrier or diluent, which does not abrogate the biological activity or properties of the compound, and is relatively non-toxic, i.e., the material may be administered to an individual without causing undesirable biological effects or interacting in a deleterious manner with any of the components of the composition in which it is contained.
- the term “pharmaceutically acceptable salt” refers to derivatives of the disclosed compounds wherein a parent compound is modified by converting an existing acid or base moiety to its salt form.
- pharmaceutically acceptable salts include, but are not limited to, mineral or organic acid salts of basic residues such as amines; alkali or organic salts of acidic residues such as carboxylic acids; and the like.
- the pharmaceutically acceptable salts described herein include the conventional non-toxic salts of the parent compound formed, for example, from non-toxic inorganic or organic acids.
- the pharmaceutically acceptable salts discussed herein can be synthesized from the parent compound which contains a basic or acidic moiety by conventional chemical methods.
- such salts can be prepared by reacting the free acid or base forms of these compounds with a stoichiometric amount of the appropriate base or acid in water or in an organic solvent, or in a mixture of the two; generally, nonaqueous media like ether, ethyl acetate, ethanol, isopropanol, or acetonitrile are used.
- pharmaceutically acceptable salt is not limited to a mono, or 1 :1 , salt.
- “pharmaceutically acceptable salt” also includes bis-salts, such as a bis-hydrochloride salt. Lists of suitable salts are found in Remington’s Pharmaceutical Sciences, 17th ed., Mack Publishing Company, Easton, Pa., 1985, p. 1418 and Journal of Pharmaceutical Science, 66, 2 (1977), each of which is incorporated herein by reference in its entirety.
- composition refers to a mixture of at least one compound with a pharmaceutically acceptable carrier.
- the pharmaceutical composition facilitates administration of the composition to a patient or subject. Multiple techniques of administering a compound exist in the art including, but not limited to, intravenous, oral, aerosol, parenteral, ophthalmic, pulmonary, and topical administration.
- the term “pharmaceutically acceptable carrier” means a pharmaceutically acceptable material, composition or carrier, such as a liquid or solid filler, stabilizer, dispersing agent, suspending agent, diluent, excipient, thickening agent, solvent or encapsulating material, involved in carrying or transporting a compound useful to the patient such that it may perform its intended function.
- a pharmaceutically acceptable material, composition or carrier such as a liquid or solid filler, stabilizer, dispersing agent, suspending agent, diluent, excipient, thickening agent, solvent or encapsulating material, involved in carrying or transporting a compound useful to the patient such that it may perform its intended function.
- Such constructs are carried or transported from one organ, or portion of the body, to another organ, or portion of the body.
- Each carrier must be “acceptable” in the sense of being compatible with the other ingredients of the formulation, including the compound disclosed herein, and not injurious to the patient.
- materials that may serve as pharmaceutically acceptable carriers include: sugars, such as lactose, glucose and sucrose; starches, such as corn starch and potato starch; cellulose, and its derivatives, such as sodium carboxymethyl cellulose, ethyl cellulose and cellulose acetate; powdered tragacanth; malt; gelatin; talc; excipients, such as cocoa butter and suppository waxes; oils, such as peanut oil, cottonseed oil, safflower oil, sesame oil, olive oil, corn oil and soybean oil; glycols, such as propylene glycol; polyols, such as glycerin, sorbitol, mannitol and polyethylene glycol; esters, such as ethyl oleate and ethyl laurate; agar; buffering agents, such as magnesium hydroxide and aluminum hydroxide; surface active agents; alginic acid; pyrogen-free water; isotonic saline
- “pharmaceutically acceptable carrier” also includes any and all coatings, antibacterial and antifungal agents, and absorption delaying agents, and the like that are compatible with the activity of a compound disclosed herein, and are physiologically acceptable to the patient. Supplementary active compounds may also be incorporated into the compositions. Other additional ingredients that may be included in the pharmaceutical compositions are known in the art and described, for example, in Remington’s Pharmaceutical Sciences (Genaro, Ed., Mack Publishing Co., 1985, Easton, PA), which is incorporated herein by reference.
- single formulation refers to a single carrier or vehicle formulated to deliver therapeutically effective amounts of both therapeutic agents to a patient.
- the single vehicle is designed to deliver a therapeutically effective amount of each of the agents, along with any pharmaceutically acceptable carriers or excipients.
- the vehicle is a tablet, capsule, pill, or a patch. In other embodiments, the vehicle is a solution or a suspension.
- MAT2A inhibitor means an agent that modulates the activity of MAT2A or inhibits the production of S-adenosylmethionine (SAM) by methionine adenosyltransferase 2A (MAT2A).
- SAM S-adenosylmethionine
- Poly (ADP-ribose) Polymerase (PARP) inhibitor refers to an agent that inhibits, PARP activity, including PARP1 and PARP2.
- PARP inhibitors include, but are not limited to, niraparib, rucaparib, olaparib, talazoparib, veliparib, AZD5305, and AZD9574, and pharmaceutically acceptable salts thereof.
- the combination of agents described herein may display a synergistic effect.
- the term “synergistic effect” or “synergy” as used herein, refers to action of two agents such as, for example, a MAT2A inhibitor and a PARP inhibitor producing an effect, for example, slowing the symptomatic progression of cancer or symptoms thereof, which is greater than the simple addition of the effects of each drug administered by themselves.
- a synergistic effect can be calculated, for example, using suitable methods such as the Sigmoid-Emax equation (Holford, N. H. G. and Scheiner, L. B., Clin. Pharmacokinet. 6: 429-453 (1981)), the equation of Loewe additivity (Loewe, S.
- a combination therapy comprising a therapeutically effective amount of a MAT2A inhibitor and a PARP inhibitor.
- a “therapeutically effective amount” of a combination of agents i.e., a MAT2A inhibitor and a PARP inhibitor
- Observable improvements include those that can be visually ascertained by a clinician and biological tests, biopsies, and assays.
- Alkyl means a linear saturated monovalent hydrocarbon radical of one to six carbon (i.e. C1-6 means one to six carbons) atoms or a branched saturated monovalent hydrocarbon radical of three to six carbon atoms (i.e. C3-6 means three to six carbons).
- Alkyl can include any number of carbons, such as C1.2, C1-3, C1-4, C1-5, C1-6, C2-3, C2-4, C2-5, C2-6, C3-4, C3-5, C3-6, C4-5, C4-6 and C5-6.
- Example of alkyl groups inlcude methyl, ethyl, propyl, 2-propyl, butyl, pentyl, and the like. It will be recognized by a person skilled in the art that the term “alkyl” may include “alkylene” groups.
- Amino means a -NH2.
- Cycloalkyl means a monocyclic monovalent hydrocarbon radical of three to six carbon atoms (e.g., C3-6 cycloalkyl) which may be saturated or contains one double bond. Cycloalkyl can include any number of carbons, such as C3-6, C4-6, and C5-6. Partially unsaturated cycloalkyl groups have one or more double in the ring, but cycloalkyl groups are not aromatic. Saturated monocyclic cycloalkyl rings include, for example, cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl.
- Halo means fluoro, chloro, bromo, or iodo, preferably fluoro or chloro.
- Haloalkyl means alkyl radical as defined above, which is substituted with one to five halogen atoms, such as fluorine or chlorine, including those substituted with different halogens, e.g., -CH2CI, -CF3, -CHF2, -CH2CF3, -CF2CF3, -CF(CH3)2, and the like. When the alkyl is substituted with only fluoro, it can be referred to as fluoroalkyl. As for alkyl group, haloalkyl groups can have any suitable number of carbon atoms, such as Ci-e.
- a combination product comprising a MAT2A inhibitor, or a pharmaceutically acceptable salt thereof, and a PARP inhibitor, or a pharmaceutically acceptable salt thereof.
- the combination product is useful for the treatment of a variety of cancers, including solid tumors.
- the combination product is useful for the treatment of any number of MAT2A-associated diseases.
- the combination product is useful for the treatment of a disease or disorder treatable by inhibiting MAT2A.
- the combination product is useful for the treatment of MTAP-deficient tumors.
- a combination of a MAT2A inhibitor and a PARP inhibitor is provided herein.
- the term “combination product” includes embodiments in which the MAT2A inhibitor and PARP inhibitor are formulated together into a single pharmaceutical composition (e.g. tablet or capsule), and alternative embodiments in which each therapeutic agent in the combination is individually formulated into its own pharmaceutical composition and each of the pharmaceutical compositions are administered in the same medical treatment (for example, the same medical treatment of cancer).
- each of the pharmaceutical compositions may have the same or different carriers, diluents or excipients.
- the carrier(s), diluent(s) or excipient(s) must be acceptable in the sense of being compatible with the other ingredients of the formulation, capable of pharmaceutical formulation, and not deleterious to the recipient thereof.
- the combination product comprises first and second pharmaceutical compositions, wherein the first pharmaceutical composition contains a PARP inhibitor (suitably selected from compounds B, C, D, E, F, AZD5305, or AZD9574 or pharmaceutically acceptable salts thereof), the second pharmaceutical composition contains Compound A or Compound A1 (or a pharmaceutically acceptable salt thereof), and the first and second pharmaceutical compositions are both administered to treat cancer.
- the first and second pharmaceutical compositions may be administered simultaneously, separately or sequentially and in any order.
- the compounds are administered in the same dosage form, e.g. one compound may be administered by injection and another compound may be administered orally.
- the disclosure provides MAT2A inhibitors.
- the MAT2A inhibitor is a compound of Formula I: (I) or a pharmaceutically acceptable salt thereof; wherein
- X is CH or N
- R 3 is halo, C1-6 haloalkyl or C3-6 cycloalkyl
- R 2 is -NR 4 R 5 ;
- R 4 is hydrogen or C1-6 alkyl
- R 5 is hydrogen, C1-6 alkyl or C3-6 cycloalkyl
- R 1 is phenyl, wherein phenyl is substituted with 0-2 halo.
- X in Formula (I) and subembodiments thereof is CH. In an embodiment, X in Formula (I) and subembodiments thereof is N.
- R 3 in formula (I) and subembodiments thereof is halo or C1-6 haloalkyl. In an embodiment, R 3 in formula (I) and subembodiments thereof is halo. In an embodiment, R 3 in formula (I) and subembodiments thereof is C1-6 haloalkyl. In an embodiment, R 3 in formula (I) and subembodiments thereof is C3-6 cycloalkyl. In an embodiment, R 3 in formula (I) and subembodiments thereof is chloro, fluoro, bromo, -CH2CI, -CF3, -CHF2, -CH2CF3, -CF2CF3, or -CF(CH 3 ) 2 .
- R 3 in formula (I) and subembodiments thereof is chloro or -CF3. In an embodiment, R 3 in formula (I) and subembodiments thereof is chloro. In an embodiment, R 3 in formula (I) and subembodiments thereof is -CF3.
- R 4 in formula (I) and subembodiments thereof is H. In an embodiment, R 4 in formula (I) and subembodiments thereof is Cvsalkyl . In an embodiment, R 4 in formula (I) and subembodiments thereof is methyl, ethyl, propyl, or isopropyl.
- R 5 in formula (I) and subembodiments thereof is H. In an embodiment, R 5 in formula (I) and subembodiments thereof is Cvsalkyl . In an embodiment, R 5 in formula (I) and subembodiments thereof is methyl, ethyl, propyl, or isopropyl. In an embodiment, R 5 in formula (I) and subembodiments thereof is C3-6 cycloalkyl.
- R 2 in formula (I) and subembodiments thereof is -NH2, - NHCi-salkyl, or -N(Ci-3alkyl)2. In an embodiment, R 2 in formula (I) and subembodiments thereof is NH2, -NHMe, or -N(Me)2. In an embodiment, R 2 in formula (I) and subembodiments thereof is NH2. In an embodiment, R 2 in formula (I) and subembodiments thereof is -NHMe.
- R 1 in formula (I) and subembodiments thereof is unsubstituted phenyl.
- R 1 in formula (I) and subembodiments thereof is phenyl substituted with 1 halo.
- R 1 in formula (I) and subembodiments thereof is phenyl substituted 1 halo selected fluoro and chloro.
- R 1 in formula (I) and subembodiments thereof is phenyl substituted chloro.
- R 1 in formula (I) and subembodiments thereof is phenyl substituted 2 halo.
- MAT2A inhibitor is selected from the group consisting of a compound from Table 1, or a pharmaceutically acceptable salt thereof.
- the MAT2A inhibitor is Compound A: Compound A or a pharmaceutically acceptable salt thereof.
- the MAT2A inhibitor is Compound A1 having the following structural formula:
- MAT2A inhibitor also includes reference to their pharmaceutically acceptable salts.
- MAT2A inhibitor is synonymous with “MAT2A inhibitor or a pharmaceutically acceptable salt thereof’.
- the disclosure provides PARP inhibitors for use with a MAT2A inhibitor.
- a number of agents with PARP inhibitory activity and methods of making the same are known in the art. Each of these is embraced by this disclosure.
- the PARP inhibitor is selected from the group consisting of the compounds in Table 2, or a pharmaceutically acceptable salt or hydrate thereof.
- the PARP inhibitor may be selected from the group consisting of AZD5305, AZD9574, THG-008, RBN-2397, TSL-1502, NMS-03305293, HWH-340, STP06-1002, JPI-547, ABT-767, simmiparib, stenoparib, IDX-1197, SC-10914, AMXI-5001 , amelparib dihydrochloride dihydrate, CK-102, IMP-4297, pamiparib, and fluzoparib or a pharmaceutically acceptable salt thereof.
- AZD5305 is described in WO 2021/013735 and is known to be 5-[4-[(7-ethyl-6-oxo- 5H-1 ,5-napthyridine-3-yl)methyl]piperazin-1-yl]-N-methyl-pyridine-2-carboxamide and has the following structure:
- AZD9574 is described in WO2021260092 and is known to be 6-fluoro-5-[4-[(5-fluoro- 2-methyl-3-oxo-4H-quinoxalin-6-yl)methyl]piperazin-1-yl]-N-methyl-pyridine-2-carboxamide and has the following structure:
- the PARP inhibitor is selected from the group consisting of AZD5305, AZD9574 and the compounds in Table 2.
- niraparib The preparation and activity of niraparib are described in US 8,071 ,579; US 8,071623; US 8,143,241; US 8,426,185; US 8,859,562; and US 11 ,091 ,459, the entire contents of which are hereby incorporated by reference in their entirety.
- the preparation and activity of rucaparib are described in US 6,495,541 ; US 7,351 ,701 ; and US 7,531 ,530, the entire contents of which are hereby incorporated by reference in their entirety.
- the PARP inhibitor is selected from the group consisting of niraparib, olaparib, talazoparib and rucaparib or a pharmaceutically acceptable salt thereof.
- the PARP inhibitor is selected from the group consisting of niraparib, talazoparib and rucaparib or a pharmaceutically acceptable salt thereof.
- the PARP inhibitor is selective for PARP1 over PARP2.
- the PARP inhibitor is AZD5305 or a pharmaceutically acceptable salt thereof, as defined above.
- the PARP inhibitor is AZD9574 or a pharmaceutically acceptable salt thereof, as defined above.
- PARP inhibitor also includes reference to their pharmaceutically acceptable salts.
- PARP inhibitor is synonymous with “PARP inhibitor or a pharmaceutically acceptable salt thereof”.
- the PARP inhibitor is niraparib or a pharmaceutically acceptable salt thereof, in particular niraparib tosylate monohydrate.
- Reference to niraparib is intended to include all versions of niraparib, for example salts including pharmaceutically acceptable salts, polymorphs and solvates, including the tosylate monohydrate.
- the PARP inhibitor is olaparib or a pharmaceutically acceptable salt thereof.
- Reference to olaparib is intended to include all versions of olaparib, for example salts including pharmaceutically acceptable salts, polymorphs and solvates.
- the PARP inhibitor is rucaparib or a pharmaceutically acceptable salt thereof, in particular rucaparib camsylate.
- rucaparib is intended to include all versions of rucaparib, for example salts including pharmaceutically acceptable salts, polymorphs and solvates.
- the PARP inhibitor is talazoparib or a pharmaceutically acceptable salt thereof, in particular talazoparib tosylate.
- Reference to talozaparib is intended to include all versions of talazoparib, for example salts including pharmaceutically acceptable salts, polymorphs and solvates.
- a combination product comprising Compound A or a pharmaceutically acceptable salt thereof, and Compounds B, C, D, E, or F or a pharmaceutically acceptable salt thereof.
- a combination product comprising Compound A1 or a pharmaceutically acceptable salt thereof, and Compounds B, C, D, E, or F or a pharmaceutically acceptable salt thereof.
- the combination product comprises Compound A or Compound A1 or a pharmaceutically acceptable salt thereof, and AZD5305 or AZD9574 or a pharmaceutically acceptable salt thereof.
- the combination product comprises Compound A or a pharmaceutically acceptable salt thereof, and AZD5305 or a pharmaceutically acceptable salt thereof.
- the combination product comprises Compound A or a pharmaceutically acceptable salt thereof, and AZD9574 or a pharmaceutically acceptable salt thereof.
- a pharmaceutical combination may result in a beneficial effect, e.g. a synergistic therapeutic effect, e.g., with regard to alleviating, delaying progression of or inhibiting the symptoms, and may also result in further surprising beneficial effects, e.g., fewer side-effects, an improved quality of life or a decreased morbidity, compared with a monotherapy applying only one of the pharmaceutically active ingredients used in the combination of the invention.
- a beneficial effect e.g. a synergistic therapeutic effect, e.g., with regard to alleviating, delaying progression of or inhibiting the symptoms
- further surprising beneficial effects e.g., fewer side-effects, an improved quality of life or a decreased morbidity
- provided herein is a method of treating cancer in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a MAT2A inhibitor and administering to the subject a therapeutically effective amount of a PARP inhibitor, thereby treating the cancer in the subject.
- methods of treating cancer in a subject in need thereof the methods comprising administering to the subject a combination comprising a MAT2A inhibitor and a PARP inhibitor, together with at least a pharmaceutically acceptable carrier, thereby treating the cancer in the subject.
- the cancer is characterized by a reduction or absence of methylthioadenosine phosphorylase (MTAP) gene expression, absence of MTAP gene, reduced function of MTAP protein, reduced level or absence of MTAP protein, MTA accumulation, or combination thereof.
- MTAP methylthioadenosine phosphorylase
- provided herein are methods of treating cancer in a subject in need thereof, the methods comprising administering to the subject a therapeutically effective amount of a pharmaceutical composition comprising a MAT2A inhibitor and a therapeutically effective amount of a pharmaceutical composition comprising a PARP inhibitor, thereby treating the cancer in the subject.
- a combination of a MAT2A inhibitor and a PARP inhibitor for the manufacture of a medicament.
- the MAT2A inhibitor is Compound A.
- the MAT2A inhibitor is Compound A1.
- provided is a combination of Compound A and Compound B for the manufacture of a medicament.
- provided is a combination of Compound A and Compound C for the manufacture of a medicament.
- provided is a combination of Compound A and Compound D for manufacture of a medicament.
- provided is a combination of Compound A and Compound E for manufacture of a medicament.
- provided is a combination of Compound A and Compound F for manufacture of a medicament.
- a combination of a MAT2A inhibitor and a PARP inhibitor for the treatment of cancer.
- the MAT2A inhibitor is a compound of Formula I.
- the MAT2A inhibitor is Compound A.
- the MAT2A inhibitor is Compound A1.
- provided is a combination of Compound A and Compound B for the treatment of cancer.
- provided is a combination of Compound A and Compound C for the treatment of cancer.
- provided is a combination of Compound A and Compound D for the the treatment of cancer.
- the provided is a combination of Compound A or Compound A1 or a pharmaceutically acceptable salt thereof, and AZD5305 or AZD9574 or a pharmaceutically acceptable salt thereof for the treatment of cancer.
- the provided is a combination of Compound A or a pharmaceutically acceptable salt thereof, and AZD5305 or a pharmaceutically acceptable salt thereof for the treatment of cancer. In further embodiments, the provided is a combination of Compound A or a pharmaceutically acceptable salt thereof, and AZD9574 or a pharmaceutically acceptable salt thereof for the treatment of cancer.
- the MAT2A inhibitor is a compound of Formula I: or a pharmaceutically acceptable salt thereof; wherein the variables are defined supra.
- the MAT2A inhibitor is selected from the group consisting of a compound from Table 1 , or a pharmaceutically acceptable salt thereof.
- the MAT2A inhibitor is Compound A or a pharmaceutically acceptable salt thereof.
- the MAT2A inhibitor is Compound A1 or a pharmaceutically acceptable salt thereof.
- the PARP inhibitor is selected from the group consisting of the compounds in Table 2, or a pharmaceutically acceptable salt or hydrate thereof.
- the PARP inhibitor is Compound B or a pharmaceutically acceptable salt thereof.
- the PARP inhibitor is Compound C or a pharmaceutically acceptable salt thereof.
- the PARP inhibitor is Compound D or a pharmaceutically acceptable salt thereof.
- the PARP inhibitor is Compound E or a pharmaceutically acceptable salt thereof.
- the PARP inhibitor is Compound F or a pharmaceutically acceptable salt thereof.
- the PARP inhibitor is AZD5305 or a pharmaceutically acceptable salt thereof.
- the PARP inhibitor is AZD9574 or a pharmaceutically acceptable salt thereof.
- provided herein is a method of treating cancer in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of Compound A or a pharmaceutically acceptable salt thereof; and administering to the subject a therapeutically effective amount of Compound B or a pharmaceutically acceptable salt thereof.
- provided herein is a method of treating cancer in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of Compound A or a pharmaceutically acceptable salt thereof; and administering to the subject a therapeutically effective amount of Compound C or a pharmaceutically acceptable salt thereof.
- provided herein is a method of treating cancer in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of Compound A or a pharmaceutically acceptable salt thereof; and administering to the subject a therapeutically effective amount of Compound D or a pharmaceutically acceptable salt thereof.
- provided herein is a method of treating cancer in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of Compound A or a pharmaceutically acceptable salt thereof; and administering to the subject a therapeutically effective amount of Compound E or a pharmaceutically acceptable salt thereof.
- a method of treating cancer in a subject in need thereof the method comprising administering to the subject a therapeutically effective amount of Compound A or a pharmaceutically acceptable salt thereof; and administering to the subject a therapeutically effective amount of Compound F or a pharmaceutically acceptable salt thereof.
- a method of treating cancer in a subject in need thereof comprising administering to the subject a therapeutically effective amount of Compound A1 or a pharmaceutically acceptable salt thereof; and administering to the subject a therapeutically effective amount of Compound B, Compound C, Compound D, Compound E, or Compound F, or a pharmaceutically acceptable salt thereof.
- a method of treating cancer in a subject in need thereof comprising administering to the subject a therapeutically effective amount of Compound A or a pharmaceutically acceptable salt thereof; and administering to the subject a therapeutically effective amount of AZD5305 or AZD9574, or a pharmaceutically acceptable salt thereof.
- a product containing a MAT2A inhibitor and a PARP inhibitor as a combination product for simultaneous, separate, or sequential use in medicine.
- the MAT2A inhibitor is a compound of Formula I.
- the MAT2A inhibitor is Compound A.
- the MAT2A inhibitor is Compound A1.
- provided is a product containing Compound A and Compound B as a combination product for simultaneous, separate, or sequential use in medicine.
- provided is a product containing Compound A and Compound C as a combination product for simultaneous, separate, or sequential use in medicine.
- a product containing Compound A and Compound D as a combination product for simultaneous, separate, or sequential use in medicine.
- a product containing a MAT2A inhibitor and a PARP inhibitor as a combination product for simultaneous, separate, or sequential use in treating cancer in a subject.
- the MAT2A inhibitor is a compound of Formula I.
- the MAT2A inhibitor is Compound A.
- the MAT2A inhibitor is Compound A1.
- provided is a product containing Compound A and Compound B as a combination product for simultaneous, separate, or sequential use in treating cancer in a subject.
- a product containing Compound A and Compound C as a combination product for simultaneous, separate, or sequential use in treating cancer in a subject.
- a product containing Compound A and AZD5305 or AZD9574 as a combination product for simultaneous, separate, or sequential treating cancer in a subject.
- the cancer is selected from the group consisting of leukemia, glioma, melanoma, pancreatic, non-small cell lung cancer, bladder cancer, astrocytoma, osteosarcoma, head and neck cancer, myxoid chondrosarcoma, ovarian cancer, endometrial cancer, breast cancer, soft tissue sarcoma, non-Hodgkin lymphoma, gastric cancer, esophagogastric cancer, esophageal cancer, malignant peripheral nerve sheath tumor, and mesothelioma.
- the cancer is mesothelioma. In an embodiment, the cancer is non-small cell lung cancer. In another embodiment, the cancer is nonsquamous non-small cell lung cancer. In one embodiment, the cancer is cancer of the colon or rectum. In an embodiment, the cancer is adenocarcinoma of the colon or rectum. In an embodiment, the cancer is breast cancer. In an embodiment, the cancer is adenocarcinoma of the breast. In an embodiment, the cancer is gastric cancer. In an embodiment, the cancer is gastric adenocarcinoma. In an embodiment, the cancer is pancreatic cancer. In an embodiment, the cancer is pancreatic adenocarcinoma. In an embodiment, the cancer is bladder cancer.
- the cancer is characterized as being MTAP-null. In an embodiment, the cancer is characterized as being MTAP-deficient.
- the cancer is a solid tumor. In still another embodiment, the cancer is a MTAP-deleted solid tumor, n still another embodiment, the cancer is a metastatic MTAP-deleted solid tumor.
- the cancer is metastatic.
- the cancer is a solid malignant tumor.
- the cancer is MTAP-deficient lung or MTAP- deficient pancreatic cancer, including MTAP-deficient NSCLC or MTAP-deficient pancreatic ductal adenocarcinoma (PDAC) or MTAP-deficient esophageal cancer.
- MTAP-deficient lung or MTAP- deficient pancreatic cancer including MTAP-deficient NSCLC or MTAP-deficient pancreatic ductal adenocarcinoma (PDAC) or MTAP-deficient esophageal cancer.
- PDAC pancreatic ductal adenocarcinoma
- the cancer is a tumor having an MTAP gene deletion.
- the cancer is a solid tumor or a haematological cancer.
- the tumor is deficient in MTAP.
- the tumor is normal in its expression of MTAP.
- the cancer is NSCLC, mesothelioma, squamous carcinoma of the head and neck, salivary gland tumors, urothelial cancers, sarcomas, or ovarian cancer.
- the cancer is NSCLC, esophagogastric cancer, or pancreatic cancers.
- the cancer is characterized by a reduction or absence of MTAP gene expression, absence of MTAP gene, reduced function of MTAP protein, reduced level or absence of MTAP protein, MTA accumulation, or combination thereof.
- the cancer is characterized by a reduction or absence of MTAP gene expression.
- the cancer is characterized by reduced function of MTAP protein.
- the cancer is characterized by reduced level or absence of MTAP protein.
- the cancer is characterized by MTA accumulation.
- the MAT2A inhibitor and the PARP inhibitor are in separate dosage forms.
- the MAT2A inhibitor and the PARP inhibitor are in the same dosage form.
- the treatment comprises administering the MAT2A inhibitor, or a pharmaceutically acceptable salt thereof, and the PARP inhibitor, or a pharmaceutically acceptable salt thereof, at substantially the same time. In yet another embodiment, the treatment comprises administering the MAT2A inhibitor, or a pharmaceutically acceptable salt thereof, and the PARP inhibitor, or a pharmaceutically acceptable salt thereof, at different times.
- the MAT2A inhibitor, or a pharmaceutically acceptable salt thereof is administered to the subject, followed by administration of the PARP inhibitor, or a pharmaceutically acceptable salt thereof.
- the PARP inhibitor, or a pharmaceutically acceptable salt thereof is administered to the subject, followed by administration of MAT2A inhibitor, or a pharmaceutically acceptable salt thereof.
- the MAT2A inhibitor, or a pharmaceutically acceptable salt thereof, and the PARP inhibitor, or a pharmaceutically acceptable salt thereof are administered orally.
- the cancer to be treated is selected from the group consisting of lung cancer, colon and rectal cancer, breast cancer, prostate cancer, liver cancer, pancreatic cancer, brain cancer, kidney cancer, ovarian cancer, stomach cancer, skin cancer, bone cancer, gastric cancer, glioma, glioblastoma, neuroblastoma, hepatocellular carcinoma, papillary renal carcinoma, head and neck squamous cell carcinoma, leukemia, lymphomas, myelomas, retinoblastoma, cervical cancer, melanoma and/or skin cancer, bladder cancer, uterine cancer, testicular cancer, esophageal cancer, thymic cancer, adenoid cystic carcinoma, gastroesophageal cancer, malignant peripheral nerve sheath tumor (MPNST), and cholangiocarcinoma.
- MPNST peripheral nerve sheath tumor
- the cancer is lung cancer, colon cancer, breast cancer, neuroblastoma, leukemia, and lymphomas. In other embodiments, the cancer is lung cancer, colon cancer, breast cancer, neuroblastoma, leukemia, or lymphoma. In a further embodiment, the cancer is non-small cell lung cancer (NSCLC) or small cell lung cancer. In yet another embodiment, the cancer is selected from the group consisting of NSCLC, pancreatic cancer, malignant peripheral nerve sheath tumor (MPNST), and esophagogastric cancer. In yet another embodiment, the cancer is selected from the group consisting of NSCLC and pancreatic cancer. In yet another embodiment, the cancer is NSCLC. In yet another embodiment, the cancer is pancreatic cancer.
- the cancer is a hematologic cancer, such as leukemia or lymphoma.
- lymphoma is Hodgkin’s lymphoma or Non-Hodgkin’s lymphoma.
- leukemia is myeloid, lymphocytic, myelocytic, lymphoblastic, or megakaryotic leukemia.
- a MAT2A inhibitor or a pharmaceutically acceptable salt thereof, and a PARP inhibitor, or a pharmaceutically acceptable salt thereof, for use in therapy.
- the MAT2A inhibitor, or a pharmaceutically acceptable salt thereof, and the PARP inhibitor, or a pharmaceutically acceptable salt thereof are for use in the treatment of cancer in a subject in need thereof.
- the method involves the administration of a therapeutically effective amount of a combination or composition comprising compounds provided herein, or pharmaceutically acceptable salts thereof, to a subject (including, but not limited to a human or animal) in need of treatment (including a subject identified as in need).
- the treatment includes co-administering the amount of the MAT2A inhibitor, or a pharmaceutically acceptable salt thereof, and the amount of the PARP inhibitor, or a pharmaceutically acceptable salt thereof.
- the amount of the MAT2A inhibitor or a pharmaceutically acceptable salt thereof and the amount of PARP inhibitor or a pharmaceutically acceptable salt thereof are in a single formulation or unit dosage form.
- the amount of MAT2A inhibitor or a pharmaceutically acceptable salt thereof and the amount of PARP inhibitor or a pharmaceutically acceptable salt thereof are in a separate formulations or unit dosage forms.
- the treatment can include administering the amount of MAT2A inhibitor or a pharmaceutically acceptable salt thereof and the amount of a PARP inhibitor or a pharmaceutically acceptable salt thereof at substantially the same time or administering the amount of MAT2A inhibitor or a pharmaceutically acceptable salt thereof and the amount of a PARP or a pharmaceutically acceptable salt thereof at different times.
- the amount of MAT2A inhibitor or a pharmaceutically acceptable salt thereof and/or the amount of PARP inhibitor or a pharmaceutically acceptable salt thereof is administered at dosages that would not be effective when either of MAT2A inhibitor or a pharmaceutically acceptable salt thereof, or PARP inhibitor or a pharmaceutically acceptable salt thereof is administered alone, but which amounts are effective in combination.
- the treatment includes co-administering the amount of Compound A, or a pharmaceutically acceptable salt thereof, and the amount of Compound B, or a pharmaceutically acceptable salt thereof.
- the amount of Compound A or a pharmaceutically acceptable salt thereof and the amount of Compound B or a pharmaceutically acceptable salt thereof are in a single formulation or unit dosage form.
- the amount of Compound A or a pharmaceutically acceptable salt thereof and the amount of Compound B or a pharmaceutically acceptable salt thereof are in a separate formulations or unit dosage forms.
- the treatment includes co-administering the amount of Compound A, or a pharmaceutically acceptable salt thereof, and the amount of Compound C, or a pharmaceutically acceptable salt thereof.
- the amount of Compound A or a pharmaceutically acceptable salt thereof and the amount of Compound C or a pharmaceutically acceptable salt thereof are in a single formulation or unit dosage form.
- the amount of Compound A or a pharmaceutically acceptable salt thereof and the amount of Compound C or a pharmaceutically acceptable salt thereof are in a separate formulations or unit dosage forms.
- the treatment includes co-administering the amount of Compound A, or a pharmaceutically acceptable salt thereof, and the amount of Compound D, or a pharmaceutically acceptable salt thereof.
- the amount of Compound A or a pharmaceutically acceptable salt thereof and the amount of Compound D or a pharmaceutically acceptable salt thereof are in a single formulation or unit dosage form.
- the amount of Compound A or a pharmaceutically acceptable salt thereof and the amount of Compound D or a pharmaceutically acceptable salt thereof are in a separate formulations or unit dosage forms.
- the treatment includes co-administering the amount of Compound A, or a pharmaceutically acceptable salt thereof, and the amount of Compound E, or a pharmaceutically acceptable salt thereof.
- the amount of Compound A or a pharmaceutically acceptable salt thereof and the amount of Compound E or a pharmaceutically acceptable salt thereof are in a single formulation or unit dosage form.
- the amount of Compound A or a pharmaceutically acceptable salt thereof and the amount of Compound E or a pharmaceutically acceptable salt thereof are in a separate formulations or unit dosage forms.
- the treatment includes co-administering the amount of Compound A, or a pharmaceutically acceptable salt thereof, and the amount of Compound F, or a pharmaceutically acceptable salt thereof.
- the amount of Compound A or a pharmaceutically acceptable salt thereof and the amount of Compound F or a pharmaceutically acceptable salt thereof are in a single formulation or unit dosage form.
- the amount of Compound A or a pharmaceutically acceptable salt thereof and the amount of Compound F or a pharmaceutically acceptable salt thereof are in a separate formulations or unit dosage forms.
- the treatment includes co-administering the amount of Compound A, or a pharmaceutically acceptable salt thereof, and the amount of AZD5305 or AZD9574, or a pharmaceutically acceptable salt thereof.
- the amount of Compound A or a pharmaceutically acceptable salt thereof and the amount of AZD5305 or AZD9574 or a pharmaceutically acceptable salt thereof are in a single formulation or unit dosage form.
- the amount of Compound A or a pharmaceutically acceptable salt thereof and the amount of AZD5305 or AZD9574 or a pharmaceutically acceptable salt thereof are in a separate formulations or unit dosage forms.
- the treatment can include administering the amount of Compound A or a pharmaceutically acceptable salt thereof and the amount of Compound B or a pharmaceutically acceptable salt thereof at substantially the same time or administering the amount of Compound A or a pharmaceutically acceptable salt thereof and the amount of Compound B or a pharmaceutically acceptable salt thereof at different times.
- the amount of Compound A or a pharmaceutically acceptable salt thereof and/or the amount of Compound B or a pharmaceutically acceptable salt thereof is administered at dosages that would not be effective when one or both of Compound A or a pharmaceutically acceptable salt thereof and Compound B or a pharmaceutically acceptable salt thereof is administered alone, but which amounts are effective in combination.
- the treatment can include administering the amount of Compound A or a pharmaceutically acceptable salt thereof and the amount of Compound C or a pharmaceutically acceptable salt thereof at substantially the same time or administering the amount of Compound A or a pharmaceutically acceptable salt thereof and the amount of Compound C or a pharmaceutically acceptable salt thereof at different times.
- the amount of Compound A or a pharmaceutically acceptable salt thereof and/or the amount of Compound C or a pharmaceutically acceptable salt thereof is administered at dosages that would not be effective when one or both of Compound A or a pharmaceutically acceptable salt thereof and Compound C or a pharmaceutically acceptable salt thereof is administered alone, but which amounts are effective in combination.
- the treatment can include administering the amount of Compound A or a pharmaceutically acceptable salt thereof and the amount of Compound D or a pharmaceutically acceptable salt thereof at substantially the same time or administering the amount of Compound A or a pharmaceutically acceptable salt thereof and the amount of Compound D or a pharmaceutically acceptable salt thereof at different times.
- the amount of Compound A or a pharmaceutically acceptable salt thereof and/or the amount of Compound D or a pharmaceutically acceptable salt thereof is administered at dosages that would not be effective when one or both of Compound A or a pharmaceutically acceptable salt thereof and Compound D or a pharmaceutically acceptable salt thereof is administered alone, but which amounts are effective in combination.
- the treatment can include administering the amount of Compound A or a pharmaceutically acceptable salt thereof and the amount of Compound E or a pharmaceutically acceptable salt thereof at substantially the same time or administering the amount of Compound A or a pharmaceutically acceptable salt thereof and the amount of Compound E or a pharmaceutically acceptable salt thereof at different times.
- the amount of Compound A or a pharmaceutically acceptable salt thereof and/or the amount of Compound E or a pharmaceutically acceptable salt thereof is administered at dosages that would not be effective when one or both of Compound A or a pharmaceutically acceptable salt thereof and Compound E or a pharmaceutically acceptable salt thereof is administered alone, but which amounts are effective in combination.
- the treatment can include administering the amount of Compound A or a pharmaceutically acceptable salt thereof and the amount of Compound F or a pharmaceutically acceptable salt thereof at substantially the same time or administering the amount of Compound A or a pharmaceutically acceptable salt thereof and the amount of Compound F or a pharmaceutically acceptable salt thereof at different times.
- the amount of Compound A or a pharmaceutically acceptable salt thereof and/or the amount of Compound F or a pharmaceutically acceptable salt thereof is administered at dosages that would not be effective when one or both of Compound A or a pharmaceutically acceptable salt thereof and Compound F or a pharmaceutically acceptable salt thereof is administered alone, but which amounts are effective in combination.
- the treatment can include administering the amount of Compound A or a pharmaceutically acceptable salt thereof and the amount of AZD5305 or AZD9574 or a pharmaceutically acceptable salt thereof at substantially the same time or administering the amount of Compound A or a pharmaceutically acceptable salt thereof and the amount of AZD5305 or AZD9574 or a pharmaceutically acceptable salt thereof at different times.
- the amount of Compound A or a pharmaceutically acceptable salt thereof and/or the amount of AZD5305 or AZD9574 or a pharmaceutically acceptable salt thereof is administered at dosages that would not be effective when one or both of Compound A or a pharmaceutically acceptable salt thereof and AZD5305 or AZD9574 or a pharmaceutically acceptable salt thereof is administered alone, but which amounts are effective in combination.
- the present disclosure includes:
- a method of treating cancer in a subject in need thereof comprising administering to the subject a therapeutically effective amount of a methionine adenosyltransferase II alpha (MAT2A) inhibitor and administering to the subject a therapeutically effective amount of a Poly (ADP-Ribose) Polymerase (PARP) inhibitor.
- MAT2A methionine adenosyltransferase II alpha
- PARP Poly (ADP-Ribose) Polymerase
- a method of treating cancer in a subject in need thereof comprising administering to the subject a therapeutically effective amount of a MAT2A inhibitor and administering to the subject a therapeutically effective amount of a PARP inhibitor, wherein the MAT2A inhibitor is a compound of Formula I: or a pharmaceutically acceptable salt thereof; wherein
- X is CH or N
- R 3 is halo, C1-6 haloalkyl or C3-6 cycloalkyl
- R 2 is -NR 4 R 5 ;
- R 4 is hydrogen or C1-6 alkyl
- R 5 is hydrogen, C1-6 alkyl or C3-6 cycloalkyl
- R 1 is phenyl, wherein phenyl is substituted with 0-2 halo.
- R 4 is hydrogen and R 5 is hydrogen or C1-3 alkyl.
- MAT2A inhibitor is selected from the group consisting of a compound from Table 1 , or a pharmaceutically acceptable salt thereof.
- the MAT2A inhibitor is Compound A or a pharmaceutically acceptable salt thereof.
- MAT2A inhibitor is Compound A1 or a pharmaceutically acceptable salt thereof.
- a method of treating cancer in a subject in need thereof comprising administering to the subject a therapeutically effective amount of Compound A or a pharmaceutically acceptable salt thereof, and administering to the subject a therapeutically effective amount of Compound B, or a pharmaceutically acceptable salt thereof.
- the cancer is selected from the group consisting of leukemia, glioma, melanoma, pancreatic, non-small cell lung cancer, bladder cancer, astrocytoma, osteosarcoma, head and neck cancer, myxoid chondrosarcoma, ovarian cancer, endometrial cancer, breast cancer, soft tissue sarcoma, non-Hodgkin lymphoma, esophagogastric cancer, malignant peripheral nerve sheath tumor, and mesothelioma. 22. In embodiment 22, provided is the method of any one of claims 1-21 , wherein the cancer is a solid tumor.
- a combination product comprising a MAT2A inhibitor, or a pharmaceutically acceptable salt thereof, and a PARP inhibitor, or a pharmaceutically acceptable salt thereof.
- the MAT2A inhibitor of embodiment 26 is a compound of Formula (I), or a pharmaceutically acceptable salt thereof.
- the MAT2A inhibitor of embodiment 26 is a compound of Formula (I), or a pharmaceutically acceptable salt thereof as defined in any one of embodiments 2 to 10.
- the MAT2A inhibitor of any one of embodiments 26 to 28 is selected from the group consisting of the compounds in Table 1 , or a pharmaceutically acceptable salt thereof.
- the MAT2A inhibitor of any one of embodiments 26 to 29 is Compound A or a pharmaceutically acceptable salt thereof.
- the MAT2A inhibitor of any one of embodiments 26 to 29 is Compound A1 or a pharmaceutically acceptable salt thereof.
- the PARP inhibitor of any one of embodiments 26 to 31 is selected from the group consisting of the compounds in Table 2, AZD5305, and AZD9574, or a pharmaceutically acceptable salt thereof.
- the PARP inhibitor of any of embodiments 26 to 32 is Compound B or a pharmaceutically acceptable salt thereof.
- the PARP inhibitor of any of embodiments 26 to 32 is Compound C or a pharmaceutically acceptable salt thereof.
- the PARP inhibitor of any of embodiments 26 to 32 is Compound D or a pharmaceutically acceptable salt thereof.
- the PARP inhibitor of any of embodiments 26 to 32 is Compound E or a pharmaceutically acceptable salt thereof.
- the PARP inhibitor of any of embodiments 26 to 32 is Compound F or a pharmaceutically acceptable salt thereof.
- the PARP inhibitor of any of embodiments 26 to 32 is AZD5305, AZD9574, or a pharmaceutically acceptable salt thereof.
- a combination product comprising a first pharmaceutical composition comprising a therapeutically effective amount of a MAT2A inhibitor and a second pharmaceutical composition comprising a therapeutically effective amount of a PARP inhibitor.
- the MAT2A inhibitor of embodiment 39 is a compound of Formula (I), or a pharmaceutically acceptable salt thereof.
- the MAT2A inhibitor of embodiment 40 is a compound of Formula (I), or a pharmaceutically acceptable salt thereof as defined in any one of embodiments 2 to 10.
- the MAT2A inhibitor of any one of embodiments 39 to 41 is selected from the group consisting of the compounds in Table 1 , or a pharmaceutically acceptable salt thereof.
- the PARP inhibitor of any of embodiments 39 to 42 is selected from the group consisting of the compounds in Table 2, AZD5305, AZD9574, or a pharmaceutically acceptable salt thereof.
- a combination product comprising a first pharmaceutical composition comprising a therapeutically effective amount of Compound A or a pharmaceutically acceptable salt thereof, and a second pharmaceutical composition comprising a therapeutically effective amount of Compound B or a pharmaceutically acceptable salt thereof.
- a combination product comprising a first pharmaceutical composition comprising a therapeutically effective amount of Compound A or a pharmaceutically acceptable salt thereof, and a second pharmaceutical composition comprising a therapeutically effective amount of Compound C or a pharmaceutically acceptable salt thereof.
- a combination product comprising a first pharmaceutical composition comprising a therapeutically effective amount of Compound A or a pharmaceutically acceptable salt thereof, and a second pharmaceutical composition comprising a therapeutically effective amount of Compound D or a pharmaceutically acceptable salt thereof.
- a combination product comprising a first pharmaceutical composition comprising a therapeutically effective amount of Compound A or a pharmaceutically acceptable salt thereof, and a second pharmaceutical composition comprising a therapeutically effective amount of Compound E or a pharmaceutically acceptable salt thereof.
- a combination product comprising a first pharmaceutical composition comprising a therapeutically effective amount of Compound A or a pharmaceutically acceptable salt thereof, and a second pharmaceutical composition comprising a therapeutically effective amount of Compound F or a pharmaceutically acceptable salt thereof.
- a combination product comprising a first pharmaceutical composition comprising a therapeutically effective amount of Compound A or a pharmaceutically acceptable salt thereof, and a second pharmaceutical composition comprising a therapeutically effective amount of AZD5305, AZD9574, or a pharmaceutically acceptable salt thereof.
- a combination product comprising a first pharmaceutical composition comprising a therapeutically effective amount of Compound A1 or a pharmaceutically acceptable salt thereof, and a second pharmaceutical composition comprising a therapeutically effective amount of Compound B or a pharmaceutically acceptable salt thereof.
- a combination product comprising a first pharmaceutical composition comprising a therapeutically effective amount of Compound A1 or a pharmaceutically acceptable salt thereof, and a second pharmaceutical composition comprising a therapeutically effective amount of Compound C or a pharmaceutically acceptable salt thereof.
- a combination product comprising a first pharmaceutical composition comprising a therapeutically effective amount of Compound A1 or a pharmaceutically acceptable salt thereof, and a second pharmaceutical composition comprising a therapeutically effective amount of Compound D or a pharmaceutically acceptable salt thereof.
- a combination product comprising a first pharmaceutical composition comprising a therapeutically effective amount of Compound A1 or a pharmaceutically acceptable salt thereof, and a second pharmaceutical composition comprising a therapeutically effective amount of Compound E or a pharmaceutically acceptable salt thereof.
- a combination product comprising a first pharmaceutical composition comprising a therapeutically effective amount of Compound A1 or a pharmaceutically acceptable salt thereof, and a second pharmaceutical composition comprising a therapeutically effective amount of Compound F or a pharmaceutically acceptable salt thereof.
- a combination product comprising a first pharmaceutical composition comprising a therapeutically effective amount of Compound A1 or a pharmaceutically acceptable salt thereof, and a second pharmaceutical composition comprising a therapeutically effective amount of AZD5305, AZD9574, or a pharmaceutically acceptable salt thereof.
- a MAT2A inhibitor for use in treating cancer, wherein the MAT2A inhibitor is to be administered simultaneously or sequentially with a PARP inhibitor.
- the MAT2A inhibitor of embodiment 56 is a compound of Formula (I), or a pharmaceutically acceptable salt thereof.
- the MAT2A inhibitor of embodiment 57 is a compound of Formula (I), or a pharmaceutically acceptable salt thereof as defined in any one of embodiments 2 to 10.
- the MAT2A inhibitor of any one of embodiments 56 to 58 is selected from the group consisting of the compounds in Table 1 , or a pharmaceutically acceptable salt thereof.
- the PARP inhibitor of any of embodiments 56 to 59 is selected from the group consisting of the compounds in Table 2, AZD5305, AZD9574, or a pharmaceutically acceptable salt thereof.
- a MAT2A inhibitor for use in treating cancer wherein the MAT2A inhibitor is to be administered simultaneously or sequentially with a PARP inhibitor; wherein the MAT2A inhibitor is Compound A or a pharmaceutically acceptable salt thereof; and the PARP inhibitor is Compound B or a pharmaceutically acceptable salt thereof.
- a MAT2A inhibitor for use in treating cancer, wherein the MAT2A inhibitor is to be administered simultaneously or sequentially with a PARP inhibitor; wherein the MAT2A inhibitor is Compound A or a pharmaceutically acceptable salt thereof; and the PARP inhibitor is Compound C or a pharmaceutically acceptable salt thereof.
- a MAT2A inhibitor for use in treating cancer wherein the MAT2A inhibitor is to be administered simultaneously or sequentially with a PARP inhibitor; wherein the MAT2A inhibitor is Compound A or a pharmaceutically acceptable salt thereof; and the PARP inhibitor is Compound D or a pharmaceutically acceptable salt thereof.
- a MAT2A inhibitor for use in treating cancer, wherein the MAT2A inhibitor is to be administered simultaneously or sequentially with a PARP inhibitor; wherein the MAT2A inhibitor is Compound A or a pharmaceutically acceptable salt thereof; and the PARP inhibitor is Compound E or a pharmaceutically acceptable salt thereof.
- a MAT2A inhibitor for use in treating cancer, wherein the MAT2A inhibitor is to be administered simultaneously or sequentially with a PARP inhibitor; wherein the MAT2A inhibitor is Compound A or a pharmaceutically acceptable salt thereof; and the PARP inhibitor is Compound F or a pharmaceutically acceptable salt thereof.
- a MAT2A inhibitor for use in treating cancer, wherein the MAT2A inhibitor is to be administered simultaneously or sequentially with a PARP inhibitor; wherein the MAT2A inhibitor is Compound A or a pharmaceutically acceptable salt thereof; and the PARP inhibitor is AZD5305, AXD9574, or a pharmaceutically acceptable salt thereof.
- a MAT2A inhibitor for use in treating cancer wherein the MAT2A inhibitor is to be administered simultaneously or sequentially with a PARP inhibitor; wherein the MAT2A inhibitor is Compound A1 or a pharmaceutically acceptable salt thereof; and the PARP inhibitor is Compound B or a pharmaceutically acceptable salt thereof.
- a MAT2A inhibitor for use in treating cancer, wherein the MAT2A inhibitor is to be administered simultaneously or sequentially with a PARP inhibitor; wherein the MAT2A inhibitor is Compound A1or a pharmaceutically acceptable salt thereof; and the PARP inhibitor Compound C or a pharmaceutically acceptable salt thereof.
- a MAT2A inhibitor for use in treating cancer wherein the MAT2A inhibitor is to be administered simultaneously or sequentially with a PARP inhibitor; wherein the MAT2A inhibitor is Compound A1 or a pharmaceutically acceptable salt thereof; and the PARP inhibitor is Compound D or a pharmaceutically acceptable salt thereof.
- a MAT2A inhibitor for use in treating cancer wherein the MAT2A inhibitor is to be administered simultaneously or sequentially with a PARP inhibitor; wherein the MAT2A inhibitor is Compound A1 or a pharmaceutically acceptable salt thereof; and the PARP inhibitor is Compound E or a pharmaceutically acceptable salt thereof.
- a MAT2A inhibitor for use in treating cancer wherein the MAT2A inhibitor is to be administered simultaneously or sequentially with a PARP inhibitor; wherein the MAT2A inhibitor is Compound A1 or a pharmaceutically acceptable salt thereof; and the PARP inhibitor is Compound F or a pharmaceutically acceptable salt thereof.
- a MAT2A inhibitor for use in treating cancer wherein the MAT2A inhibitor is to be administered simultaneously or sequentially with a PARP inhibitor; wherein the MAT2A inhibitor is Compound A1 or a pharmaceutically acceptable salt thereof; and the PARP inhibitor is AZD5305, AXD9574, or a pharmaceutically acceptable salt thereof.
- a MAT2A inhibitor in the manufacture of a medicament for treating cancer, wherein the MAT2A inhibitor is to be administered simultaneously or sequentially with a PARP inhibitor.
- the MAT2A inhibitor of embodiment 73 is a compound of Formula (I), or a pharmaceutically acceptable salt thereof.
- the MAT2A inhibitor of embodiment 74 is a compound of Formula (I), or a pharmaceutically acceptable salt thereof as defined in any one of embodiments 2 to 10.
- the MAT2A inhibitor of any one of embodiments 73 to 75 is selected from the group consisting of the compounds in Table 1 , or a pharmaceutically acceptable salt thereof.
- the PARP inhibitor of any of embodiments 73 to 76 is selected from the group consisting of the compounds in Table 2, or a pharmaceutically acceptable salt thereof.
- a MAT2A inhibitor in the manufacture of a medicament for treating cancer, wherein the MAT2A inhibitor is to be administered simultaneously or sequentially with a PARP inhibitor; wherein the MAT2A inhibitor is Compound A or a pharmaceutically acceptable salt thereof; and the PARP inhibitor is Compound B or a pharmaceutically acceptable salt thereof.
- a MAT2A inhibitor in the manufacture of a medicament for treating cancer, wherein the MAT2A inhibitor is to be administered simultaneously or sequentially with a PARP inhibitor; wherein the MAT2A inhibitor is Compound A or a pharmaceutically acceptable salt thereof; and the PARP inhibitor is Compound C or a pharmaceutically acceptable salt thereof.
- a MAT2A inhibitor in the manufacture of a medicament for treating cancer, wherein the MAT2A inhibitor is to be administered simultaneously or sequentially with a PARP inhibitor; wherein the MAT2A inhibitor is Compound A or a pharmaceutically acceptable salt thereof; and the PARP inhibitor is Compound D or a pharmaceutically acceptable salt thereof.
- a MAT2A inhibitor in the manufacture of a medicament for treating cancer, wherein the MAT2A inhibitor is to be administered simultaneously or sequentially with a PARP inhibitor; wherein the MAT2A inhibitor is Compound A or a pharmaceutically acceptable salt thereof; and the PARP inhibitor is Compound E or a pharmaceutically acceptable salt thereof.
- a MAT2A inhibitor in the manufacture of a medicament for treating cancer, wherein the MAT2A inhibitor is to be administered simultaneously or sequentially with a PARP inhibitor; wherein the MAT2A inhibitor is Compound A or a pharmaceutically acceptable salt thereof; and the PARP inhibitor is Compound F or a pharmaceutically acceptable salt thereof.
- a MAT2A inhibitor in the manufacture of a medicament for treating cancer, wherein the MAT2A inhibitor is to be administered simultaneously or sequentially with a PARP inhibitor; wherein the MAT2A inhibitor is Compound A or a pharmaceutically acceptable salt thereof; and the PARP inhibitor is AZD5305, AZD9574, or a pharmaceutically acceptable salt thereof.
- a MAT2A inhibitor in the manufacture of a medicament for treating cancer, wherein the MAT2A inhibitor is to be administered simultaneously or sequentially with a PARP inhibitor; wherein the MAT2A inhibitor is Compound A1 or a pharmaceutically acceptable salt thereof; and the PARP inhibitor is Compound B or a pharmaceutically acceptable salt thereof.
- a MAT2A inhibitor in the manufacture of a medicament for treating cancer, wherein the MAT2A inhibitor is to be administered simultaneously or sequentially with a PARP inhibitor; wherein the MAT2A inhibitor is Compound A1 or a pharmaceutically acceptable salt thereof; and the PARP inhibitor is Compound C or a pharmaceutically acceptable salt thereof.
- a MAT2A inhibitor in the manufacture of a medicament for treating cancer, wherein the MAT2A inhibitor is to be administered simultaneously or sequentially with a PARP inhibitor; wherein the MAT2A inhibitor is Compound A1 or a pharmaceutically acceptable salt thereof; and the PARP inhibitor is Compound D or a pharmaceutically acceptable salt thereof.
- a MAT2A inhibitor in the manufacture of a medicament for treating cancer, wherein the MAT2A inhibitor is to be administered simultaneously or sequentially with a PARP inhibitor; wherein the MAT2A inhibitor is Compound A1 or a pharmaceutically acceptable salt thereof; and the PARP inhibitor is Compound E or a pharmaceutically acceptable salt thereof.
- a MAT2A inhibitor in the manufacture of a medicament for treating cancer, wherein the MAT2A inhibitor is to be administered simultaneously or sequentially with a PARP inhibitor; wherein the MAT2A inhibitor is Compound A1 or a pharmaceutically acceptable salt thereof; and the PARP inhibitor is Compound F or a pharmaceutically acceptable salt thereof.
- a MAT2A inhibitor in the manufacture of a medicament for treating cancer, wherein the MAT2A inhibitor is to be administered simultaneously or sequentially with a PARP inhibitor; wherein the MAT2A inhibitor is Compound A1 or a pharmaceutically acceptable salt thereof; and the PARP inhibitor is AZD5305, AZD9574, or a pharmaceutically acceptable salt thereof.
- any one of embodiments 56 to 89, wherein the cancer is selected from the group consisting of leukemia, glioma, melanoma, pancreatic, non-smali cell lung cancer, bladder cancer, astrocytoma, osteosarcoma, head and neck cancer, myxoid chondrosarcoma, ovarian cancer, endometrial cancer, breast cancer, soft tissue sarcoma, non-Hodgkin lymphoma, esophagogastric cancer, malignant peripheral nerve sheath tumor, and mesothelioma.
- the cancer is selected from the group consisting of leukemia, glioma, melanoma, pancreatic, non-smali cell lung cancer, bladder cancer, astrocytoma, osteosarcoma, head and neck cancer, myxoid chondrosarcoma, ovarian cancer, endometrial cancer, breast cancer, soft tissue sarcoma, non-Hodgkin lymphoma
- a pharmaceutical composition comprising a MAT2A inhibitor, or a pharmaceutically acceptable salt thereof, a PARP inhibitor, or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable carrier.
- a pharmaceutical composition comprising a therapeutically effective amount of a MAT2A inhibitor and a second pharmaceutical composition comprising a therapeutically effective amount of a PARP inhibitor is provided.
- a combination product comprising a first pharmaceutical composition comprising a therapeutically effective amount of a MAT2A inhibitor and a second pharmaceutical composition comprising a therapeutically effective amount of a PARP inhibitor.
- the MAT2A inhibitor is a compound of Formula (I): or a pharmaceutically acceptable salt thereof; wherein the variables are defined supra.
- the MAT2A inhibitor is selected from the group consisting of a compound from Table 1 , or a pharmaceutically acceptable salt thereof.
- the PARP inhibitor is selected from the group consisting of the compounds in Table 2, AZD5305, AZD9574, or a pharmaceutically acceptable salt or hydrate thereof.
- the MAT2A inhibitor is Compound A: Compound A or a pharmaceutically acceptable salt thereof.
- the MAT2A inhibitor is Compound A1 or a pharmaceutically acceptable salt thereof.
- the PARP inhibitor is Compound B :
- the PARP inhibitor is Compound C: or a pharmaceutically acceptable salt thereof.
- the PARP inhibitor is Compound D:
- the PARP inhibitor is Compound E:
- the PARP inhibitor is Compound F:
- the PARP inhibitor is AZD5305 or AZD9574 or a pharmaceutically acceptable salt thereof
- a combination product comprising a first pharmaceutical composition comprising a therapeutically effective amount of Compound A or a pharmaceutically acceptable salt thereof; and a second pharmaceutical composition comprising a therapeutically effective amount of Compound B or a pharmaceutically acceptable salt thereof.
- a combination product comprising a first pharmaceutical composition comprising a therapeutically effective amount of Compound A or a pharmaceutically acceptable salt thereof; and a second pharmaceutical composition comprising a therapeutically effective amount of Compound C, or a pharmaceutically acceptable salt thereof.
- a combination product comprising a first pharmaceutical composition comprising a therapeutically effective amount of Compound A or a pharmaceutically acceptable salt thereof; and a second pharmaceutical composition comprising a therapeutically effective amount of Compound D or a pharmaceutically acceptable salt thereof.
- a combination product comprising a first pharmaceutical composition comprising a therapeutically effective amount of Compound A or a pharmaceutically acceptable salt thereof; and a second pharmaceutical composition comprising a therapeutically effective amount of Compound E or a pharmaceutically acceptable salt thereof.
- a combination product comprising a first pharmaceutical composition comprising a therapeutically effective amount of Compound A or a pharmaceutically acceptable salt thereof; and a second pharmaceutical composition comprising a therapeutically effective amount of Compound F or a pharmaceutically acceptable salt thereof.
- a combination product comprising a first pharmaceutical composition comprising a therapeutically effective amount of Compound A or a pharmaceutically acceptable salt thereof; and a second pharmaceutical composition comprising a therapeutically effective amount of AZD5305, AZD9574, or a pharmaceutically acceptable salt thereof.
- a pharmaceutical composition comprising a therapeutically effective amount of Compound A or a pharmaceutically acceptable salt thereof; Compound B or a pharmaceutically acceptable salt thereof; and a pharmaceutically acceptable carrier.
- a pharmaceutical composition comprising a therapeutically effective amount of Compound A or a pharmaceutically acceptable salt thereof; Compound C, or a pharmaceutically acceptable salt thereof; and a pharmaceutically acceptable carrier.
- a pharmaceutical composition comprising a therapeutically effective amount of Compound A or a pharmaceutically acceptable salt thereof; Compound D or a pharmaceutically acceptable salt thereof; and a pharmaceutically acceptable carrier.
- composition comprising a therapeutically effective amount of Compound A or a pharmaceutically acceptable salt thereof; Compound E or a pharmaceutically acceptable salt thereof; and a pharmaceutically acceptable carrier.
- a pharmaceutical composition comprising a therapeutically effective amount of Compound A or a pharmaceutically acceptable salt thereof; Compound F or a pharmaceutically acceptable salt thereof; and a pharmaceutically acceptable carrier.
- a pharmaceutical composition comprising a therapeutically effective amount of Compound A or a pharmaceutically acceptable salt thereof; AZD5305, AZD9574, or a pharmaceutically acceptable salt thereof; and a pharmaceutically acceptable carrier.
- the pharmaceutical composition is for use in the treatment of cancer in a patient. In an embodiment, the pharmaceutical composition is for use in the treatment of a solid tumor in a patient. In an embodiment, the pharmaceutical composition is for use in the treatment of a solid malignant tumor in a patient.
- a pharmaceutical composition or pharmaceutical combination comprising the compounds disclosed herein, together with a pharmaceutically acceptable carrier.
- MAT2A inhibitor, or a pharmaceutically acceptable salt thereof, and PARP inhibitor, or a pharmaceutically acceptable salt thereof are in the same formulation.
- MAT2A inhibitor and a PARP inhibitor are in separate formulations.
- the formulations are for simultaneous or sequential administration.
- Administration of the combination includes administration of the combination in a single formulation or unit dosage form, administration of the individual agents of the combination concurrently but separately, or administration of the individual agents of the combination sequentially by any suitable route.
- the dosage of the individual agents of the combination may require more frequent administration of one of the agent(s) as compared to the other agent(s) in the combination. Therefore, to permit appropriate dosing, packaged pharmaceutical products may contain one or more dosage forms that contain the combination of agents, and one or more dosage forms that contain one of the combination of agents, but not the other agent(s) of the combination.
- Actual dosage levels of the active ingredients in the pharmaceutical compositions may be varied so as to obtain an amount of the active ingredient that is effective to achieve the desired therapeutic response for a particular patient, composition, and mode of administration, without being toxic to the patient.
- the selected dosage level will depend upon a variety of factors including the activity of the particular compound employed, the time of administration, the rate of excretion of the compound, the duration of the treatment, other drugs, compounds or materials used in combination with the compound, the age, sex, weight, condition, general health and prior medical history of the patient being treated, and like factors well, known in the medical arts.
- a medical doctor e.g., physician or veterinarian, having ordinary skill in the art may readily determine and prescribe the effective amount of the pharmaceutical composition required.
- physician or veterinarian could begin administration of the pharmaceutical composition to dose the disclosed compound at levels lower than that required in order to achieve the desired therapeutic effect and gradually increase the dosage until the desired effect is achieved.
- Dosage unit form refers to physically discrete units suited as unitary dosages for the patients to be treated; each unit containing a predetermined quantity of the disclosed compound calculated to produce the desired therapeutic effect in association with the required pharmaceutical vehicle.
- the dosage unit forms are dictated by and directly dependent on (a) the unique characteristics of the disclosed compound and the particular therapeutic effect to be achieved, and (b) the limitations inherent in the art of compounding/formulating such a disclosed compound for the treatment of pain, a depressive disorder, or drug addiction in a patient.
- the compounds provided herein are formulated using one or more pharmaceutically acceptable excipients or carriers.
- the pharmaceutical compositions provided herein comprise a therapeutically effective amount of a disclosed compound and a pharmaceutically acceptable carrier.
- Routes of administration of any of the compositions discussed herein include oral, nasal, rectal, intravaginal, parenteral, buccal, sublingual or topical.
- the compounds may be formulated for administration by any suitable route, such as for oral or parenteral, for example, transdermal, transmucosal (e.g., sublingual, lingual, (trans)buccal, (trans)urethral, vaginal (e.g., trans- and perivaginally), (intra)nasal and (trans)rectal), intravesical, intrapulmonary, intraduodenal, intragastrical, intrathecal, subcutaneous, intramuscular, intradermal, intra-arterial, intravenous, intrabronchial, inhalation, and topical administration.
- the preferred route of administration is oral.
- compositions and dosage forms include, for example, tablets, capsules, caplets, pills, gel caps, troches, dispersions, suspensions, solutions, syrups, granules, beads, transdermal patches, gels, powders, pellets, magmas, lozenges, creams, pastes, plasters, lotions, discs, suppositories, liquid sprays for nasal or oral administration, dry powder or aerosolized formulations for inhalation, compositions and formulations for intravesical administration and the like. It should be understood that the formulations and compositions are not limited to the particular formulations and compositions that are described herein.
- compositions intended for oral use may be prepared according to any method known in the art and such compositions may contain one or more agents selected from the group consisting of inert, non-toxic pharmaceutically excipients that are suitable for the manufacture of tablets.
- excipients include, for example an inert diluent such as lactose; granulating and disintegrating agents such as cornstarch; binding agents such as starch; and lubricating agents such as magnesium stearate.
- the tablets may be uncoated or they may be coated by known techniques for elegance or to delay the release of the active ingredients.
- Formulations for oral use may also be presented as hard gelatin capsules wherein the active ingredient is mixed with an inert diluent.
- the disclosed compounds may be formulated for injection or infusion, for example, intravenous, intramuscular or subcutaneous injection or infusion, or for administration in a bolus dose or continuous infusion.
- Suspensions, solutions or emulsions in an oily or aqueous vehicle, optionally containing other formulatory agents such as suspending, stabilizing or dispersing agents may be used.
- the total daily dose of niraparib is 100 mg, 200 mg or 300 mg taken once daily. In a particular embodiment, the total daily dose of niraparib is 200 mg or 300 mg taken once daily.
- the dose may be provided as 100 mg capsules (in particular, hard capsules) or 100 mg tablets. In an embodiment, each capsule or tablet contains niraparib tosylate monohydrate equivalent to 100 mg niraparib.
- the PARP inhibitor when it is niraparib, it may be administered orally by capsule or tablet. In one embodiment, niraparib is administered by capsule. In another embodiment, niraparib is administered by tablet.
- the dose of olaparib is 300 mg taken twice daily, equivalent to a total daily dose of 600 mg.
- the dose may be provided as capsules, in particular hard capsules containing 50 mg of olaparib. Therefore, to achieve a dose of 300 mg it is necessary for a patient to take six capsules.
- the dose may also be provided as 100 mg or 150 mg tablets, where the tablets may be film-coated.
- the dose of rucaparib is 600 mg taken twice daily, equivalent to a total daily dose of rucaparib of 1200 mg.
- the dose may be provided as tablets available as 200 mg, 250 mg and 300 mg tablets, which may be film-coated.
- the dose of talazoparib is 1 mg taken once daily.
- the dose may be provided as capsules containing talazoparib tosylate equivalent to 0.25 mg or 1 mg talazoparib.
- the PARP inhibitor is administered daily.
- the present disclosure provides a kit for treating cancer comprising a MAT2A inhibitor, or a pharmaceutically acceptable salt thereof, and a PARP inhibitor or a pharmaceutically acceptable salt thereof.
- the kit comprises a pharmaceutical product comprising a pharmaceutical composition comprising MAT2A inhibitor, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier or diluent; and a pharmaceutical composition comprising Poly (ADP-ribose)Polymerase (PARP) inhibitor or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier or diluent.
- a pharmaceutical product comprising a pharmaceutical composition comprising MAT2A inhibitor, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier or diluent
- PARP Poly (ADP-ribose)Polymerase
- the kit comprises a pharmaceutical composition comprising MAT2A inhibitor, or a pharmaceutically acceptable salt thereof; Poly (ADP-ribose) Polymerase (PARP) inhibitor, or a pharmaceutically acceptable salt thereof; and a pharmaceutically acceptable carrier or diluent.
- MAT2A inhibitor or a pharmaceutically acceptable salt thereof
- PARP Poly (ADP-ribose) Polymerase
- kits are provided.
- the kit includes a sealed container approved for the storage of pharmaceutical compositions, the container containing one of the above-described pharmaceutical compositions.
- the sealed container minimizes the contact of air with the ingredients, e.g. an airless bottle.
- the sealed container is a sealed tube.
- An instruction for the use of the composition and the information about the composition are to be included in the kit.
- the compounds of the combination can be dosed on the same schedule, whether by administering a single formulation or unit dosage form containing all of the compounds of the combination, or by administering separate formulations or unit dosage forms of the compounds of the combination.
- some of the compounds used in the combination may be administered more frequently than once per day, or with different frequencies that other compounds in the combination. Therefore, in one embodiment, the kit contains a formulation or unit dosage form containing all of the compounds in the combination of compounds, and an additional formulation or unit dosage form that includes one of the compounds in the combination of agents, with no additional active compound, in a container, with instructions for administering the dosage forms on a fixed schedule.
- kits provided herein include prescribing information, for example, to a patient or health care provider, or as a label in a packaged pharmaceutical formulation.
- Prescribing information may include for example efficacy, dosage and administration, contraindication and adverse reaction information pertaining to the pharmaceutical formulation.
- a kit provided herein can be designed for conditions necessary to properly maintain the components housed therein (e.g., refrigeration or freezing).
- a kit can contain a label or packaging insert including identifying information for the components therein and instructions for their use (e.g., dosing parameters, clinical pharmacology of the active ingredient(s), including mechanism(s) of action, pharmacokinetics and pharmacodynamics, adverse effects, contraindications, etc.).
- Each component of the kit can be enclosed within an individual container, and all of the various containers can be within a single package.
- Labels or inserts can include manufacturer information such as lot numbers and expiration dates.
- the label or packaging insert can be, e.g., integrated into the physical structure housing the components, contained separately within the physical structure, or affixed to a component of the kit (e.g., an ampule, syringe or vial).
- Example 1 Proliferation screen identifies combination benefit with MAT2A and PARP inhibition
- a 10-day proliferation screen was performed in 15 pancreatic, non-small cell lung, and bladder cancer cell lines: 9 MTAP null, 1 MTAP CRISPR knock-out, and 5 MTAP wildtype.
- Optimal cell seeding for all cell lines was determined by assessing the growth over a range of seeding densities in a 384-well format to identify conditions that permitted proliferation for 10 days. Cells were then plated at the optimal seeding density in the presence of 20-150 nM of Compound A or DMSO vehicle control. Cells were incubated at 37°C with 5% CO2 for 4 days to allow for target engagement of the pre-treatment compound.
- cells were also treated with an 11-point, three-fold titration series of compounds from a chemically diverse library.
- the combination compound concentrations ranged from 0.2 nM to 14,679 nM.
- a plate of cells was harvested at the time of combination compound addition to quantify the number of cells at the start of the combination (To).
- the harvested cells were lysed with CellTiter-Glo (CTG) (Promega) reagent according to the manufacturer’s protocol and the chemiluminescent signal was detected on a Synergy Neo plate reader (ThermoFisher, serial # 140715A).
- CTG estimates cell number through detection of cellular ATP levels.
- the PARP inhibitor Talazoparib was identified as a combination hit in the NCI-H838, HuP-T4, RT112/84, and UMUC5 cell lines where 5.2-, 7.5-, 2.5-, and 2.9-fold shifts in growth IC50 were observed, respectively (Table 3). Combination benefit was not observed in any of the MTAP wild type cell lines tested.
- the PARP inhibitor Olaparib was identified as a combination hit in the UMUC5 cell line where a 3-fold shift in growth IC50 was observed.
- a 10-day proliferation assay was performed in a panel of 8 pancreatic, non-small cell lung, and bladder cancer cell lines: 4 MTAP null, 1 MTAP CRISPR knock-out, and 3 MTAP wild type.
- Combinations included double titrations of MAT2A inhibitor Compound A with three different PARP inhibitor compounds including Talazoparib, Niraparib, and Olaparib.
- Optimal cell seeding for all cell lines was determined by assessing the growth over a range of seeding densities in a 384-well format to identify conditions that permitted proliferation for 10 days. Cells were then plated at the optimal seeding density and treated with a double titration of a 16-point two-fold dilution series of Compound A and a 16-point two-fold dilution series of the PARP inhibitor compounds. This double titration was compared to 16-point two-fold dilution series of each single agent alone or to 0.15% DMSO. An untreated plate of cells was harvested at the time of compound addition (To) to quantify the starting number of cells using CTG as described in example 1.
- Concentrations tested for Compound A and the PARP inhibitors alone or in combination ranged from 0.6 nM to 19,250 nM.
- the double matrix design allowed for an assessment across the full titration of each compound in the combination. Plates were incubated for 10 days at 37 °C in 5% CO2. Cells were then lysed and measured with CTG.
- Combination synergy was assessed using the Excess over Bliss model for the combinations of compound doses across the full dose range tested.
- the observed growth inhibition was compared to the predicted inhibition based on the additive activity of each single agent. Predicted inhibition was calculated using (Ea+Eb) - (Ea*Eb) where E equals the effect (inhibition) of each single agent (a and b). A difference between the observed inhibition percentage and the predicted inhibition percentage greater than 10% was considered synergistic.
- An Excess over Bliss score was only calculated for combinations eliciting >20% growth inhibition.
- Tables 4A-4C Excess over Bliss Synergy of Compound A and PART inhibitor combinations in NCI-H838 cell line.
- Tables 5A-5C Excess over Bliss Synergy of Compound A and PART inhibitor combinations in NCI-H2228 cell line.
- Tables 6A-6C Excess over Bliss Synergy of Compound A and PART inhibitor combinations in RT112/84 cell line.
- Tables 7A-7C Excess over Bliss Synergy of Compound A and PART inhibitor combinations in UMUC5 cell line.
- Tables 8A-8C Excess over Bliss Synergy of Compound A and PART inhibitor combinations in Pane 03.27 MTAP CRISPR knock-out cell line
- Tables 9A-9C Excess over Bliss Synergy of Compound A and PART inhibitor combinations in Pane 03.27 MTAP wild type cell line.
- Tables 10A-10C Excess over Bliss Synergy of Compound A and PART inhibitor combinations in NCI-H520 MTAP wild type cell line.
- Tables 11A-11C Excess over Bliss Synergy of Compound A and PARP inhibitor combinations in TCCSUP MTAP wild type cell line.
Abstract
Provided herein is a combination of a MAT2A inhibitor and a PARP inhibitor. Also provided are methods of using such combinations to treat diseases or disorders, for example, cancer.
Description
COMBINATION THERAPY COMPRISING A MAT2A INHIBITOR AND A PARP INHIBITOR
CROSS-REFERENCES TO RELATED APPLICATIONS
This application claims the benefit under 35 U.S.C. 119(e) of U.S. Provisional Application No. 63/331 ,619, filed on April 15, 2022, the contents of which is hereby incorporated by reference in its entirety for all purposes.
BACKGROUND
Cancer is a leading cause of death throughout the world. A limitation of prevailing therapeutic approaches, e.g. chemotherapy and immunotherapy, is that their cytotoxic effects are not restricted to cancer cells and adverse side effects can occur within normal tissues.
Methionine adenosyltransferase 2A (MAT2A) is an enzyme that utilizes methionine (Met) and adenosine triphosphate (ATP) to generate s-adenosyl methionine (SAM). SAM is a primary methyl donor in cells used to methylate several substrates including DNA, RNA and proteins. One methylase that utilizes SAM as a methyl donor is protein arginine N- methyltransferase 5 (PRMT5). While SAM is required for PRMT5 activity, PRMT5 is competitively inhibited by 5’methylthioadenosine (MTA). Since MTA is part of the methionine salvage pathway, cellular MTA levels stay low in a process initiated by methylthioadenosine phosphorylase (MTAP).
MTAP is in a locus on chromosome 9 that is often deleted in cells of patients with cancers from several tissues of origin including central nervous system, pancreas, esophageal, bladder and lung (cBioPortal database). Loss of MTAP results in the accumulation of MTA making MTAP-deleted cells more dependent on SAM production, and thus MAT2A activity, compared to cells that express MTAP. In an shRNA cell-line screen across approximately 400 cancer cell lines, MAT2A knockdown resulted in the loss of viability in a larger percentage of MTAP-deleted cells compare to MTAP WT cells (see McDonald et. al. 2017 Cell 170, 577-592). Furthermore, inducible knockdown of MAT2A protein decreased tumor growth in vivo (see Marjon et. al., 2016 Cell Reports 15(3), 574- 587). These results indicate that MAT2A inhibitors may provide a novel therapy for cancer patients including those with MTAP-deleted tumors.
Poly (ADP-ribose) polymerases (PARP) are a family of enzymes involved in DNA damage repair (DDR) by resolving single-strand breaks (SSBs) and double-strand breaks (DSBs), and by inducing base excision repair (BER). PARP inhibition leads to accumulation of single-strand breaks (SSBs) and which renders cells more dependent on other DNA repair pathways, namely, the homologous recombination (HR) repair pathway. Cancer cells with
HR deficiencies are in turn susceptible to PARP impairment of the BER pathway. Poly (ADP- ribose) Polymerase (PARP) inhibitors are a class of compounds that act as inhibitors of Poly (ADP-ribose) polymerase. It is believed that PARP inhibitors are useful in the treatment of cancer by preventing cancer cells from repairing their DNA, leading to cellular death.
There are currently four approved PARP inhibitors (niraparib, olaparib, rucaparib and talazoparib), with many more currently in clinical trials.
Niraparib is approved as a PARP inhibitor for the maintenance treatment of adult patients with advanced or recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to first-line platinum-based chemotherapy; and for the treatment of adult patients with advanced ovarian, fallopian tube, or primary peritoneal cancer who have been treated with three or more prior chemotherapy regimens and whose cancer is associated with homologous recombination deficiency (HRD) status defined by either a deleterious or suspected deleterious BRCA mutation, or genomic instability and who have progressed more than six months after response to the last platinum-based chemotherapy.
Olaparib is approved as a PARP inhibitor for use in the treatment of ovarian cancer, breast cancer, pancreatic cancer and prostate cancer in certain patient subgroups. In ovarian cancer, olaparib is used for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy; for the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer, who are in complete or partial response to platinum-based chemotherapy; and for the treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm) advanced ovarian cancer who have been treated with three or more prior lines of chemotherapy.
Rucaparib is approved as PARP inhibitor for use in the treatment of ovarian and prostate cancer in certain patient subgroups. Talazoparib is approved for use in the treatment of breast cancer in adult patients with deleterious or suspected deleterious germline BRCA-mutated HER2-negative locally advanced metastatic breast cancer.
Despite many recent advances in cancer therapies, there remains a need for more effective and/or enhanced treatment for those individuals suffering the effects of cancer.
SUMMARY
Provided herein is a combination comprising a methionine adenosyltransferase II alpha (MAT2A) inhibitor and a Poly (ADP-ribose) Polymerase (PARP) inhibitor. The
combination is useful for the treatment of a variety of cancers, including solid tumors. The combination is also useful for the treatment of any number of MAT2A-associated diseases. The combination is also useful for the treatment of a variety of diseases or disorders treatable by inhibiting MAT2A. The combination is useful for treating MTAP-deficient tumors. The combination is also useful for the treatment of a variety of diseases or disorders treatable by inhibiting PARP.
Provided herein is a combination product comprising a methionine adenosyltransferase II alpha (MAT2A) inhibitor and a Poly (ADP-ribose)Polymerase (PARP) inhibitor. The combination product is useful for the treatment of a variety of cancers, including solid tumors. The combination product is also useful for the treatment of any number of MAT2A-associated diseases. The combination product is also useful for the treatment of a variety of diseases or disorders treatable by inhibiting MAT2A. The combination product is useful for the treatment of MTAP-deficient tumors. The combination product is also useful for the treatment of a variety of diseases or disorders treatable by inhibiting PARP.
In an embodiment, provided herein is a combination of a MAT2A inhibitor and a PARP inhibitor.
In an embodiment, provided herein is a pharmaceutical composition comprising a therapeutically effective amount of a MAT2A inhibitor and a second pharmaceutical composition comprising a therapeutically effective amount of a PARP inhibitor.
In an embodiment, provided herein are methods of treating cancer in a subject in need thereof, the methods comprising administering to the subject a combination comprising a MAT2A inhibitor and a PARP inhibitor, thereby treating the cancer in the subject.
In an embodiment, provided herein are methods of treating cancer in a subject in need thereof, the methods comprising administering to the subject a combination comprising a MAT2A inhibitor and a PARP inhibitor together with at least a pharmaceutically acceptable carrier, thereby treating the cancer in the subject.
In still another embodiment, the cancer is characterized by a reduction or absence of methylthioadenosine phosphorylase (MTAP) gene expression, absence of MTAP gene, reduced function of MTAP protein, reduced level or absence of MTAP protein, MTA accumulation, or combination thereof.
In an embodiment, provided herein are methods of treating cancer in a subject in need thereof, the methods comprising administering to the subject a therapeutically effective amount of a pharmaceutical composition comprising a MAT2A inhibitor and a therapeutically effective amount of a pharmaceutical composition comprising a PARP inhibitor, thereby treating the cancer in the subject.
In an embodiment, provided herein are methods of treating a disease or disorder treatable by inhibiting MAT2A in a subject in need thereof, the methods comprising administering to the subject a combination comprising a MAT2A inhibitor and a PARP inhibitor, thereby treating the disease or disorder in the subject. In an embodiment, the disease or disorder is cancer.
In an embodiment, provided herein are methods of treating a disease or disorder treatable by inhibiting MAT2A in a subject in need thereof, the methods comprising administering to the subject a combination comprising a MAT2A inhibitor and a PARP inhibitor, together with at least a pharmaceutically acceptable carrier, thereby treating the disease or disorder in the subject. In an embodiment, the PARP inhibitor is niraparib, or a pharmaceutically acceptable salt thereof. In an embodiment, the disease or disorder is cancer.
In an embodiment, the MAT2A inhibitor is a compound of Formula (I):
or a pharmaceutically acceptable salt thereof, wherein the variables of Formula I are defined below.
Compound A or a pharmaceutically acceptable salt thereof. Compound A, and methods of making Compound A are disclosed in PCT/US 19/65260 (WO 2020/123395).
In another embodiment, the MAT2A inhibitor is Compound A1 having the following structural formula:
Compound A1 or a pharmaceutically acceptable salt thereof. Compound A1 , and methods of making Compound A1 are disclosed in PCT/US 19/65260 (WO 2020/123395).
MAT2A inhibitors for use in the combination therapy described herein are described in WO 2020/123395 (PCT/US19/65260), the generic and specific compounds described in this application can be used to treats cancer as described herein.
In yet another embodiment, the PARP inhibitor is niraparib (Compound B) having the following structural formula:
Compound B or a pharmaceutically acceptable salt thereof. The chemical name for niraparib is (S)-
2-(4-(piperidin-3-yl)phenyl)-2H-indazole-7-carboxamide (or alternatively 2-{4-[(3S)-piperidin-
3-yl]phenyl}-2H-indazole-7-carboxamide).
In still another embodiment, the PARP inhibitor is rucaparib (Compound C) having the following structural formula
Compound C or a pharmaceutically acceptable salt thereof. The chemical name for rucaparib is 8- fluoro-5-(4-((methylamino)methyl)phenyl)-2,3,4,6-tetrahydro-1H-azepino[5,4,3-cd]indol-1- one.
Compound D or a pharmaceutically acceptable salt thereof. The chemical name for olaparib is 4- (3-(4-(cyclopropanecarbonyl)piperazine-1 -carbonyl )-4-fluorobenzyl)phthalazin-1(2H)-one.
In another embodiment, the PARP inhibitor is talazoparib (Compound E):
Compound E or a pharmaceutically acceptable salt thereof. The chemical name for talazoparib is (8S,9R)-5-fluoro-8-(4-fluorophenyl)-9-(1-methyl-1 H-1 ,2,4-triazol-5-yl)-2,7,8,9-tetrahydro-3H- pyrido[4,3,2-de]phthalazin-3-one.
In another embodiment, the PARP inhibitor is veliparib (Compound F):
Compound F or a pharmaceutically acceptable salt thereof. The chemical name for veliparib is (R)-
2-(2-methylpyrrolidin-2-yl)-1H-benzo[d]imidazole-7-carboxamide.
In another embodiment, the PARP inhibitor is AZD5305:
or a pharmaceutically acceptable salt thereof. The chemical name for AZD5305 is 5- [4-[(7-ethyl-6-oxo-5H-1 ,5-napthyridine-3-yl)methyl]piperazin-1-yl]-N-methyl-pyridine-2- carboxamide.
In another embodiment, the PARP inhibitor is AZD9574:
or a pharmaceutically acceptable salt thereof. The chemical name for AZD9574 is 6- fluoro-5-[4-[(5-fluoro-2-methyl-3-oxo-4H-quinoxalin-6-yl)methyl]piperazin-1-yl]-N-methyl- pyridine-2-carboxamide.
BRIEF DESCRIPTION OF THE DRAWINGS
FIG. 1 A-1C depict excess over Bliss synergy of Compound A and PARP inhibitor combinations in NCI-H838 cell line.
FIG. 2A-2C depict excess over Bliss synergy of Compound A and PARP inhibitor combinations in NCI-H2228 cell line.
FIG. 3A-3C depict excess over Bliss synergy of Compound A and PARP inhibitor combinations in RT112/84 cell line.
FIG. 4A-4C depict excess over Bliss synergy of Compound A and PARP inhibitor combinations in UMUC5 cell line.
FIG. 5A-5C depict excess over Bliss synergy of Compound A and PARP inhibitor combinations in Pane 03.27 MTAP CRISPR knock-out cell line (Clone 31).
FIG. 6A-6C depict excess over Bliss synergy of Compound A and PARP inhibitor combinations in Pane 03.27 MTAP wild type cell line.
FIG. 7A-7C depict excess over Bliss synergy of Compound A and PARP inhibitor combinations in NCI-H520 MTAP wild type cell line.
FIG. 8A-8C depict excess over Bliss synergy of Compound A and PARP inhibitor combinations in TCCSUP MTAP wild type cell line.
DETAILED DESCRIPTION
Provided herein is a combination therapy comprising a MAT2A inhibitor, or a pharmaceutically acceptable salt thereof, and a PARP inhibitor, or a pharmaceutically acceptable salt thereof. The combination therapy is useful for the treatment of a variety of cancers, including, for example, pancreatic cancer and lung cancer. In another aspect, the combination therapy is useful for the treatment of any number of MAT2A-associated diseases.
Administering a combination of a MAT2A inhibitor and a PARP inhibitor can provide beneficial effects for treating cancer, e.g., solid tumors, in a subject. Such an approach - combination or co-administration of the two types of agents - may offer an uninterrupted treatment to a subject in need over a clinically relevant treatment period.
Definitions
Listed below are definitions of various terms used herein. These definitions apply to the terms as they are used throughout this specification and claims, unless otherwise limited in specific instances, either individually or as part of a larger group.
Unless defined otherwise, all technical and scientific terms used herein generally have the same meaning as commonly understood by one of ordinary skill in the art. Generally, the nomenclature used herein and the laboratory procedures in cell culture, molecular genetics, organic chemistry, and peptide chemistry are those well-known and commonly employed in the art.
As used herein, the articles “a” and “an” refer to one or to more than one (i.e., to at least one) of the grammatical object of the article. By way of example, “an element” means one element or more than one element. Furthermore, use of the term “including” as well as other forms, such as “include,” “includes,” and “included,” is not limiting.
As used herein, the term “about” will be understood by persons of ordinary skill in the art and will vary to some extent on the context in which it is used. As used herein when referring to a measurable value such as an amount, a temporal duration, and the like, the term “about” is meant to encompass variations of ±20% or ±10%, including ±5%, ±1%, and ±0.1% from the specified value, as such variations are appropriate to perform the disclosed methods.
As used in the specification and in the claims, the term “comprising” may include the embodiments “consisting of’ and “consisting essentially of.” The terms “comprise(s),” “include(s),” “having,” “has,” “may,” “contain(s),” and variants thereof, as used herein, are intended to be open-ended transitional phrases, terms, or words that require the presence of the named ingredients/steps and permit the presence of other ingredients/steps.
It should be noted that ratios, concentrations, amounts, and other numerical data may be expressed herein in a range format. It is to be understood that such a range format is used for convenience and brevity, and thus, should be interpreted in a flexible manner to include not only the numerical values explicitly recited as the limits of the range, but also to include all the individual numerical values or sub-ranges encompassed within that range as if each numerical value and sub-range is explicitly recited. In addition, the phrase “about ‘x’ to ‘y’” includes “about ‘x’ to about ‘y’”.
The terms “combination,” “therapeutic combination,” “pharmaceutical combination,” or “combination product” as used herein refer to either a fixed combination in one dosage unit form, or non-fixed combination in separate dosage forms, or a kit of parts for the
combined administration where two or more therapeutic agents may be administered independently, at the same time or separately within time intervals.
The term “combination therapy” refers to the administration of two or more therapeutic agents to treat a therapeutic condition or disorder described in the present disclosure. Such administration encompasses co-administration of these therapeutic agents in a substantially simultaneous manner, such as in a single formulation having a fixed ratio of active ingredients or in separate formulations (e.g., capsules and/or intravenous formulations) for each active ingredient. In addition, such administration also encompasses use of each type of therapeutic agent in a sequential or separate manner, either at approximately the same time or at different times. Regardless of whether the active ingredients are administered as a single formulation or in separate formulations, the drugs are administered to the same patient as part of the same course of therapy. In any case, the treatment regimen will provide beneficial effects in treating the conditions or disorders described herein.
As used herein, the term “treating” or “treatment” refers to inhibiting a disease; for example, inhibiting a disease, condition, or disorder in an individual who is experiencing or displaying the pathology or symptomology of the disease, condition, or disorder (j.e. , arresting further development of the pathology and/or symptomology) or ameliorating the disease; for example, ameliorating a disease, condition, or disorder in an individual who is experiencing or displaying the pathology or symptomology of the disease, condition, or disorder (i.e., reversing the pathology and/or symptomology) such as decreasing the severity of the disease.
As used herein, the term “patient,” “individual,” or “subject” refers to a human.
As used herein, the terms “effective amount,” “pharmaceutically effective amount,” and “therapeutically effective amount” refer to a nontoxic but sufficient amount of an agent to provide the desired biological result. That result may be reduction or alleviation of the signs, symptoms, or causes of a disease, or any other desired alteration of a biological system. An appropriate therapeutic amount in any individual case may be determined by one of ordinary skill in the art using routine experimentation.
As used herein, the term “pharmaceutically acceptable” refers to a material, such as a carrier or diluent, which does not abrogate the biological activity or properties of the compound, and is relatively non-toxic, i.e., the material may be administered to an individual without causing undesirable biological effects or interacting in a deleterious manner with any of the components of the composition in which it is contained.
As used herein, the term “pharmaceutically acceptable salt” refers to derivatives of the disclosed compounds wherein a parent compound is modified by converting an existing
acid or base moiety to its salt form. Examples of pharmaceutically acceptable salts include, but are not limited to, mineral or organic acid salts of basic residues such as amines; alkali or organic salts of acidic residues such as carboxylic acids; and the like. The pharmaceutically acceptable salts described herein include the conventional non-toxic salts of the parent compound formed, for example, from non-toxic inorganic or organic acids. The pharmaceutically acceptable salts discussed herein can be synthesized from the parent compound which contains a basic or acidic moiety by conventional chemical methods. Generally, such salts can be prepared by reacting the free acid or base forms of these compounds with a stoichiometric amount of the appropriate base or acid in water or in an organic solvent, or in a mixture of the two; generally, nonaqueous media like ether, ethyl acetate, ethanol, isopropanol, or acetonitrile are used. The phrase “pharmaceutically acceptable salt” is not limited to a mono, or 1 :1 , salt. For example, “pharmaceutically acceptable salt” also includes bis-salts, such as a bis-hydrochloride salt. Lists of suitable salts are found in Remington’s Pharmaceutical Sciences, 17th ed., Mack Publishing Company, Easton, Pa., 1985, p. 1418 and Journal of Pharmaceutical Science, 66, 2 (1977), each of which is incorporated herein by reference in its entirety.
As used herein, the term “composition” or “pharmaceutical composition” refers to a mixture of at least one compound with a pharmaceutically acceptable carrier. The pharmaceutical composition facilitates administration of the composition to a patient or subject. Multiple techniques of administering a compound exist in the art including, but not limited to, intravenous, oral, aerosol, parenteral, ophthalmic, pulmonary, and topical administration.
As used herein, the term “pharmaceutically acceptable carrier” means a pharmaceutically acceptable material, composition or carrier, such as a liquid or solid filler, stabilizer, dispersing agent, suspending agent, diluent, excipient, thickening agent, solvent or encapsulating material, involved in carrying or transporting a compound useful to the patient such that it may perform its intended function. Typically, such constructs are carried or transported from one organ, or portion of the body, to another organ, or portion of the body. Each carrier must be “acceptable” in the sense of being compatible with the other ingredients of the formulation, including the compound disclosed herein, and not injurious to the patient. Some examples of materials that may serve as pharmaceutically acceptable carriers include: sugars, such as lactose, glucose and sucrose; starches, such as corn starch and potato starch; cellulose, and its derivatives, such as sodium carboxymethyl cellulose, ethyl cellulose and cellulose acetate; powdered tragacanth; malt; gelatin; talc; excipients, such as cocoa butter and suppository waxes; oils, such as peanut oil, cottonseed oil, safflower oil, sesame oil, olive oil, corn oil and soybean oil; glycols, such as propylene
glycol; polyols, such as glycerin, sorbitol, mannitol and polyethylene glycol; esters, such as ethyl oleate and ethyl laurate; agar; buffering agents, such as magnesium hydroxide and aluminum hydroxide; surface active agents; alginic acid; pyrogen-free water; isotonic saline; Ringer’s solution; ethyl alcohol; phosphate buffer solutions; and other non-toxic compatible substances employed in pharmaceutical formulations.
As used herein, “pharmaceutically acceptable carrier” also includes any and all coatings, antibacterial and antifungal agents, and absorption delaying agents, and the like that are compatible with the activity of a compound disclosed herein, and are physiologically acceptable to the patient. Supplementary active compounds may also be incorporated into the compositions. Other additional ingredients that may be included in the pharmaceutical compositions are known in the art and described, for example, in Remington’s Pharmaceutical Sciences (Genaro, Ed., Mack Publishing Co., 1985, Easton, PA), which is incorporated herein by reference.
The term “single formulation” as used herein refers to a single carrier or vehicle formulated to deliver therapeutically effective amounts of both therapeutic agents to a patient. The single vehicle is designed to deliver a therapeutically effective amount of each of the agents, along with any pharmaceutically acceptable carriers or excipients. In some embodiments, the vehicle is a tablet, capsule, pill, or a patch. In other embodiments, the vehicle is a solution or a suspension.
As used herein “methionine adenosyltransferase II alpha inhibitor” or “MAT2A inhibitor” means an agent that modulates the activity of MAT2A or inhibits the production of S-adenosylmethionine (SAM) by methionine adenosyltransferase 2A (MAT2A).
As used herein, “Poly (ADP-ribose) Polymerase (PARP) inhibitor” refers to an agent that inhibits, PARP activity, including PARP1 and PARP2. Examples of PARP inhibitors include, but are not limited to, niraparib, rucaparib, olaparib, talazoparib, veliparib, AZD5305, and AZD9574, and pharmaceutically acceptable salts thereof.
The combination of agents described herein may display a synergistic effect. The term “synergistic effect” or “synergy” as used herein, refers to action of two agents such as, for example, a MAT2A inhibitor and a PARP inhibitor producing an effect, for example, slowing the symptomatic progression of cancer or symptoms thereof, which is greater than the simple addition of the effects of each drug administered by themselves. A synergistic effect can be calculated, for example, using suitable methods such as the Sigmoid-Emax equation (Holford, N. H. G. and Scheiner, L. B., Clin. Pharmacokinet. 6: 429-453 (1981)), the equation of Loewe additivity (Loewe, S. and Muischnek, H., Arch. Exp. Pathol Pharmacol. 114: 313-326 (1926)) and the median-effect equation (Chou, T. C. and Talalay, P., Adv. Enzyme Regul. 22: 27-55 (1984)). Each equation referred to above can be applied to
experimental data to generate a corresponding graph to aid in assessing the effects of the drug combination. The corresponding graphs associated with the equations referred to above are the concentration-effect curve, isobologram curve and combination index curve, respectively.
In an embodiment, provided herein is a combination therapy comprising a therapeutically effective amount of a MAT2A inhibitor and a PARP inhibitor. A “therapeutically effective amount” of a combination of agents (i.e., a MAT2A inhibitor and a PARP inhibitor) is an amount sufficient to provide an observable improvement over the baseline clinically observable signs and symptoms of the disorders treated with the combination. Observable improvements include those that can be visually ascertained by a clinician and biological tests, biopsies, and assays.
“Alkyl” means a linear saturated monovalent hydrocarbon radical of one to six carbon (i.e. C1-6 means one to six carbons) atoms or a branched saturated monovalent hydrocarbon radical of three to six carbon atoms (i.e. C3-6 means three to six carbons). Alkyl can include any number of carbons, such as C1.2, C1-3, C1-4, C1-5, C1-6, C2-3, C2-4, C2-5, C2-6, C3-4, C3-5, C3-6, C4-5, C4-6 and C5-6. Example of alkyl groups inlcude methyl, ethyl, propyl, 2-propyl, butyl, pentyl, and the like. It will be recognized by a person skilled in the art that the term “alkyl” may include “alkylene” groups.
“Amino” means a -NH2.
“Cycloalkyl” means a monocyclic monovalent hydrocarbon radical of three to six carbon atoms (e.g., C3-6 cycloalkyl) which may be saturated or contains one double bond. Cycloalkyl can include any number of carbons, such as C3-6, C4-6, and C5-6. Partially unsaturated cycloalkyl groups have one or more double in the ring, but cycloalkyl groups are not aromatic. Saturated monocyclic cycloalkyl rings include, for example, cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl.
“Halo” means fluoro, chloro, bromo, or iodo, preferably fluoro or chloro.
“Haloalkyl” means alkyl radical as defined above, which is substituted with one to five halogen atoms, such as fluorine or chlorine, including those substituted with different halogens, e.g., -CH2CI, -CF3, -CHF2, -CH2CF3, -CF2CF3, -CF(CH3)2, and the like. When the alkyl is substituted with only fluoro, it can be referred to as fluoroalkyl. As for alkyl group, haloalkyl groups can have any suitable number of carbon atoms, such as Ci-e.
Combination Product
Provided herein is a combination product comprising a MAT2A inhibitor, or a pharmaceutically acceptable salt thereof, and a PARP inhibitor, or a pharmaceutically acceptable salt thereof. The combination product is useful for the treatment of a variety of
cancers, including solid tumors. In another aspect, the combination product is useful for the treatment of any number of MAT2A-associated diseases. In another aspect, the combination product is useful for the treatment of a disease or disorder treatable by inhibiting MAT2A. In another aspect, the combination product is useful for the treatment of MTAP-deficient tumors.
In an embodiment, provided herein is a combination of a MAT2A inhibitor and a PARP inhibitor.
As used herein, the term “combination product” includes embodiments in which the MAT2A inhibitor and PARP inhibitor are formulated together into a single pharmaceutical composition (e.g. tablet or capsule), and alternative embodiments in which each therapeutic agent in the combination is individually formulated into its own pharmaceutical composition and each of the pharmaceutical compositions are administered in the same medical treatment (for example, the same medical treatment of cancer). In this embodiment, each of the pharmaceutical compositions may have the same or different carriers, diluents or excipients. The carrier(s), diluent(s) or excipient(s) must be acceptable in the sense of being compatible with the other ingredients of the formulation, capable of pharmaceutical formulation, and not deleterious to the recipient thereof.
In one embodiment, the combination product comprises first and second pharmaceutical compositions, wherein the first pharmaceutical composition contains a PARP inhibitor (suitably selected from compounds B, C, D, E, F, AZD5305, or AZD9574 or pharmaceutically acceptable salts thereof), the second pharmaceutical composition contains Compound A or Compound A1 (or a pharmaceutically acceptable salt thereof), and the first and second pharmaceutical compositions are both administered to treat cancer. The first and second pharmaceutical compositions may be administered simultaneously, separately or sequentially and in any order. Furthermore, it does not matter if the compounds are administered in the same dosage form, e.g. one compound may be administered by injection and another compound may be administered orally.
MAT2A inhibitors
The disclosure provides MAT2A inhibitors. In an embodiment, the MAT2A inhibitor is a compound of Formula I:
(I) or a pharmaceutically acceptable salt thereof; wherein
X is CH or N;
R3 is halo, C1-6 haloalkyl or C3-6 cycloalkyl;
R2 is -NR4R5;
R4 is hydrogen or C1-6 alkyl;
R5 is hydrogen, C1-6 alkyl or C3-6 cycloalkyl; and
R1 is phenyl, wherein phenyl is substituted with 0-2 halo.
In an embodiment, X in Formula (I) and subembodiments thereof is CH. In an embodiment, X in Formula (I) and subembodiments thereof is N.
In still another embodiment, R3 in formula (I) and subembodiments thereof is halo or C1-6 haloalkyl. In an embodiment, R3 in formula (I) and subembodiments thereof is halo. In an embodiment, R3 in formula (I) and subembodiments thereof is C1-6 haloalkyl. In an embodiment, R3 in formula (I) and subembodiments thereof is C3-6 cycloalkyl. In an embodiment, R3 in formula (I) and subembodiments thereof is chloro, fluoro, bromo, -CH2CI, -CF3, -CHF2, -CH2CF3, -CF2CF3, or -CF(CH3)2. In an embodiment, R3 in formula (I) and subembodiments thereof is chloro or -CF3. In an embodiment, R3 in formula (I) and subembodiments thereof is chloro. In an embodiment, R3 in formula (I) and subembodiments thereof is -CF3.
In still another embodiment, R4 in formula (I) and subembodiments thereof is H. In an embodiment, R4 in formula (I) and subembodiments thereof is Cvsalkyl . In an embodiment, R4 in formula (I) and subembodiments thereof is methyl, ethyl, propyl, or isopropyl.
In still another embodiment, R5 in formula (I) and subembodiments thereof is H. In an embodiment, R5 in formula (I) and subembodiments thereof is Cvsalkyl . In an embodiment, R5 in formula (I) and subembodiments thereof is methyl, ethyl, propyl, or isopropyl. In an embodiment, R5 in formula (I) and subembodiments thereof is C3-6 cycloalkyl.
In still another embodiment, R2 in formula (I) and subembodiments thereof is -NH2, - NHCi-salkyl, or -N(Ci-3alkyl)2. In an embodiment, R2 in formula (I) and subembodiments thereof is NH2, -NHMe, or -N(Me)2. In an embodiment, R2 in formula (I) and subembodiments thereof is NH2. In an embodiment, R2 in formula (I) and subembodiments thereof is -NHMe.
In still another embodiment, R1 in formula (I) and subembodiments thereof is unsubstituted phenyl. In an embodiment, R1 in formula (I) and subembodiments thereof is phenyl substituted with 1 halo. In an embodiment, R1 in formula (I) and subembodiments thereof is phenyl substituted 1 halo selected fluoro and chloro. In an embodiment, R1 in
formula (I) and subembodiments thereof is phenyl substituted chloro. In an embodiment, R1 in formula (I) and subembodiments thereof is phenyl substituted 2 halo.
In yet another embodiment, MAT2A inhibitor is selected from the group consisting of a compound from Table 1, or a pharmaceutically acceptable salt thereof.
In another embodiment, the MAT2A inhibitor is Compound A:
Compound A or a pharmaceutically acceptable salt thereof.
Compound A1 or a pharmaceutically acceptable salt thereof.
The preparation and activity of the MAT2A inhibitors provided herein are disclosed in PCT/US2019/065260 (WO 2020/123395), the entire contents of which are hereby incorporated by reference in their entirety.
It should be noted that reference to a MAT2A inhibitor also includes reference to their pharmaceutically acceptable salts. In other words, “MAT2A inhibitor” is synonymous with “MAT2A inhibitor or a pharmaceutically acceptable salt thereof’. PARP Inhibitors
The disclosure provides PARP inhibitors for use with a MAT2A inhibitor. A number of agents with PARP inhibitory activity and methods of making the same are known in the art. Each of these is embraced by this disclosure. In an embodiment the PARP inhibitor is selected from the group consisting of the compounds in Table 2, or a pharmaceutically acceptable salt or hydrate thereof.
In other embodiments, the PARP inhibitor may be selected from the group consisting of AZD5305, AZD9574, THG-008, RBN-2397, TSL-1502, NMS-03305293, HWH-340, STP06-1002, JPI-547, ABT-767, simmiparib, stenoparib, IDX-1197, SC-10914, AMXI-5001 , amelparib dihydrochloride dihydrate, CK-102, IMP-4297, pamiparib, and fluzoparib or a pharmaceutically acceptable salt thereof.
AZD5305 is described in WO 2021/013735 and is known to be 5-[4-[(7-ethyl-6-oxo- 5H-1 ,5-napthyridine-3-yl)methyl]piperazin-1-yl]-N-methyl-pyridine-2-carboxamide and has the following structure:
AZD9574 is described in WO2021260092 and is known to be 6-fluoro-5-[4-[(5-fluoro- 2-methyl-3-oxo-4H-quinoxalin-6-yl)methyl]piperazin-1-yl]-N-methyl-pyridine-2-carboxamide and has the following structure:
In some cases, the PARP inhibitor is selected from the group consisting of AZD5305, AZD9574 and the compounds in Table 2.
The preparation and activity of niraparib are described in US 8,071 ,579; US 8,071623; US 8,143,241; US 8,426,185; US 8,859,562; and US 11 ,091 ,459, the entire contents of which are hereby incorporated by reference in their entirety.
The preparation and activity of rucaparib are described in US 6,495,541 ; US 7,351 ,701 ; and US 7,531 ,530, the entire contents of which are hereby incorporated by reference in their entirety.
The preparation and activity of olaparib are described in US 7, 151 , 102; US 7,449,464; US 7,981 ,889; and US 8,071 ,579, the entire contents of which are hereby incorporated by reference in their entirety.
The preparation and activity of talazoparib are described in US 8,012,976; US 8,420,650; and US 8,735,392, the entire contents of which are hereby incorporated by reference in their entirety.
In an embodiment, the PARP inhibitor is selected from the group consisting of niraparib, olaparib, talazoparib and rucaparib or a pharmaceutically acceptable salt thereof.
In a further embodiment, the PARP inhibitor is selected from the group consisting of niraparib, talazoparib and rucaparib or a pharmaceutically acceptable salt thereof.
In an embodiment, the PARP inhibitor is selective for PARP1 over PARP2.
In an embodiment, the PARP inhibitor is AZD5305 or a pharmaceutically acceptable salt thereof, as defined above.
In an embodiment, the PARP inhibitor is AZD9574 or a pharmaceutically acceptable salt thereof, as defined above.
It should be noted that reference to a PARP inhibitor also includes reference to their pharmaceutically acceptable salts. In other words, “PARP inhibitor” is synonymous with “PARP inhibitor or a pharmaceutically acceptable salt thereof”.
In one embodiment, the PARP inhibitor is niraparib or a pharmaceutically acceptable salt thereof, in particular niraparib tosylate monohydrate. Reference to niraparib is intended to include all versions of niraparib, for example salts including pharmaceutically acceptable salts, polymorphs and solvates, including the tosylate monohydrate.
In another embodiment, the PARP inhibitor is olaparib or a pharmaceutically acceptable salt thereof. Reference to olaparib is intended to include all versions of olaparib, for example salts including pharmaceutically acceptable salts, polymorphs and solvates.
In another embodiment, the PARP inhibitor is rucaparib or a pharmaceutically acceptable salt thereof, in particular rucaparib camsylate. Reference to rucaparib is intended to include all versions of rucaparib, for example salts including pharmaceutically acceptable salts, polymorphs and solvates.
In another embodiment, the PARP inhibitor is talazoparib or a pharmaceutically acceptable salt thereof, in particular talazoparib tosylate. Reference to talozaparib is intended to include all versions of talazoparib, for example salts including pharmaceutically acceptable salts, polymorphs and solvates.
Combinations of MAT2A inhibitors and PARP Inhibitors
In another aspect, provided herein is a combination product comprising Compound A or a pharmaceutically acceptable salt thereof, and Compounds B, C, D, E, or F or a pharmaceutically acceptable salt thereof.
Compound B or a pharmaceutically acceptable salt thereof.
Compound A or a pharmaceutically acceptable salt thereof, and Compound C
or a pharmaceutically acceptable salt thereof.
In another aspect, provided herein is a combination product comprising Compound
Compound D or a pharmaceutically acceptable salt thereof.
In another aspect, provided herein is a combination product comprising Compound
Compound E or a pharmaceutically acceptable salt thereof.
In another aspect, provided herein is a combination product comprising Compound
Compound F or a pharmaceutically acceptable salt thereof.
In another aspect, provided herein is a combination product comprising Compound A1 or a pharmaceutically acceptable salt thereof, and Compounds B, C, D, E, or F or a pharmaceutically acceptable salt thereof. In further embodiments, the combination product comprises Compound A or Compound A1 or a pharmaceutically acceptable salt thereof, and AZD5305 or AZD9574 or a pharmaceutically acceptable salt thereof.
In further embodiments, the combination product comprises Compound A or a pharmaceutically acceptable salt thereof, and AZD5305 or a pharmaceutically acceptable salt thereof.
In further embodiments, the combination product comprises Compound A or a pharmaceutically acceptable salt thereof, and AZD9574 or a pharmaceutically acceptable salt thereof.
The administration of a pharmaceutical combination provided herein may result in a beneficial effect, e.g. a synergistic therapeutic effect, e.g., with regard to alleviating, delaying progression of or inhibiting the symptoms, and may also result in further surprising beneficial effects, e.g., fewer side-effects, an improved quality of life or a decreased morbidity, compared with a monotherapy applying only one of the pharmaceutically active ingredients used in the combination of the invention.
Methods of Treatment
In an embodiment, provided herein is a method of treating cancer in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a MAT2A inhibitor and administering to the subject a therapeutically effective amount of a PARP inhibitor, thereby treating the cancer in the subject.
In an embodiment, provided herein are methods of treating cancer in a subject in need thereof, the methods comprising administering to the subject a combination comprising a MAT2A inhibitor and a PARP inhibitor, together with at least a pharmaceutically acceptable carrier, thereby treating the cancer in the subject.
In still another embodiment, the cancer is characterized by a reduction or absence of methylthioadenosine phosphorylase (MTAP) gene expression, absence of MTAP gene, reduced function of MTAP protein, reduced level or absence of MTAP protein, MTA accumulation, or combination thereof.
In an embodiment, provided herein are methods of treating cancer in a subject in need thereof, the methods comprising administering to the subject a therapeutically effective amount of a pharmaceutical composition comprising a MAT2A inhibitor and a therapeutically effective amount of a pharmaceutical composition comprising a PARP inhibitor, thereby treating the cancer in the subject.
In an embodiment, use of a combination of a MAT2A inhibitor and a PARP inhibitor for the manufacture of a medicament is provided. In one embodiment, the MAT2A inhibitor is Compound A. In one embodiment, the MAT2A inhibitor is Compound A1. In one embodiment, provided is a combination of Compound A and Compound B for the manufacture of a medicament. In one embodiment, provided is a combination of Compound A and Compound C for the manufacture of a medicament. In one embodiment, provided is a combination of Compound A and Compound D for manufacture of a medicament. In one embodiment, provided is a combination of Compound A and Compound E for manufacture of a medicament. In one embodiment, provided is a combination of Compound A and Compound F for manufacture of a medicament. In one embodiment, provided is a combination of Compound A1 and Compound B for the manufacture of a medicament. In one embodiment, provided is a combination of Compound A1 and Compound C for the manufacture of a medicament. In one embodiment, provided is a combination of Compound A1 and Compound D for manufacture of a medicament. In one embodiment, provided is a combination of Compound A1 and Compound E for manufacture of a medicament. In one embodiment, provided is a combination of Compound A1 and Compound F for manufacture of a medicament. In further embodiemnts, provided is a combination of Compound A or Compound A1 and AZD5305 or AZD9574 for manufacture of a medicament. In further embodiemnts, provided is a combination of Compound A and AZD5305 for manufacture of a medicament. In further embodiemnts, provided is a combination of Compound A and AZD9574 for manufacture of a medicament.
In another embodiment, use of a combination of a MAT2A inhibitor and a PARP inhibitor for the treatment of cancer is provided. In one embodiment, the MAT2A inhibitor is a
compound of Formula I. In one embodiment, the MAT2A inhibitor is Compound A. In one embodiment, the MAT2A inhibitor is Compound A1. In one embodiment, provided is a combination of Compound A and Compound B for the treatment of cancer. In one embodiment, provided is a combination of Compound A and Compound C for the treatment of cancer. In one embodiment, provided is a combination of Compound A and Compound D for the the treatment of cancer. In one embodiment, provided is a combination of Compound A and Compound E for the treatment of cancer. In one embodiment, provided is a combination of Compound A and Compound F for the treatment of cancer. In one embodiment, provided is a combination of Compound A1 and Compound B for the treatment of cancer. In one embodiment, provided is a combination of Compound A1 and Compound C for the treatment of cancer. In one embodiment, provided is a combination of Compound A1 and Compound D for the treatment of cancer. In one embodiment, provided is a combination of Compound A1 and Compound E for the treatment of cancer. In one embodiment, provided is a combination of Compound A1 and Compound F for the treatment of cancer.
In further embodiments, the provided is a combination of Compound A or Compound A1 or a pharmaceutically acceptable salt thereof, and AZD5305 or AZD9574 or a pharmaceutically acceptable salt thereof for the treatment of cancer.
In further embodiments, the provided is a combination of Compound A or a pharmaceutically acceptable salt thereof, and AZD5305 or a pharmaceutically acceptable salt thereof for the treatment of cancer. In further embodiments, the provided is a combination of Compound A or a pharmaceutically acceptable salt thereof, and AZD9574 or a pharmaceutically acceptable salt thereof for the treatment of cancer.
In an embodiment, the MAT2A inhibitor is a compound of Formula I:
or a pharmaceutically acceptable salt thereof; wherein the variables are defined supra.
In another embodiment, the MAT2A inhibitor is selected from the group consisting of a compound from Table 1 , or a pharmaceutically acceptable salt thereof.
In yet another embodiment, the MAT2A inhibitor is Compound A or a pharmaceutically acceptable salt thereof.
In yet another embodiment, the MAT2A inhibitor is Compound A1 or a pharmaceutically acceptable salt thereof.
In an embodiment, the PARP inhibitor is selected from the group consisting of the compounds in Table 2, or a pharmaceutically acceptable salt or hydrate thereof.
In another embodiment, the PARP inhibitor is Compound B or a pharmaceutically acceptable salt thereof.
In another embodiment, the PARP inhibitor is Compound C or a pharmaceutically acceptable salt thereof.
In another embodiment, the PARP inhibitor is Compound D or a pharmaceutically acceptable salt thereof.
In another embodiment, the PARP inhibitor is Compound E or a pharmaceutically acceptable salt thereof.
In another embodiment, the PARP inhibitor is Compound F or a pharmaceutically acceptable salt thereof.
In another embodiment, the PARP inhibitor is AZD5305 or a pharmaceutically acceptable salt thereof.
In another embodiment, the PARP inhibitor is AZD9574 or a pharmaceutically acceptable salt thereof.
In another aspect, provided herein is a method of treating cancer in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of Compound A or a pharmaceutically acceptable salt thereof; and administering to the subject a therapeutically effective amount of Compound B or a pharmaceutically acceptable salt thereof.
In yet another aspect, provided herein is a method of treating cancer in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of Compound A or a pharmaceutically acceptable salt thereof; and administering to the subject a therapeutically effective amount of Compound C or a pharmaceutically acceptable salt thereof.
In still another aspect, provided herein is a method of treating cancer in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of Compound A or a pharmaceutically acceptable salt thereof; and administering to the subject a therapeutically effective amount of Compound D or a pharmaceutically acceptable salt thereof.
In another aspect, provided herein is a method of treating cancer in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of Compound A or a pharmaceutically acceptable salt thereof; and administering to the subject a therapeutically effective amount of Compound E or a pharmaceutically acceptable salt thereof.
In another aspect, provided herein is a method of treating cancer in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of Compound A or a pharmaceutically acceptable salt thereof; and administering to the subject a therapeutically effective amount of Compound F or a pharmaceutically acceptable salt thereof.
In another aspect, provided herein is a method of treating cancer in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of Compound A1 or a pharmaceutically acceptable salt thereof; and administering to the subject a therapeutically effective amount of Compound B, Compound C, Compound D, Compound E, or Compound F, or a pharmaceutically acceptable salt thereof.
In another aspect, provided herein is a method of treating cancer in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of Compound A or a pharmaceutically acceptable salt thereof; and administering to the subject a therapeutically effective amount of AZD5305 or AZD9574, or a pharmaceutically acceptable salt thereof.
In another embodiment, provided is a product containing a MAT2A inhibitor and a PARP inhibitor as a combination product for simultaneous, separate, or sequential use in medicine. In one embodiment, the MAT2A inhibitor is a compound of Formula I. In one embodiment, the MAT2A inhibitor is Compound A. In one embodiment, the MAT2A inhibitor is Compound A1. In one embodiment, provided is a product containing Compound A and Compound B as a combination product for simultaneous, separate, or sequential use in medicine. In one embodiment, provided is a product containing Compound A and Compound C as a combination product for simultaneous, separate, or sequential use in medicine. In one embodiment, provided is a product containing Compound A and Compound D as a combination product for simultaneous, separate, or sequential use in medicine. In one embodiment, provided is a product containing Compound A and Compound E as a combination product for simultaneous, separate, or sequential use in medicine. In one embodiment, provided is a product containing Compound A and Compound F as a combination product for simultaneous, separate, or sequential use in medicine. In one embodiment, provided is a product containing Compound A and AZD5305 or AZD9574 as a combination product for simultaneous, separate, or sequential use in medicine.
In another embodiment, provided is a product containing a MAT2A inhibitor and a PARP inhibitor as a combination product for simultaneous, separate, or sequential use in treating cancer in a subject. In one embodiment, the MAT2A inhibitor is a compound of Formula I. In one embodiment, the MAT2A inhibitor is Compound A. In one embodiment, the MAT2A inhibitor is Compound A1. In one embodiment, provided is a product containing
Compound A and Compound B as a combination product for simultaneous, separate, or sequential use in treating cancer in a subject. In one embodiment, provided is a product containing Compound A and Compound C as a combination product for simultaneous, separate, or sequential use in treating cancer in a subject. In one embodiment, provided is a product containing Compound A and Compound D as a combination product for simultaneous, separate, or sequential use in treating cancer in a subject. In one embodiment, provided is a product containing Compound A and Compound E as a combination product for simultaneous, separate, or sequential use in treating cancer in a subject. In one embodiment, provided is a product containing Compound A and Compound F as a combination product for simultaneous, separate, or sequential use in treating cancer in a subject. In one embodiment, provided is a product containing Compound A and AZD5305 or AZD9574 as a combination product for simultaneous, separate, or sequential treating cancer in a subject.
In yet another embodiment, the cancer is selected from the group consisting of leukemia, glioma, melanoma, pancreatic, non-small cell lung cancer, bladder cancer, astrocytoma, osteosarcoma, head and neck cancer, myxoid chondrosarcoma, ovarian cancer, endometrial cancer, breast cancer, soft tissue sarcoma, non-Hodgkin lymphoma, gastric cancer, esophagogastric cancer, esophageal cancer, malignant peripheral nerve sheath tumor, and mesothelioma.
In an embodiment, the cancer is mesothelioma. In an embodiment, the cancer is non-small cell lung cancer. In another embodiment, the cancer is nonsquamous non-small cell lung cancer. In one embodiment, the cancer is cancer of the colon or rectum. In an embodiment, the cancer is adenocarcinoma of the colon or rectum. In an embodiment, the cancer is breast cancer. In an embodiment, the cancer is adenocarcinoma of the breast. In an embodiment, the cancer is gastric cancer. In an embodiment, the cancer is gastric adenocarcinoma. In an embodiment, the cancer is pancreatic cancer. In an embodiment, the cancer is pancreatic adenocarcinoma. In an embodiment, the cancer is bladder cancer.
In an embodiment, the cancer is characterized as being MTAP-null. In an embodiment, the cancer is characterized as being MTAP-deficient.
In still another embodiment, the cancer is a solid tumor. In still another embodiment, the cancer is a MTAP-deleted solid tumor, n still another embodiment, the cancer is a metastatic MTAP-deleted solid tumor.
In still another embodiment, the cancer is metastatic.
In still another embodiment, the cancer is a solid malignant tumor.
In still another embodiment, the cancer is MTAP-deficient lung or MTAP- deficient pancreatic cancer, including MTAP-deficient NSCLC or MTAP-deficient pancreatic ductal adenocarcinoma (PDAC) or MTAP-deficient esophageal cancer.
In another embodiment, the cancer is a tumor having an MTAP gene deletion.
In any one of the embodiments herein, the cancer is a solid tumor or a haematological cancer. In one embodiment, the tumor is deficient in MTAP. In another embodiment, the tumor is normal in its expression of MTAP.
In still another embodiment, the cancer is NSCLC, mesothelioma, squamous carcinoma of the head and neck, salivary gland tumors, urothelial cancers, sarcomas, or ovarian cancer. In still another embodiment, the cancer is NSCLC, esophagogastric cancer, or pancreatic cancers.
In still another embodiment, the cancer is characterized by a reduction or absence of MTAP gene expression, absence of MTAP gene, reduced function of MTAP protein, reduced level or absence of MTAP protein, MTA accumulation, or combination thereof.
In still another embodiment, the cancer is characterized by a reduction or absence of MTAP gene expression.
In still another embodiment, the cancer is characterized by reduced function of MTAP protein.
In still another embodiment, the cancer is characterized by reduced level or absence of MTAP protein.
In still another embodiment, the cancer is characterized by MTA accumulation.
In an embodiment, the MAT2A inhibitor and the PARP inhibitor are in separate dosage forms.
In another embodiment, the MAT2A inhibitor and the PARP inhibitor are in the same dosage form.
In another embodiment, the treatment comprises administering the MAT2A inhibitor, or a pharmaceutically acceptable salt thereof, and the PARP inhibitor, or a pharmaceutically acceptable salt thereof, at substantially the same time. In yet another embodiment, the treatment comprises administering the MAT2A inhibitor, or a pharmaceutically acceptable salt thereof, and the PARP inhibitor, or a pharmaceutically acceptable salt thereof, at different times.
In still another embodiment, the MAT2A inhibitor, or a pharmaceutically acceptable salt thereof, is administered to the subject, followed by administration of the PARP inhibitor, or a pharmaceutically acceptable salt thereof. In an embodiment, the PARP inhibitor, or a pharmaceutically acceptable salt thereof, is administered to the subject, followed by administration of MAT2A inhibitor, or a pharmaceutically acceptable salt thereof.
In an embodiment, the MAT2A inhibitor, or a pharmaceutically acceptable salt thereof, and the PARP inhibitor, or a pharmaceutically acceptable salt thereof, are administered orally.
In another embodiment, the cancer to be treated is selected from the group consisting of lung cancer, colon and rectal cancer, breast cancer, prostate cancer, liver cancer, pancreatic cancer, brain cancer, kidney cancer, ovarian cancer, stomach cancer, skin cancer, bone cancer, gastric cancer, glioma, glioblastoma, neuroblastoma, hepatocellular carcinoma, papillary renal carcinoma, head and neck squamous cell carcinoma, leukemia, lymphomas, myelomas, retinoblastoma, cervical cancer, melanoma and/or skin cancer, bladder cancer, uterine cancer, testicular cancer, esophageal cancer, thymic cancer, adenoid cystic carcinoma, gastroesophageal cancer, malignant peripheral nerve sheath tumor (MPNST), and cholangiocarcinoma. In some embodiments, the cancer is lung cancer, colon cancer, breast cancer, neuroblastoma, leukemia, and lymphomas. In other embodiments, the cancer is lung cancer, colon cancer, breast cancer, neuroblastoma, leukemia, or lymphoma. In a further embodiment, the cancer is non-small cell lung cancer (NSCLC) or small cell lung cancer. In yet another embodiment, the cancer is selected from the group consisting of NSCLC, pancreatic cancer, malignant peripheral nerve sheath tumor (MPNST), and esophagogastric cancer. In yet another embodiment, the cancer is selected from the group consisting of NSCLC and pancreatic cancer. In yet another embodiment, the cancer is NSCLC. In yet another embodiment, the cancer is pancreatic cancer.
In an embodiment, the cancer is a hematologic cancer, such as leukemia or lymphoma. In a certain embodiment, lymphoma is Hodgkin’s lymphoma or Non-Hodgkin’s lymphoma. In certain embodiments, leukemia is myeloid, lymphocytic, myelocytic, lymphoblastic, or megakaryotic leukemia.
In an aspect, provided herein is a MAT2A inhibitor, or a pharmaceutically acceptable salt thereof, and a PARP inhibitor, or a pharmaceutically acceptable salt thereof, for use in therapy.
In an embodiment, the MAT2A inhibitor, or a pharmaceutically acceptable salt thereof, and the PARP inhibitor, or a pharmaceutically acceptable salt thereof, are for use in the treatment of cancer in a subject in need thereof.
In an embodiment of the methods, the method involves the administration of a therapeutically effective amount of a combination or composition comprising compounds provided herein, or pharmaceutically acceptable salts thereof, to a subject (including, but not limited to a human or animal) in need of treatment (including a subject identified as in need).
In another embodiment of the methods, the treatment includes co-administering the amount of the MAT2A inhibitor, or a pharmaceutically acceptable salt thereof, and the
amount of the PARP inhibitor, or a pharmaceutically acceptable salt thereof. In an embodiment, the amount of the MAT2A inhibitor or a pharmaceutically acceptable salt thereof and the amount of PARP inhibitor or a pharmaceutically acceptable salt thereof are in a single formulation or unit dosage form. In still other embodiments, the amount of MAT2A inhibitor or a pharmaceutically acceptable salt thereof and the amount of PARP inhibitor or a pharmaceutically acceptable salt thereof are in a separate formulations or unit dosage forms.
In the foregoing methods, the treatment can include administering the amount of MAT2A inhibitor or a pharmaceutically acceptable salt thereof and the amount of a PARP inhibitor or a pharmaceutically acceptable salt thereof at substantially the same time or administering the amount of MAT2A inhibitor or a pharmaceutically acceptable salt thereof and the amount of a PARP or a pharmaceutically acceptable salt thereof at different times. In some embodiments of the foregoing methods, the amount of MAT2A inhibitor or a pharmaceutically acceptable salt thereof and/or the amount of PARP inhibitor or a pharmaceutically acceptable salt thereof is administered at dosages that would not be effective when either of MAT2A inhibitor or a pharmaceutically acceptable salt thereof, or PARP inhibitor or a pharmaceutically acceptable salt thereof is administered alone, but which amounts are effective in combination.
In another embodiment of the methods, the treatment includes co-administering the amount of Compound A, or a pharmaceutically acceptable salt thereof, and the amount of Compound B, or a pharmaceutically acceptable salt thereof. In an embodiment, the amount of Compound A or a pharmaceutically acceptable salt thereof and the amount of Compound B or a pharmaceutically acceptable salt thereof are in a single formulation or unit dosage form. In still other embodiments, the amount of Compound A or a pharmaceutically acceptable salt thereof and the amount of Compound B or a pharmaceutically acceptable salt thereof are in a separate formulations or unit dosage forms.
In another embodiment of the methods, the treatment includes co-administering the amount of Compound A, or a pharmaceutically acceptable salt thereof, and the amount of Compound C, or a pharmaceutically acceptable salt thereof. In an embodiment, the amount of Compound A or a pharmaceutically acceptable salt thereof and the amount of Compound C or a pharmaceutically acceptable salt thereof are in a single formulation or unit dosage form. In still other embodiments, the amount of Compound A or a pharmaceutically acceptable salt thereof and the amount of Compound C or a pharmaceutically acceptable salt thereof are in a separate formulations or unit dosage forms.
In another embodiment of the methods, the treatment includes co-administering the amount of Compound A, or a pharmaceutically acceptable salt thereof, and the amount of Compound D, or a pharmaceutically acceptable salt thereof. In an embodiment, the amount
of Compound A or a pharmaceutically acceptable salt thereof and the amount of Compound D or a pharmaceutically acceptable salt thereof are in a single formulation or unit dosage form. In still other embodiments, the amount of Compound A or a pharmaceutically acceptable salt thereof and the amount of Compound D or a pharmaceutically acceptable salt thereof are in a separate formulations or unit dosage forms.
In another embodiment of the methods, the treatment includes co-administering the amount of Compound A, or a pharmaceutically acceptable salt thereof, and the amount of Compound E, or a pharmaceutically acceptable salt thereof. In an embodiment, the amount of Compound A or a pharmaceutically acceptable salt thereof and the amount of Compound E or a pharmaceutically acceptable salt thereof are in a single formulation or unit dosage form. In still other embodiments, the amount of Compound A or a pharmaceutically acceptable salt thereof and the amount of Compound E or a pharmaceutically acceptable salt thereof are in a separate formulations or unit dosage forms.
In another embodiment of the methods, the treatment includes co-administering the amount of Compound A, or a pharmaceutically acceptable salt thereof, and the amount of Compound F, or a pharmaceutically acceptable salt thereof. In an embodiment, the amount of Compound A or a pharmaceutically acceptable salt thereof and the amount of Compound F or a pharmaceutically acceptable salt thereof are in a single formulation or unit dosage form. In still other embodiments, the amount of Compound A or a pharmaceutically acceptable salt thereof and the amount of Compound F or a pharmaceutically acceptable salt thereof are in a separate formulations or unit dosage forms.
In another embodiment of the methods, the treatment includes co-administering the amount of Compound A, or a pharmaceutically acceptable salt thereof, and the amount of AZD5305 or AZD9574, or a pharmaceutically acceptable salt thereof. In an embodiment, the amount of Compound A or a pharmaceutically acceptable salt thereof and the amount of AZD5305 or AZD9574 or a pharmaceutically acceptable salt thereof are in a single formulation or unit dosage form. In still other embodiments, the amount of Compound A or a pharmaceutically acceptable salt thereof and the amount of AZD5305 or AZD9574 or a pharmaceutically acceptable salt thereof are in a separate formulations or unit dosage forms.
In the foregoing methods, the treatment can include administering the amount of Compound A or a pharmaceutically acceptable salt thereof and the amount of Compound B or a pharmaceutically acceptable salt thereof at substantially the same time or administering the amount of Compound A or a pharmaceutically acceptable salt thereof and the amount of Compound B or a pharmaceutically acceptable salt thereof at different times. In some embodiments of the foregoing methods, the amount of Compound A or a pharmaceutically acceptable salt thereof and/or the amount of Compound B or a pharmaceutically acceptable
salt thereof is administered at dosages that would not be effective when one or both of Compound A or a pharmaceutically acceptable salt thereof and Compound B or a pharmaceutically acceptable salt thereof is administered alone, but which amounts are effective in combination.
In the foregoing methods, the treatment can include administering the amount of Compound A or a pharmaceutically acceptable salt thereof and the amount of Compound C or a pharmaceutically acceptable salt thereof at substantially the same time or administering the amount of Compound A or a pharmaceutically acceptable salt thereof and the amount of Compound C or a pharmaceutically acceptable salt thereof at different times. In some embodiments of the foregoing methods, the amount of Compound A or a pharmaceutically acceptable salt thereof and/or the amount of Compound C or a pharmaceutically acceptable salt thereof is administered at dosages that would not be effective when one or both of Compound A or a pharmaceutically acceptable salt thereof and Compound C or a pharmaceutically acceptable salt thereof is administered alone, but which amounts are effective in combination.
In the foregoing methods, the treatment can include administering the amount of Compound A or a pharmaceutically acceptable salt thereof and the amount of Compound D or a pharmaceutically acceptable salt thereof at substantially the same time or administering the amount of Compound A or a pharmaceutically acceptable salt thereof and the amount of Compound D or a pharmaceutically acceptable salt thereof at different times. In some embodiments of the foregoing methods, the amount of Compound A or a pharmaceutically acceptable salt thereof and/or the amount of Compound D or a pharmaceutically acceptable salt thereof is administered at dosages that would not be effective when one or both of Compound A or a pharmaceutically acceptable salt thereof and Compound D or a pharmaceutically acceptable salt thereof is administered alone, but which amounts are effective in combination.
In the foregoing methods, the treatment can include administering the amount of Compound A or a pharmaceutically acceptable salt thereof and the amount of Compound E or a pharmaceutically acceptable salt thereof at substantially the same time or administering the amount of Compound A or a pharmaceutically acceptable salt thereof and the amount of Compound E or a pharmaceutically acceptable salt thereof at different times. In some embodiments of the foregoing methods, the amount of Compound A or a pharmaceutically acceptable salt thereof and/or the amount of Compound E or a pharmaceutically acceptable salt thereof is administered at dosages that would not be effective when one or both of Compound A or a pharmaceutically acceptable salt thereof and Compound E or a
pharmaceutically acceptable salt thereof is administered alone, but which amounts are effective in combination.
In the foregoing methods, the treatment can include administering the amount of Compound A or a pharmaceutically acceptable salt thereof and the amount of Compound F or a pharmaceutically acceptable salt thereof at substantially the same time or administering the amount of Compound A or a pharmaceutically acceptable salt thereof and the amount of Compound F or a pharmaceutically acceptable salt thereof at different times. In some embodiments of the foregoing methods, the amount of Compound A or a pharmaceutically acceptable salt thereof and/or the amount of Compound F or a pharmaceutically acceptable salt thereof is administered at dosages that would not be effective when one or both of Compound A or a pharmaceutically acceptable salt thereof and Compound F or a pharmaceutically acceptable salt thereof is administered alone, but which amounts are effective in combination.
In the foregoing methods, the treatment can include administering the amount of Compound A or a pharmaceutically acceptable salt thereof and the amount of AZD5305 or AZD9574 or a pharmaceutically acceptable salt thereof at substantially the same time or administering the amount of Compound A or a pharmaceutically acceptable salt thereof and the amount of AZD5305 or AZD9574 or a pharmaceutically acceptable salt thereof at different times. In some embodiments of the foregoing methods, the amount of Compound A or a pharmaceutically acceptable salt thereof and/or the amount of AZD5305 or AZD9574 or a pharmaceutically acceptable salt thereof is administered at dosages that would not be effective when one or both of Compound A or a pharmaceutically acceptable salt thereof and AZD5305 or AZD9574 or a pharmaceutically acceptable salt thereof is administered alone, but which amounts are effective in combination.
Non-Limiting Exemplary Embodiments:
In further embodiments 1 to 96 below, the present disclosure includes:
1 . In embodiment 1 , provided is a method of treating cancer in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a methionine adenosyltransferase II alpha (MAT2A) inhibitor and administering to the subject a therapeutically effective amount of a Poly (ADP-Ribose) Polymerase (PARP) inhibitor.
2. In embodiment 2, provided is a method of treating cancer in a subject in need thereof, the method comprising administering to the subject a therapeutically effective
amount of a MAT2A inhibitor and administering to the subject a therapeutically effective amount of a PARP inhibitor, wherein the MAT2A inhibitor is a compound of Formula I:
or a pharmaceutically acceptable salt thereof; wherein
X is CH or N;
R3 is halo, C1-6 haloalkyl or C3-6 cycloalkyl;
R2 is -NR4R5;
R4 is hydrogen or C1-6 alkyl;
R5 is hydrogen, C1-6 alkyl or C3-6 cycloalkyl; and
R1 is phenyl, wherein phenyl is substituted with 0-2 halo.
3. In embodiment 3, provided is the method of embodiment 2, wherein X is N.
4. In embodiment 4, provided is the method of embodiment 2, wherein X is CH.
5. In embodiment 5, provided is the method of any one of embodiments 2 to 4, wherein
R4 is hydrogen and R5 is hydrogen or C1-3 alkyl.
6. In embodiment 6, provided is the method of any one of embodiments 2 to 5, wherein R5 is hydrogen or methyl.
7. In embodiment 7, provided is the method of any one of embodiments 2 to 6, wherein R1 is phenyl substituted with chloro.
8. In embodiment 8, provided is the method of any one of embodiments 2 to 7, wherein R3 is C1-3 haloalkyl or halo.
9. In embodiment 9, provided is the method of any one of embodiments 2 to 8, wherein R3 is trifl uromethyl or chloro.
10. In embodiment 10, provided is the method of any one of embodiments 2 to 7, wherein R3 is cyclopropyl.
11. In embodiment 11 , provided is the method of any one of embodiments 1 to 10, wherein the MAT2A inhibitor is selected from the group consisting of a compound from Table 1 , or a pharmaceutically acceptable salt thereof.
12. In embodiment 12, provided is the method of any one of embodiments 1 to 11 , wherein the MAT2A inhibitor is Compound A or a pharmaceutically acceptable salt thereof.
13. In embodiment 13, provided is the method of any one of embodiments 1 to 11 , wherein the MAT2A inhibitor is Compound A1 or a pharmaceutically acceptable salt thereof.
14. In embodiment 14, provided is the method of any one of embodiments 1 to 13, wherein the PARP inhibitor is selected from the group consisting of Compound B, Compound C, Compound D, Compound E, Compound F, AZD5305, and AZD9574, or a pharmaceutically acceptable salt thereof.
15. In embodiment 15, provided is the method of any one of embodiments 1 to 14, wherein the PARP inhibitor is Compound B or a pharmaceutically acceptable salt thereof.
16. In embodiment 16, provided is the method of any one of embodiments 1 to 14, wherein the PARP inhibitor is Compound C or a pharmaceutically acceptable salt thereof.
17. In embodiment 17, provided is the method of any one of embodiments 1 to 14, wherein the PARP inhibitor is Compound D or a pharmaceutically acceptable salt thereof.
18. In embodiment 18, provided is the method of any one of embodiments 1 to 14, wherein the PARP inhibitor is Compound E or a pharmaceutically acceptable salt thereof.
19. In embodiment 19, provided is the method of any one of embodiments 1 to 14, wherein the PARP inhibitor is Compound F or a pharmaceutically acceptable salt thereof.
20. In embodiment 20, provided is a method of treating cancer in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of Compound A or a pharmaceutically acceptable salt thereof, and administering to the subject a therapeutically effective amount of Compound B, or a pharmaceutically acceptable salt thereof.
21. In embodiment 21 , provided is the method of any one of claims 1-20, wherein the cancer is selected from the group consisting of leukemia, glioma, melanoma, pancreatic, non-small cell lung cancer, bladder cancer, astrocytoma, osteosarcoma, head and neck cancer, myxoid chondrosarcoma, ovarian cancer, endometrial cancer, breast cancer, soft tissue sarcoma, non-Hodgkin lymphoma, esophagogastric cancer, malignant peripheral nerve sheath tumor, and mesothelioma.
22. In embodiment 22, provided is the method of any one of claims 1-21 , wherein the cancer is a solid tumor.
23. In embodiment 23, provided is the method of any one of claims 1-22, wherein the cancer is a solid malignant tumor.
24. In embodiment 24, provided is the method of any one of claims 1-23, wherein the tumor has an MTAP gene deletion.
25. In embodiment 25, provided is the method of any one of claims 1-24, wherein the MAT2A inhibitor and the PARP inhibitor are in separate dosage forms.
26. In embodiment 26, provided is a combination product comprising a MAT2A inhibitor, or a pharmaceutically acceptable salt thereof, and a PARP inhibitor, or a pharmaceutically acceptable salt thereof.
27. In embodiment 27, the MAT2A inhibitor of embodiment 26 is a compound of Formula (I), or a pharmaceutically acceptable salt thereof.
28. In embodiment 28, the MAT2A inhibitor of embodiment 26 is a compound of Formula (I), or a pharmaceutically acceptable salt thereof as defined in any one of embodiments 2 to 10.
29. In embodiment 29, the MAT2A inhibitor of any one of embodiments 26 to 28 is selected from the group consisting of the compounds in Table 1 , or a pharmaceutically acceptable salt thereof.
30. In embodiment 30, the MAT2A inhibitor of any one of embodiments 26 to 29 is Compound A or a pharmaceutically acceptable salt thereof.
31. In embodiment 31 , the MAT2A inhibitor of any one of embodiments 26 to 29 is Compound A1 or a pharmaceutically acceptable salt thereof.
32. In embodiment 32, the PARP inhibitor of any one of embodiments 26 to 31 is selected from the group consisting of the compounds in Table 2, AZD5305, and AZD9574, or a pharmaceutically acceptable salt thereof.
33. In embodiment 33, the PARP inhibitor of any of embodiments 26 to 32 is Compound B or a pharmaceutically acceptable salt thereof.
34. In embodiment 34, the PARP inhibitor of any of embodiments 26 to 32 is Compound C or a pharmaceutically acceptable salt thereof.
35. In embodiment 35, the PARP inhibitor of any of embodiments 26 to 32 is Compound D or a pharmaceutically acceptable salt thereof.
36. In embodiment 36, the PARP inhibitor of any of embodiments 26 to 32 is Compound E or a pharmaceutically acceptable salt thereof.
37. In embodiment 37, the PARP inhibitor of any of embodiments 26 to 32 is Compound F or a pharmaceutically acceptable salt thereof.
38. In embodiment 38, the PARP inhibitor of any of embodiments 26 to 32 is AZD5305, AZD9574, or a pharmaceutically acceptable salt thereof.
39. In embodiment 39, provided is a combination product comprising a first pharmaceutical composition comprising a therapeutically effective amount of a MAT2A inhibitor and a second pharmaceutical composition comprising a therapeutically effective amount of a PARP inhibitor.
40. In embodiment 40, the MAT2A inhibitor of embodiment 39 is a compound of Formula (I), or a pharmaceutically acceptable salt thereof.
41. In embodiment 41 , the MAT2A inhibitor of embodiment 40 is a compound of Formula (I), or a pharmaceutically acceptable salt thereof as defined in any one of embodiments 2 to 10.
42. In embodiment 42, the MAT2A inhibitor of any one of embodiments 39 to 41 is selected from the group consisting of the compounds in Table 1 , or a pharmaceutically acceptable salt thereof.
43. In embodiment 43, the PARP inhibitor of any of embodiments 39 to 42 is selected from the group consisting of the compounds in Table 2, AZD5305, AZD9574, or a pharmaceutically acceptable salt thereof.
44. In embodiment 44, provided is a combination product comprising a first pharmaceutical composition comprising a therapeutically effective amount of Compound A or a pharmaceutically acceptable salt thereof, and a second pharmaceutical composition
comprising a therapeutically effective amount of Compound B or a pharmaceutically acceptable salt thereof.
45 In embodiment 45, provided is a combination product comprising a first pharmaceutical composition comprising a therapeutically effective amount of Compound A or a pharmaceutically acceptable salt thereof, and a second pharmaceutical composition comprising a therapeutically effective amount of Compound C or a pharmaceutically acceptable salt thereof.
46. In embodiment 47, provided is a combination product comprising a first pharmaceutical composition comprising a therapeutically effective amount of Compound A or a pharmaceutically acceptable salt thereof, and a second pharmaceutical composition comprising a therapeutically effective amount of Compound D or a pharmaceutically acceptable salt thereof.
47. In embodiment 47, provided is a combination product comprising a first pharmaceutical composition comprising a therapeutically effective amount of Compound A or a pharmaceutically acceptable salt thereof, and a second pharmaceutical composition comprising a therapeutically effective amount of Compound E or a pharmaceutically acceptable salt thereof.
48. In embodiment48, provided is a combination product comprising a first pharmaceutical composition comprising a therapeutically effective amount of Compound A or a pharmaceutically acceptable salt thereof, and a second pharmaceutical composition comprising a therapeutically effective amount of Compound F or a pharmaceutically acceptable salt thereof.
49. In embodiment 49, provided is a combination product comprising a first pharmaceutical composition comprising a therapeutically effective amount of Compound A or a pharmaceutically acceptable salt thereof, and a second pharmaceutical composition comprising a therapeutically effective amount of AZD5305, AZD9574, or a pharmaceutically acceptable salt thereof.
50. In embodiment 50, provided is a combination product comprising a first pharmaceutical composition comprising a therapeutically effective amount of Compound A1 or a pharmaceutically acceptable salt thereof, and a second pharmaceutical composition comprising a therapeutically effective amount of Compound B or a pharmaceutically acceptable salt thereof.
51. In embodiment 51 , provided is a combination product comprising a first pharmaceutical composition comprising a therapeutically effective amount of Compound A1 or a pharmaceutically acceptable salt thereof, and a second pharmaceutical composition comprising a therapeutically effective amount of Compound C or a pharmaceutically acceptable salt thereof.
52. In embodiment 52, provided is a combination product comprising a first pharmaceutical composition comprising a therapeutically effective amount of Compound A1 or a pharmaceutically acceptable salt thereof, and a second pharmaceutical composition comprising a therapeutically effective amount of Compound D or a pharmaceutically acceptable salt thereof.
53. In embodiment 53, provided is a combination product comprising a first pharmaceutical composition comprising a therapeutically effective amount of Compound A1 or a pharmaceutically acceptable salt thereof, and a second pharmaceutical composition comprising a therapeutically effective amount of Compound E or a pharmaceutically acceptable salt thereof.
54. In embodiment 54, provided is a combination product comprising a first pharmaceutical composition comprising a therapeutically effective amount of Compound A1 or a pharmaceutically acceptable salt thereof, and a second pharmaceutical composition comprising a therapeutically effective amount of Compound F or a pharmaceutically acceptable salt thereof.
55. In embodiment 55, provided is a combination product comprising a first pharmaceutical composition comprising a therapeutically effective amount of Compound A1 or a pharmaceutically acceptable salt thereof, and a second pharmaceutical composition comprising a therapeutically effective amount of AZD5305, AZD9574, or a pharmaceutically acceptable salt thereof.
56. In embodiment 56, provided is a MAT2A inhibitor for use in treating cancer, wherein the MAT2A inhibitor is to be administered simultaneously or sequentially with a PARP inhibitor.
57. In embodiment 57, the MAT2A inhibitor of embodiment 56 is a compound of Formula (I), or a pharmaceutically acceptable salt thereof.
58. In embodiment 58, the MAT2A inhibitor of embodiment 57 is a compound of Formula (I), or a pharmaceutically acceptable salt thereof as defined in any one of embodiments 2 to 10.
59. In embodiment 59, the MAT2A inhibitor of any one of embodiments 56 to 58 is selected from the group consisting of the compounds in Table 1 , or a pharmaceutically acceptable salt thereof.
60. In embodiment 60, the PARP inhibitor of any of embodiments 56 to 59 is selected from the group consisting of the compounds in Table 2, AZD5305, AZD9574, or a pharmaceutically acceptable salt thereof.
61. In embodiment 61 , provided is a MAT2A inhibitor for use in treating cancer, wherein the MAT2A inhibitor is to be administered simultaneously or sequentially with a PARP inhibitor; wherein the MAT2A inhibitor is Compound A or a pharmaceutically acceptable salt thereof; and the PARP inhibitor is Compound B or a pharmaceutically acceptable salt thereof.
62. In embodiment 62, provided is a MAT2A inhibitor for use in treating cancer, wherein the MAT2A inhibitor is to be administered simultaneously or sequentially with a PARP inhibitor; wherein the MAT2A inhibitor is Compound A or a pharmaceutically acceptable salt thereof; and the PARP inhibitor is Compound C or a pharmaceutically acceptable salt thereof.
63. In embodiment 63, provided is a MAT2A inhibitor for use in treating cancer, wherein the MAT2A inhibitor is to be administered simultaneously or sequentially with a PARP inhibitor; wherein the MAT2A inhibitor is Compound A or a pharmaceutically acceptable salt thereof; and the PARP inhibitor is Compound D or a pharmaceutically acceptable salt thereof.
64. In embodiment 64, provided is a MAT2A inhibitor for use in treating cancer, wherein the MAT2A inhibitor is to be administered simultaneously or sequentially with a PARP inhibitor; wherein the MAT2A inhibitor is Compound A or a pharmaceutically acceptable salt thereof; and the PARP inhibitor is Compound E or a pharmaceutically acceptable salt thereof.
65. In embodiment 65, provided is a MAT2A inhibitor for use in treating cancer, wherein the MAT2A inhibitor is to be administered simultaneously or sequentially with a PARP
inhibitor; wherein the MAT2A inhibitor is Compound A or a pharmaceutically acceptable salt thereof; and the PARP inhibitor is Compound F or a pharmaceutically acceptable salt thereof.
66. In embodiment 66, provided is a MAT2A inhibitor for use in treating cancer, wherein the MAT2A inhibitor is to be administered simultaneously or sequentially with a PARP inhibitor; wherein the MAT2A inhibitor is Compound A or a pharmaceutically acceptable salt thereof; and the PARP inhibitor is AZD5305, AXD9574, or a pharmaceutically acceptable salt thereof.
67. In embodiment 67, provided is a MAT2A inhibitor for use in treating cancer, wherein the MAT2A inhibitor is to be administered simultaneously or sequentially with a PARP inhibitor; wherein the MAT2A inhibitor is Compound A1 or a pharmaceutically acceptable salt thereof; and the PARP inhibitor is Compound B or a pharmaceutically acceptable salt thereof.
68. In embodiment 68, provided is a MAT2A inhibitor for use in treating cancer, wherein the MAT2A inhibitor is to be administered simultaneously or sequentially with a PARP inhibitor; wherein the MAT2A inhibitor is Compound A1or a pharmaceutically acceptable salt thereof; and the PARP inhibitor Compound C or a pharmaceutically acceptable salt thereof.
69. In embodiment 69, provided is a MAT2A inhibitor for use in treating cancer, wherein the MAT2A inhibitor is to be administered simultaneously or sequentially with a PARP inhibitor; wherein the MAT2A inhibitor is Compound A1 or a pharmaceutically acceptable salt thereof; and the PARP inhibitor is Compound D or a pharmaceutically acceptable salt thereof.
70. In embodiment 70, provided is a MAT2A inhibitor for use in treating cancer, wherein the MAT2A inhibitor is to be administered simultaneously or sequentially with a PARP inhibitor; wherein the MAT2A inhibitor is Compound A1 or a pharmaceutically acceptable salt thereof; and the PARP inhibitor is Compound E or a pharmaceutically acceptable salt thereof.
71. In embodiment 71 , provided is a MAT2A inhibitor for use in treating cancer, wherein the MAT2A inhibitor is to be administered simultaneously or sequentially with a PARP inhibitor; wherein the MAT2A inhibitor is Compound A1 or a pharmaceutically acceptable salt thereof; and the PARP inhibitor is Compound F or a pharmaceutically acceptable salt thereof.
72. In embodiment 72, provided is a MAT2A inhibitor for use in treating cancer, wherein the MAT2A inhibitor is to be administered simultaneously or sequentially with a PARP inhibitor; wherein the MAT2A inhibitor is Compound A1 or a pharmaceutically acceptable salt thereof; and the PARP inhibitor is AZD5305, AXD9574, or a pharmaceutically acceptable salt thereof.
73. In embodiment 73, provided is a use of a MAT2A inhibitor in the manufacture of a medicament for treating cancer, wherein the MAT2A inhibitor is to be administered simultaneously or sequentially with a PARP inhibitor.
74. In embodiment 74, the MAT2A inhibitor of embodiment 73 is a compound of Formula (I), or a pharmaceutically acceptable salt thereof.
75. In embodiment 75, the MAT2A inhibitor of embodiment 74 is a compound of Formula (I), or a pharmaceutically acceptable salt thereof as defined in any one of embodiments 2 to 10.
76. In embodiment 76, the MAT2A inhibitor of any one of embodiments 73 to 75 is selected from the group consisting of the compounds in Table 1 , or a pharmaceutically acceptable salt thereof.
77. In embodiment 77, the PARP inhibitor of any of embodiments 73 to 76 is selected from the group consisting of the compounds in Table 2, or a pharmaceutically acceptable salt thereof.
78. In embodiment 78, provided is a use of a MAT2A inhibitor in the manufacture of a medicament for treating cancer, wherein the MAT2A inhibitor is to be administered simultaneously or sequentially with a PARP inhibitor; wherein the MAT2A inhibitor is Compound A or a pharmaceutically acceptable salt thereof; and the PARP inhibitor is Compound B or a pharmaceutically acceptable salt thereof.
79. In embodiment 79, provided is a use of a MAT2A inhibitor in the manufacture of a medicament for treating cancer, wherein the MAT2A inhibitor is to be administered simultaneously or sequentially with a PARP inhibitor; wherein the MAT2A inhibitor is Compound A or a pharmaceutically acceptable salt thereof; and the PARP inhibitor is Compound C or a pharmaceutically acceptable salt thereof.
80. In embodiment 80, provided is a use of a MAT2A inhibitor in the manufacture of a medicament for treating cancer, wherein the MAT2A inhibitor is to be administered
simultaneously or sequentially with a PARP inhibitor; wherein the MAT2A inhibitor is Compound A or a pharmaceutically acceptable salt thereof; and the PARP inhibitor is Compound D or a pharmaceutically acceptable salt thereof.
81. In embodiment 81 , provided is a use of a MAT2A inhibitor in the manufacture of a medicament for treating cancer, wherein the MAT2A inhibitor is to be administered simultaneously or sequentially with a PARP inhibitor; wherein the MAT2A inhibitor is Compound A or a pharmaceutically acceptable salt thereof; and the PARP inhibitor is Compound E or a pharmaceutically acceptable salt thereof.
82. In embodiment 82, provided is a use of a MAT2A inhibitor in the manufacture of a medicament for treating cancer, wherein the MAT2A inhibitor is to be administered simultaneously or sequentially with a PARP inhibitor; wherein the MAT2A inhibitor is Compound A or a pharmaceutically acceptable salt thereof; and the PARP inhibitor is Compound F or a pharmaceutically acceptable salt thereof.
83. In embodiment 83, provided is a use of a MAT2A inhibitor in the manufacture of a medicament for treating cancer, wherein the MAT2A inhibitor is to be administered simultaneously or sequentially with a PARP inhibitor; wherein the MAT2A inhibitor is Compound A or a pharmaceutically acceptable salt thereof; and the PARP inhibitor is AZD5305, AZD9574, or a pharmaceutically acceptable salt thereof.
84. In embodiment 84, provided is a use of a MAT2A inhibitor in the manufacture of a medicament for treating cancer, wherein the MAT2A inhibitor is to be administered simultaneously or sequentially with a PARP inhibitor; wherein the MAT2A inhibitor is Compound A1 or a pharmaceutically acceptable salt thereof; and the PARP inhibitor is Compound B or a pharmaceutically acceptable salt thereof.
85. In embodiment 85, provided is a use of a MAT2A inhibitor in the manufacture of a medicament for treating cancer, wherein the MAT2A inhibitor is to be administered simultaneously or sequentially with a PARP inhibitor; wherein the MAT2A inhibitor is Compound A1 or a pharmaceutically acceptable salt thereof; and the PARP inhibitor is Compound C or a pharmaceutically acceptable salt thereof.
86. In embodiment 86, provided is a use of a MAT2A inhibitor in the manufacture of a medicament for treating cancer, wherein the MAT2A inhibitor is to be administered simultaneously or sequentially with a PARP inhibitor; wherein the MAT2A inhibitor is
Compound A1 or a pharmaceutically acceptable salt thereof; and the PARP inhibitor is Compound D or a pharmaceutically acceptable salt thereof.
87 In embodiment 87, provided is a use of a MAT2A inhibitor in the manufacture of a medicament for treating cancer, wherein the MAT2A inhibitor is to be administered simultaneously or sequentially with a PARP inhibitor; wherein the MAT2A inhibitor is Compound A1 or a pharmaceutically acceptable salt thereof; and the PARP inhibitor is Compound E or a pharmaceutically acceptable salt thereof.
88. In embodiment 88, provided is a use of a MAT2A inhibitor in the manufacture of a medicament for treating cancer, wherein the MAT2A inhibitor is to be administered simultaneously or sequentially with a PARP inhibitor; wherein the MAT2A inhibitor is Compound A1 or a pharmaceutically acceptable salt thereof; and the PARP inhibitor is Compound F or a pharmaceutically acceptable salt thereof.
89. In embodiment 89, provided is a use of a MAT2A inhibitor in the manufacture of a medicament for treating cancer, wherein the MAT2A inhibitor is to be administered simultaneously or sequentially with a PARP inhibitor; wherein the MAT2A inhibitor is Compound A1 or a pharmaceutically acceptable salt thereof; and the PARP inhibitor is AZD5305, AZD9574, or a pharmaceutically acceptable salt thereof.
90. In embodiment 90, the use of any one of embodiments 56 to 89, wherein the cancer is selected from the group consisting of leukemia, glioma, melanoma, pancreatic, non-smali cell lung cancer, bladder cancer, astrocytoma, osteosarcoma, head and neck cancer, myxoid chondrosarcoma, ovarian cancer, endometrial cancer, breast cancer, soft tissue sarcoma, non-Hodgkin lymphoma, esophagogastric cancer, malignant peripheral nerve sheath tumor, and mesothelioma.
91. In embodiment 91 , the use of any one of embodiments 56 to 90, wherein the cancer is a solid tumor.
92. In embodiment 92, the use of any one of embodiments 56 to 91 , wherein the cancer is a solid malignant tumor.
93. In embodiment 93, the use of any one of embodiments 56 to 92, wherein the tumor has an MTAP gene deletion.
94. In embodiment 94, the use of any one of embodiments 56 to 93, wherein the MAT2A inhibitor and the PARP inhibitor are in separate dosage forms.
95. In embodiment 95, the use of any one of embodiments 56 to 93, wherein the MAT2A inhibitor and the PARP inhibitor are in the same dosage form.
96. In embodiment 96, provided is the method of any one of claims 1-24, wherein the MAT2A inhibitor and the PARP inhibitor are in same dosage forms.
In an aspect, provided herein is a pharmaceutical composition comprising a MAT2A inhibitor, or a pharmaceutically acceptable salt thereof, a PARP inhibitor, or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable carrier.
In an embodiment, a pharmaceutical composition comprising a therapeutically effective amount of a MAT2A inhibitor and a second pharmaceutical composition comprising a therapeutically effective amount of a PARP inhibitor is provided.
In another aspect, provided herein is a combination product comprising a first pharmaceutical composition comprising a therapeutically effective amount of a MAT2A inhibitor and a second pharmaceutical composition comprising a therapeutically effective amount of a PARP inhibitor.
In an embodiment, the MAT2A inhibitor is a compound of Formula (I):
or a pharmaceutically acceptable salt thereof; wherein the variables are defined supra.
In another embodiment, the MAT2A inhibitor is selected from the group consisting of a compound from Table 1 , or a pharmaceutically acceptable salt thereof.
In another embodiment, the PARP inhibitor is selected from the group consisting of the compounds in Table 2, AZD5305, AZD9574, or a pharmaceutically acceptable salt or hydrate thereof.
In another embodiment, the MAT2A inhibitor is Compound A:
Compound A or a pharmaceutically acceptable salt thereof.
In another embodiment, the MAT2A inhibitor is Compound A1 or a pharmaceutically acceptable salt thereof.
Compound B or a pharmaceutically acceptable salt thereof. In another embodiment, the PARP inhibitor is Compound C:
or a pharmaceutically acceptable salt thereof.
Compound D or a pharmaceutically acceptable salt thereof. In another embodiment, the PARP inhibitor is Compound E:
Compound E or a pharmaceutically acceptable salt thereof. In another embodiment, the PARP inhibitor is Compound F:
Compound F or a pharmaceutically acceptable salt thereof.
In another embodiment, the PARP inhibitor is AZD5305 or AZD9574 or a pharmaceutically acceptable salt thereof
In yet another aspect, provided herein is a combination product comprising a first pharmaceutical composition comprising a therapeutically effective amount of Compound A or a pharmaceutically acceptable salt thereof; and a second pharmaceutical composition comprising a therapeutically effective amount of Compound B or a pharmaceutically acceptable salt thereof.
In still another aspect, provided herein is a combination product comprising a first pharmaceutical composition comprising a therapeutically effective amount of Compound A or a pharmaceutically acceptable salt thereof; and a second pharmaceutical composition comprising a therapeutically effective amount of Compound C, or a pharmaceutically acceptable salt thereof.
In an aspect, provided herein is a combination product comprising a first pharmaceutical composition comprising a therapeutically effective amount of Compound A or a pharmaceutically acceptable salt thereof; and a second pharmaceutical composition comprising a therapeutically effective amount of Compound D or a pharmaceutically acceptable salt thereof.
In yet another aspect, provided herein is a combination product comprising a first pharmaceutical composition comprising a therapeutically effective amount of Compound A or a pharmaceutically acceptable salt thereof; and a second pharmaceutical composition comprising a therapeutically effective amount of Compound E or a pharmaceutically acceptable salt thereof.
In yet another aspect, provided herein is a combination product comprising a first pharmaceutical composition comprising a therapeutically effective amount of Compound A or a pharmaceutically acceptable salt thereof; and a second pharmaceutical composition comprising a therapeutically effective amount of Compound F or a pharmaceutically acceptable salt thereof.
In yet another aspect, provided herein is a combination product comprising a first pharmaceutical composition comprising a therapeutically effective amount of Compound A or a pharmaceutically acceptable salt thereof; and a second pharmaceutical composition
comprising a therapeutically effective amount of AZD5305, AZD9574, or a pharmaceutically acceptable salt thereof.
In another aspect, provided herein is a pharmaceutical composition comprising a therapeutically effective amount of Compound A or a pharmaceutically acceptable salt thereof; Compound B or a pharmaceutically acceptable salt thereof; and a pharmaceutically acceptable carrier.
In yet another aspect, provided herein is a pharmaceutical composition comprising a therapeutically effective amount of Compound A or a pharmaceutically acceptable salt thereof; Compound C, or a pharmaceutically acceptable salt thereof; and a pharmaceutically acceptable carrier.
In still another aspect, provided herein is a pharmaceutical composition comprising a therapeutically effective amount of Compound A or a pharmaceutically acceptable salt thereof; Compound D or a pharmaceutically acceptable salt thereof; and a pharmaceutically acceptable carrier.
In another aspect, provided herein is a pharmaceutical composition comprising a therapeutically effective amount of Compound A or a pharmaceutically acceptable salt thereof; Compound E or a pharmaceutically acceptable salt thereof; and a pharmaceutically acceptable carrier.
In another aspect, provided herein is a pharmaceutical composition comprising a therapeutically effective amount of Compound A or a pharmaceutically acceptable salt thereof; Compound F or a pharmaceutically acceptable salt thereof; and a pharmaceutically acceptable carrier.
In another aspect, provided herein is a pharmaceutical composition comprising a therapeutically effective amount of Compound A or a pharmaceutically acceptable salt thereof; AZD5305, AZD9574, or a pharmaceutically acceptable salt thereof; and a pharmaceutically acceptable carrier.
In an embodiment, the pharmaceutical composition is for use in the treatment of cancer in a patient. In an embodiment, the pharmaceutical composition is for use in the treatment of a solid tumor in a patient. In an embodiment, the pharmaceutical composition is for use in the treatment of a solid malignant tumor in a patient.
Administration / Dosac/e / Formulations
In another aspect, provided herein is a pharmaceutical composition or pharmaceutical combination comprising the compounds disclosed herein, together with a pharmaceutically acceptable carrier.
In an embodiment of the combination product, MAT2A inhibitor, or a pharmaceutically acceptable salt thereof, and PARP inhibitor, or a pharmaceutically acceptable salt thereof, are in the same formulation. In another embodiment of the combination product, MAT2A inhibitor and a PARP inhibitor are in separate formulations. In a further embodiment of this embodiment, the formulations are for simultaneous or sequential administration.
Administration of the combination includes administration of the combination in a single formulation or unit dosage form, administration of the individual agents of the combination concurrently but separately, or administration of the individual agents of the combination sequentially by any suitable route. The dosage of the individual agents of the combination may require more frequent administration of one of the agent(s) as compared to the other agent(s) in the combination. Therefore, to permit appropriate dosing, packaged pharmaceutical products may contain one or more dosage forms that contain the combination of agents, and one or more dosage forms that contain one of the combination of agents, but not the other agent(s) of the combination.
Actual dosage levels of the active ingredients in the pharmaceutical compositions may be varied so as to obtain an amount of the active ingredient that is effective to achieve the desired therapeutic response for a particular patient, composition, and mode of administration, without being toxic to the patient.
In particular, the selected dosage level will depend upon a variety of factors including the activity of the particular compound employed, the time of administration, the rate of excretion of the compound, the duration of the treatment, other drugs, compounds or materials used in combination with the compound, the age, sex, weight, condition, general health and prior medical history of the patient being treated, and like factors well, known in the medical arts.
A medical doctor, e.g., physician or veterinarian, having ordinary skill in the art may readily determine and prescribe the effective amount of the pharmaceutical composition required. For example, the physician or veterinarian could begin administration of the pharmaceutical composition to dose the disclosed compound at levels lower than that required in order to achieve the desired therapeutic effect and gradually increase the dosage until the desired effect is achieved.
In particular embodiments, it is especially advantageous to formulate the compound in dosage unit form for ease of administration and uniformity of dosage. Dosage unit form as used herein refers to physically discrete units suited as unitary dosages for the patients to be treated; each unit containing a predetermined quantity of the disclosed compound calculated to produce the desired therapeutic effect in association with the required pharmaceutical
vehicle. The dosage unit forms are dictated by and directly dependent on (a) the unique characteristics of the disclosed compound and the particular therapeutic effect to be achieved, and (b) the limitations inherent in the art of compounding/formulating such a disclosed compound for the treatment of pain, a depressive disorder, or drug addiction in a patient.
In one embodiment, the compounds provided herein are formulated using one or more pharmaceutically acceptable excipients or carriers. In one embodiment, the pharmaceutical compositions provided herein comprise a therapeutically effective amount of a disclosed compound and a pharmaceutically acceptable carrier.
The optimum ratios, individual and combined dosages, and concentrations of the drug compounds that yield efficacy without toxicity are based on the kinetics of the active ingredients’ availability to target sites.
Routes of administration of any of the compositions discussed herein include oral, nasal, rectal, intravaginal, parenteral, buccal, sublingual or topical. The compounds may be formulated for administration by any suitable route, such as for oral or parenteral, for example, transdermal, transmucosal (e.g., sublingual, lingual, (trans)buccal, (trans)urethral, vaginal (e.g., trans- and perivaginally), (intra)nasal and (trans)rectal), intravesical, intrapulmonary, intraduodenal, intragastrical, intrathecal, subcutaneous, intramuscular, intradermal, intra-arterial, intravenous, intrabronchial, inhalation, and topical administration. In one embodiment, the preferred route of administration is oral.
Suitable compositions and dosage forms include, for example, tablets, capsules, caplets, pills, gel caps, troches, dispersions, suspensions, solutions, syrups, granules, beads, transdermal patches, gels, powders, pellets, magmas, lozenges, creams, pastes, plasters, lotions, discs, suppositories, liquid sprays for nasal or oral administration, dry powder or aerosolized formulations for inhalation, compositions and formulations for intravesical administration and the like. It should be understood that the formulations and compositions are not limited to the particular formulations and compositions that are described herein.
For oral application, particularly suitable are tablets, dragees, liquids, drops, suppositories, or capsules, caplets and gel caps. The compositions intended for oral use may be prepared according to any method known in the art and such compositions may contain one or more agents selected from the group consisting of inert, non-toxic pharmaceutically excipients that are suitable for the manufacture of tablets. Such excipients include, for example an inert diluent such as lactose; granulating and disintegrating agents such as cornstarch; binding agents such as starch; and lubricating agents such as magnesium stearate. The tablets may be uncoated or they may be coated by known
techniques for elegance or to delay the release of the active ingredients. Formulations for oral use may also be presented as hard gelatin capsules wherein the active ingredient is mixed with an inert diluent.
For parenteral administration, the disclosed compounds may be formulated for injection or infusion, for example, intravenous, intramuscular or subcutaneous injection or infusion, or for administration in a bolus dose or continuous infusion. Suspensions, solutions or emulsions in an oily or aqueous vehicle, optionally containing other formulatory agents such as suspending, stabilizing or dispersing agents may be used.
In an embodiment, the total daily dose of niraparib is 100 mg, 200 mg or 300 mg taken once daily. In a particular embodiment, the total daily dose of niraparib is 200 mg or 300 mg taken once daily. The dose may be provided as 100 mg capsules (in particular, hard capsules) or 100 mg tablets. In an embodiment, each capsule or tablet contains niraparib tosylate monohydrate equivalent to 100 mg niraparib.
In one embodiment, in particular when the PARP inhibitor is niraparib, it may be administered orally by capsule or tablet. In one embodiment, niraparib is administered by capsule. In another embodiment, niraparib is administered by tablet.
In an embodiment, the dose of olaparib is 300 mg taken twice daily, equivalent to a total daily dose of 600 mg. The dose may be provided as capsules, in particular hard capsules containing 50 mg of olaparib. Therefore, to achieve a dose of 300 mg it is necessary for a patient to take six capsules. The dose may also be provided as 100 mg or 150 mg tablets, where the tablets may be film-coated.
In an embodiment, the dose of rucaparib is 600 mg taken twice daily, equivalent to a total daily dose of rucaparib of 1200 mg. The dose may be provided as tablets available as 200 mg, 250 mg and 300 mg tablets, which may be film-coated.
In an embodiment, the dose of talazoparib is 1 mg taken once daily. The dose may be provided as capsules containing talazoparib tosylate equivalent to 0.25 mg or 1 mg talazoparib.
In an embodiment, the PARP inhibitor is administered daily.
Kits
In an aspect, the present disclosure provides a kit for treating cancer comprising a MAT2A inhibitor, or a pharmaceutically acceptable salt thereof, and a PARP inhibitor or a pharmaceutically acceptable salt thereof.
In certain embodiments, the kit comprises a pharmaceutical product comprising a pharmaceutical composition comprising MAT2A inhibitor, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier or diluent; and a pharmaceutical
composition comprising Poly (ADP-ribose)Polymerase (PARP) inhibitor or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier or diluent.
In some embodiments, the kit comprises a pharmaceutical composition comprising MAT2A inhibitor, or a pharmaceutically acceptable salt thereof; Poly (ADP-ribose) Polymerase (PARP) inhibitor, or a pharmaceutically acceptable salt thereof; and a pharmaceutically acceptable carrier or diluent.
In additional embodiments, pharmaceutical kits are provided. The kit includes a sealed container approved for the storage of pharmaceutical compositions, the container containing one of the above-described pharmaceutical compositions. In some embodiments, the sealed container minimizes the contact of air with the ingredients, e.g. an airless bottle. In other embodiments, the sealed container is a sealed tube. An instruction for the use of the composition and the information about the composition are to be included in the kit.
In a particular embodiment, the compounds of the combination can be dosed on the same schedule, whether by administering a single formulation or unit dosage form containing all of the compounds of the combination, or by administering separate formulations or unit dosage forms of the compounds of the combination. However, some of the compounds used in the combination may be administered more frequently than once per day, or with different frequencies that other compounds in the combination. Therefore, in one embodiment, the kit contains a formulation or unit dosage form containing all of the compounds in the combination of compounds, and an additional formulation or unit dosage form that includes one of the compounds in the combination of agents, with no additional active compound, in a container, with instructions for administering the dosage forms on a fixed schedule.
The kits provided herein include prescribing information, for example, to a patient or health care provider, or as a label in a packaged pharmaceutical formulation. Prescribing information may include for example efficacy, dosage and administration, contraindication and adverse reaction information pertaining to the pharmaceutical formulation.
In all of the foregoing the combination of compounds of the invention can be administered alone, as mixtures, or with additional active agents.
A kit provided herein can be designed for conditions necessary to properly maintain the components housed therein (e.g., refrigeration or freezing). A kit can contain a label or packaging insert including identifying information for the components therein and instructions for their use (e.g., dosing parameters, clinical pharmacology of the active ingredient(s), including mechanism(s) of action, pharmacokinetics and pharmacodynamics, adverse effects, contraindications, etc.).
Each component of the kit can be enclosed within an individual container, and all of the various containers can be within a single package. Labels or inserts can include manufacturer information such as lot numbers and expiration dates. The label or packaging insert can be, e.g., integrated into the physical structure housing the components, contained separately within the physical structure, or affixed to a component of the kit (e.g., an ampule, syringe or vial).
Those skilled in the art will recognize, or be able to ascertain using no more than routine experimentation, numerous equivalents to the specific procedures, embodiments, claims, and examples described herein. Such equivalents were considered to be within the scope of this disclosure and covered by the claims appended hereto.
It is to be understood that wherever values and ranges are provided herein, all values and ranges encompassed by these values and ranges, are meant to be encompassed within the scope of the present disclosure. Moreover, all values that fall within these ranges, as well as the upper or lower limits of a range of values, are also contemplated by the present application.
The following examples further illustrate aspects of the present disclosure. However, they are in no way a limitation of the teachings of the present disclosure as set forth.
EXAMPLES
The compounds and methods disclosed herein are further illustrated by the following examples, which should not be construed as further limiting. The practice of the present disclosure will employ, unless otherwise indicated, conventional techniques of organic synthesis, cell biology, cell culture, and molecular biology, which are within the skill of the art.
Example 1. Proliferation screen identifies combination benefit with MAT2A and PARP inhibition
A 10-day proliferation screen was performed in 15 pancreatic, non-small cell lung, and bladder cancer cell lines: 9 MTAP null, 1 MTAP CRISPR knock-out, and 5 MTAP wildtype. Optimal cell seeding for all cell lines was determined by assessing the growth over a range of seeding densities in a 384-well format to identify conditions that permitted proliferation for 10 days. Cells were then plated at the optimal seeding density in the presence of 20-150 nM of Compound A or DMSO vehicle control. Cells were incubated at 37°C with 5% CO2 for 4 days to allow for target engagement of the pre-treatment compound. Maintaining the pre-treatment condition, cells were also treated with an 11-point, three-fold titration series of compounds from a chemically diverse library. The combination compound
concentrations ranged from 0.2 nM to 14,679 nM. A plate of cells was harvested at the time of combination compound addition to quantify the number of cells at the start of the combination (To). For cell quantification, the harvested cells were lysed with CellTiter-Glo (CTG) (Promega) reagent according to the manufacturer’s protocol and the chemiluminescent signal was detected on a Synergy Neo plate reader (ThermoFisher, serial # 140715A). CTG estimates cell number through detection of cellular ATP levels. Cells were incubated with the drug combinations at 37°C with 5% CO2 for an additional 6 days for a total of a 10-day assay including the pre-treatment. Cells were then lysed with CTG and the chemiluminescent signal was measured. CTG values obtained after the 10-day treatment were background subtracted, expressed as a percent of the To value, and plotted against compound concentration. Data were fit with a four-parameter equation to generate concentration response curves. Growth IC50 values and maximal growth inhibition were compared between the DMSO and the Compound A pre-treated cells for each combination titration. Combination hit calling was based on the observation of >2-fold shift in growth IC50 and/or greater than 20% decrease in growth inhibition.
Of the compounds tested, the PARP inhibitor Talazoparib was identified as a combination hit in the NCI-H838, HuP-T4, RT112/84, and UMUC5 cell lines where 5.2-, 7.5-, 2.5-, and 2.9-fold shifts in growth IC50 were observed, respectively (Table 3). Combination benefit was not observed in any of the MTAP wild type cell lines tested. In addition to Talazoparib, the PARP inhibitor Olaparib was identified as a combination hit in the UMUC5 cell line where a 3-fold shift in growth IC50 was observed.
Example 2: MAT2A inhibitor and PARP inhibitor Combinations
A 10-day proliferation assay was performed in a panel of 8 pancreatic, non-small cell lung, and bladder cancer cell lines: 4 MTAP null, 1 MTAP CRISPR knock-out, and 3 MTAP wild type. Combinations included double titrations of MAT2A inhibitor Compound A with three different PARP inhibitor compounds including Talazoparib, Niraparib, and Olaparib.
Optimal cell seeding for all cell lines was determined by assessing the growth over a range of seeding densities in a 384-well format to identify conditions that permitted proliferation for 10 days. Cells were then plated at the optimal seeding density and treated with a double titration of a 16-point two-fold dilution series of Compound A and a 16-point two-fold dilution series of the PARP inhibitor compounds. This double titration was compared to 16-point two-fold dilution series of each single agent alone or to 0.15% DMSO. An untreated plate of cells was harvested at the time of compound addition (To) to quantify the starting number of cells using CTG as described in example 1. Concentrations tested for Compound A and the PARP inhibitors alone or in combination ranged from 0.6 nM to 19,250 nM. The double matrix design allowed for an assessment across the full titration of each compound in the combination. Plates were incubated for 10 days at 37 °C in 5% CO2. Cells were then lysed and measured with CTG.
Combination synergy was assessed using the Excess over Bliss model for the combinations of compound doses across the full dose range tested. The observed growth inhibition was compared to the predicted inhibition based on the additive activity of each single agent. Predicted inhibition was calculated using (Ea+Eb) - (Ea*Eb) where E equals the effect (inhibition) of each single agent (a and b). A difference between the observed inhibition percentage and the predicted inhibition percentage greater than 10% was considered synergistic. An Excess over Bliss score was only calculated for combinations eliciting >20% growth inhibition.
Synergistic growth inhibition was observed with Compound A in combination with all three PARP inhibitors across numerous combination concentrations as assessed by Excess over Bliss in /WTAP-deficient cell lines. This was most readily observed in the NCI-H838 cell line where a focused area of synergy was observed across several concentrations for all three PARP inhibitors (Table 4A-4C and Figures 1A-1C). Combination synergy was observed in three additional /WTAP-deficient cell lines and one /WTAP-knock-out cell line for
all three PARP inhibitors albeit with fewer doses of the inhibitors than in the NCI-H838 cell line (Tables 5A-5C, 6A-6C, 7A-7C, and 8A-8C; Figures 2A-2C, 3A-3C, 4A-4C, and 5A-5C). Synergy is measured at all tested concentrations of Compound A across all concentrations of Talazoparib (A), Niraparib (B), or Olaparib (C) using excess over Bliss analyses. Scores between 1 and 10 (highlighted light gray) were considered additive, scores >10 (highlighted black) were considered synergistic. Excess over Bliss scores were only calculated for combinations exhibiting greater than 20% growth inhibition. Beyond the combination doses where synergy was observed, additive growth inhibition was observed at additional concentrations in all /WTAP-deficient cell lines tested. The MTAP wild type cell lines also exhibited enhanced growth inhibition at some of the combination dose combinations (Tables 9A-9C, 10A-10C, and 11A-11C; Figures 6A-6C, 7A-7C, and 8A-8C), but to a lesser extent than in the /WTAP-deficient cell lines. Increased growth inhibition was also observed for the PARP inhibitor combinations with Compound A in the /WTAP-deficient cell lines over that observed in the wild type cell lines.
Tables 4A-4C: Excess over Bliss Synergy of Compound A and PART inhibitor combinations in NCI-H838 cell line.
Tables 5A-5C: Excess over Bliss Synergy of Compound A and PART inhibitor combinations in NCI-H2228 cell line.
Tables 6A-6C: Excess over Bliss Synergy of Compound A and PART inhibitor combinations in RT112/84 cell line.
Tables 7A-7C: Excess over Bliss Synergy of Compound A and PART inhibitor combinations in UMUC5 cell line.
Tables 8A-8C: Excess over Bliss Synergy of Compound A and PART inhibitor combinations in Pane 03.27 MTAP CRISPR knock-out cell line
(Clone 31).
Tables 9A-9C: Excess over Bliss Synergy of Compound A and PART inhibitor combinations in Pane 03.27 MTAP wild type cell line.
Tables 10A-10C: Excess over Bliss Synergy of Compound A and PART inhibitor combinations in NCI-H520 MTAP wild type cell line.
Tables 11A-11C: Excess over Bliss Synergy of Compound A and PARP inhibitor combinations in TCCSUP MTAP wild type cell line.
Particular embodiments of this invention are described herein, including the best mode known to the inventors for carrying out the invention. Upon reading the foregoing, description, variations of the disclosed embodiments may become apparent to individuals working in the art, and it is expected that those skilled artisans may employ such variations as appropriate. Accordingly, it is intended that the invention be practiced otherwise than as specifically described herein, and that the invention includes all modifications and equivalents of the subject matter recited in the claims appended hereto as permitted by applicable law. Moreover, any combination of the above-described elements in all possible variations thereof is encompassed by the invention unless otherwise indicated herein or otherwise clearly contradicted by context.
All patent applications, patents, and printed publications cited herein are incorporated herein by reference in the entireties, except for any definitions, subject matter disclaimers or disavowals, and except to the extent that the incorporated material is inconsistent with the express disclosure herein, in which case the language in this disclosure controls. Other embodiments are within the following claims.
Claims
1 . A method of treating cancer in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a MAT2A inhibitor and administering to the subject a therapeutically effective amount of a PARP inhibitor, wherein the MAT2A inhibitor is a compound of Formula I:
or a pharmaceutically acceptable salt thereof; wherein
X is N or CH;
R3 is C1-6 haloalkyl, halo, or C3-6 cycloalkyl;
R2 is -NR4R5;
R4 is hydrogen or C1-6 alkyl;
R5 is hydrogen, C1-6 alkyl or C3-6 cycloalkyl; and
R1 is phenyl, wherein phenyl is substituted with 0-2 halo.
2. The method of claim 1 , wherein X is N.
3. The method of claim 1 , wherein X is CH.
4. The method of any one of claims 1 to 3, wherein R4 is hydrogen and R5 is hydrogen or C1-3 alkyl.
5. The method of any one of claims 1 to 4, wherein R5 is hydrogen or methyl.
6. The method of any one of claims 1 to 5, wherein R1 is phenyl substituted with chloro.
7. The method of any one of claims 1 to 6, wherein R3 is C1-3 haloalkyl or halo.
8. The method of any one of claims 1 to 7, wherein R3 is trifl uromethyl or chloro.
9. The method of any one of claims 1 to 6, wherein R3 is cyclopropyl.
10. The method of any one of claims 1 to 9, wherein the MAT2A inhibitor is selected from the group consisting of a compound from Table 1 , or a pharmaceutically acceptable salt thereof.
Compound A or a pharmaceutically acceptable salt thereof.
12. The method of any one of claims 1 to 10, wherein the MAT2A inhibitor is Compound
Compound A1 or a pharmaceutically acceptable salt thereof.
13. The method of any one of claims 1 to 12, wherein the PARP inhibitor is selected from the group consisting of
Compound B or a pharmaceutically acceptable salt thereof.
15. The method of any one of claims 1 to 13, wherein the PARP inhibitor is Compound
or a pharmaceutically acceptable salt thereof.
Compound D or a pharmaceutically acceptable salt thereof.
Compound E or a pharmaceutically acceptable salt thereof.
Compound F or a pharmaceutically acceptable salt thereof.
19. A method of treating cancer in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of Compound A
Compound A or a pharmaceutically acceptable salt thereof, and administering to the subject a therapeutically effective amount of a PARP inhibitor, or a pharmaceutically acceptable salt thereof.
Compound B or a pharmaceutically acceptable salt thereof.
21. The method of claim 19, wherein the PARP inhibitor is Compound C:
Compound C or a pharmaceutically acceptable salt thereof. The method of claim 19, wherein the PARP inhibitor is Compound D:
Compound D or a pharmaceutically acceptable salt thereof. The method of claim 19, wherein the PARP inhibitor is Compound E:
Compound E or a pharmaceutically acceptable salt thereof. The method of claim 19, wherein the PARP inhibitor is Compound F:
Compound F or a pharmaceutically acceptable salt thereof. The method of claim 19, wherine the PARP inhibitor is:
26. The method of any one of claims 1 to 25, wherein the cancer is selected from the group consisting of leukemia, glioma, melanoma, pancreatic, non-small cell lung cancer, bladder cancer, astrocytoma, osteosarcoma, head and neck cancer, myxoid chondrosarcoma, ovarian cancer, endometrial cancer, breast cancer, soft tissue sarcoma, non-Hodgkin lymphoma, esophagogastric cancer, malignant peripheral nerve sheath tumor, and mesothelioma.
27. The method of any of claims 1 to 26, wherein the cancer is a solid tumor.
28. The method of any of claims 1 to 27, wherein the cancer is a solid malignant tumor.
29. The method of claim 27 or 28, wherein the tumor has an MTAP gene deletion.
30. The method of any one of claims 1 to 29, wherein the MAT2A inhibitor and the PARP inhibitor are in separate dosage forms.
31. The method of any one of claims 1 to 29, wherein the MAT2A inhibitor and the PARP inhibitor are in the same dosage form.
32. A combination comprising a MAT2A inhibitor, or a pharmaceutically acceptable salt thereof, and a PARP inhibitor, or a pharmaceutically acceptable salt thereof.
33. The combination of claim 32, wherein the MAT2A inhibitor is a compound of Formula I and the PARP inhibitor is selected from the group consisting of a Compound B, Compound C, Compound D, Compound E, Compound F, AZD5305, and AZD9574, or a pharmaceutically acceptable salt thereof.
34. The combination of claim 32 or 33, wherein the MAT2A inhibitor is Compound A or
Compound A1 , and the PARP inhibitor is is selected from the group consisting of a Compound B, Compound C, Compound D, Compound E, and Compound F or a pharmaceutically acceptable salt thereof.
35. A MAT2A inhibitor for use in treating cancer, wherein the MAT2A inhibitor is to be administered simultaneously or sequentially with a PARP inhibitor, and wherein the MAT2A inhibitor is a compound of Formula I:
or a pharmaceutically acceptable salt thereof; wherein
X is N or CH;
R3 is C1-6 haloalkyl, halo, or C3-6 cycloalkyl;
R2 is -NR4R5;
R4 is hydrogen or C1-6 alkyl;
R5 is hydrogen, C1-6 alkyl or C3-6 cycloalkyl; and
R1 is phenyl, wherein phenyl is substituted with 0-2 halo.
36. The use of claim 35, wherein the PARP inhibitor is selected from the group consisting of Compound B, Compound C, Compound D, Compound E, Compound F, AZD5305, and AZD9574, or a pharmaceutically acceptable salt thereof.
37. The use of claim 36, wherein the MAT2A inhibitor is Compound A or Compound A1.
38. Use of a MAT2A inhibitor in the manufacture of a medicament for treating cancer, wherein the MAT2A inhibitor is to be adminisered simultaneously or sequentially with a PARP inhibitor, and wherein the MAT2A inhibitor is a compound of Formula I:
or a pharmaceutically acceptable salt thereof; wherein
X is N or CH;
R3 is C1-6 haloalkyl, halo, or C3-6 cycloalkyl;
R2 is -NR4R5;
R4 is hydrogen or C1-6 alkyl; R5 is hydrogen, C1-6 alkyl or C3-6 cycloalkyl; and
R1 is phenyl, wherein phenyl is substituted with 0-2 halo.
39. The use of claim 38, wherein the PARP inhibitor is selected from the group consisting of Compound B, Compound C, Compound D, Compound E, Compound F, AZD5303, and AZD9574 or a pharmaceutically acceptable salt thereof. 40. The use of claim 39, wherein the MAT2A inhibitor is Compound A.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202263331619P | 2022-04-15 | 2022-04-15 | |
US63/331,619 | 2022-04-15 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2023201338A1 true WO2023201338A1 (en) | 2023-10-19 |
Family
ID=86378621
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2023/065780 WO2023201338A1 (en) | 2022-04-15 | 2023-04-14 | Combination therapy comprising a mat2a inhibitor and a parp inhibitor |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2023201338A1 (en) |
Citations (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6495541B1 (en) | 1999-01-11 | 2002-12-17 | Agouron Pharmaceuticals, Inc. | Tricyclic inhibitors of poly(ADP-ribose) polymerases |
US7151102B2 (en) | 2000-10-30 | 2006-12-19 | Kudos Pharmaceuticals Limited | Phthalazinone derivatives |
US7351701B2 (en) | 2003-07-25 | 2008-04-01 | Cancer Research Technology Limited | Therapeutic compounds |
US7449464B2 (en) | 2003-03-12 | 2008-11-11 | Kudos Pharmaceuticals Limited | Phthalazinone derivatives |
US7981889B2 (en) | 2003-03-12 | 2011-07-19 | Kudos Pharmaceuticals Limited | Phthalazinone derivatives |
US8012976B2 (en) | 2008-08-06 | 2011-09-06 | Biomarin Pharmaceutical Inc. | Dihydropyridophthalazinone inhibitors of poly(ADP-ribose)polymerase (PARP) |
US8071579B2 (en) | 2003-12-01 | 2011-12-06 | The Institute Of Cancer Research: Royal Cancer Hospital | DNA damage repair inhibitors for the treatment of cancer |
US8071623B2 (en) | 2007-01-10 | 2011-12-06 | Instituto Di Ricerche Di Biologia Molecolare P. Angeletti Spa | Amide substituted indazoles as poly(ADP-ribose)polymerase(PARP) inhibitors |
US8426185B2 (en) | 2008-01-31 | 2013-04-23 | Battelle Energy Alliance, Llc | Thermophilic and thermoacidophilic biopolymer-degrading genes and enzymes from Alicyclobacillus acidocaldarius and related organisms, methods |
US8735392B2 (en) | 2010-10-21 | 2014-05-27 | Biomarin Pharmaceutical Inc. | Crystalline (8S,9R)-5-fluoro-8-(4-fluorophenyl)-9-(1-methyl-1H-1,2,4-triazol-5-yl)-8,9-dihydro-2H-pyrido[4,3,2-de]phthalazin-3(7H)-one tosylate salt |
US8859562B2 (en) | 2003-07-25 | 2014-10-14 | The University Of Sheffield | Use of RNAI inhibiting PARP activity for the manufacture of a medicament for the treatment of cancer |
WO2020123395A1 (en) | 2018-12-10 | 2020-06-18 | Ideaya Biosciences, Inc. | 2-oxoquinazoline derivatives as methionine adenosyltransferase 2a inhibitors |
WO2021013735A1 (en) | 2019-07-19 | 2021-01-28 | Astrazeneca Ab | Parp1 inhibitors |
US11091459B2 (en) | 2017-03-27 | 2021-08-17 | Tesaro, Inc. | Niraparib compositions |
WO2021260092A1 (en) | 2020-06-25 | 2021-12-30 | Astrazeneca Ab | Quinoxaline derivatives as anti-cancer drugs |
WO2022036067A1 (en) * | 2020-08-12 | 2022-02-17 | Servier Pharmaceuticals, Llc | Combination therapies for use in treating cancer |
-
2023
- 2023-04-14 WO PCT/US2023/065780 patent/WO2023201338A1/en unknown
Patent Citations (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6495541B1 (en) | 1999-01-11 | 2002-12-17 | Agouron Pharmaceuticals, Inc. | Tricyclic inhibitors of poly(ADP-ribose) polymerases |
US7151102B2 (en) | 2000-10-30 | 2006-12-19 | Kudos Pharmaceuticals Limited | Phthalazinone derivatives |
US7449464B2 (en) | 2003-03-12 | 2008-11-11 | Kudos Pharmaceuticals Limited | Phthalazinone derivatives |
US7981889B2 (en) | 2003-03-12 | 2011-07-19 | Kudos Pharmaceuticals Limited | Phthalazinone derivatives |
US7351701B2 (en) | 2003-07-25 | 2008-04-01 | Cancer Research Technology Limited | Therapeutic compounds |
US7531530B2 (en) | 2003-07-25 | 2009-05-12 | Cancer Research Technology Limited | Therapeutic compounds |
US8859562B2 (en) | 2003-07-25 | 2014-10-14 | The University Of Sheffield | Use of RNAI inhibiting PARP activity for the manufacture of a medicament for the treatment of cancer |
US8143241B2 (en) | 2003-12-01 | 2012-03-27 | Kudos Pharmaceuticals Limited | DNA damage repair inhibitors for treatment of cancer |
US8071579B2 (en) | 2003-12-01 | 2011-12-06 | The Institute Of Cancer Research: Royal Cancer Hospital | DNA damage repair inhibitors for the treatment of cancer |
US8071623B2 (en) | 2007-01-10 | 2011-12-06 | Instituto Di Ricerche Di Biologia Molecolare P. Angeletti Spa | Amide substituted indazoles as poly(ADP-ribose)polymerase(PARP) inhibitors |
US8426185B2 (en) | 2008-01-31 | 2013-04-23 | Battelle Energy Alliance, Llc | Thermophilic and thermoacidophilic biopolymer-degrading genes and enzymes from Alicyclobacillus acidocaldarius and related organisms, methods |
US8420650B2 (en) | 2008-08-06 | 2013-04-16 | Biomarin Pharmaceutical Inc. | Dihydropyridophthalazinone inhibitors of poly(ADP-ribose)polymerase (PARP) |
US8012976B2 (en) | 2008-08-06 | 2011-09-06 | Biomarin Pharmaceutical Inc. | Dihydropyridophthalazinone inhibitors of poly(ADP-ribose)polymerase (PARP) |
US8735392B2 (en) | 2010-10-21 | 2014-05-27 | Biomarin Pharmaceutical Inc. | Crystalline (8S,9R)-5-fluoro-8-(4-fluorophenyl)-9-(1-methyl-1H-1,2,4-triazol-5-yl)-8,9-dihydro-2H-pyrido[4,3,2-de]phthalazin-3(7H)-one tosylate salt |
US11091459B2 (en) | 2017-03-27 | 2021-08-17 | Tesaro, Inc. | Niraparib compositions |
WO2020123395A1 (en) | 2018-12-10 | 2020-06-18 | Ideaya Biosciences, Inc. | 2-oxoquinazoline derivatives as methionine adenosyltransferase 2a inhibitors |
WO2021013735A1 (en) | 2019-07-19 | 2021-01-28 | Astrazeneca Ab | Parp1 inhibitors |
WO2021260092A1 (en) | 2020-06-25 | 2021-12-30 | Astrazeneca Ab | Quinoxaline derivatives as anti-cancer drugs |
WO2022036067A1 (en) * | 2020-08-12 | 2022-02-17 | Servier Pharmaceuticals, Llc | Combination therapies for use in treating cancer |
Non-Patent Citations (7)
Title |
---|
"Remington's Pharmaceutical Sciences", 1985, MACK PUBLISHING COMPANY, pages: 1418 |
CHOU, T. C.TALALAY, P., ADV. ENZYME REGUL., vol. 22, 1984, pages 27 - 55 |
HOLFORD, N. H. G.SCHEINER, L. B., CLIN. PHARMACOKINET., vol. 6, 1981, pages 429 - 453 |
JOURNAL OF PHARMACEUTICAL SCIENCE, vol. 66, no. 2, 1977 |
LOEWE, S.MUISCHNEK, H., ARCH. EXP. PATHOL PHARMACOL., vol. 114, 1926, pages 313 - 326 |
MARJON, CELL REPORTS, vol. 15, no. 3, 2016, pages 574 - 587 |
MCDONALD, CELL, vol. 170, 2017, pages 577 - 592 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2020002146A (en) | Ibrutinib combination therapy | |
US10799508B2 (en) | Methods for treating cancer using HSP90 inhibitors | |
EP3148532B1 (en) | Pharmaceutical combination comprising a cdk inhibitor and a thioredoxin reductase inhibitor for the treatment of cancer | |
EP3038652B1 (en) | Combination of an alk inhibitor and a cdk inhibitor for the treatment of cell proliferative diseases | |
JP6716585B2 (en) | Apilimod for use in the treatment of colorectal cancer | |
CA2914310A1 (en) | Pharmaceutical combinations | |
AU2013202507B2 (en) | Inhibition of drug resistant cancer cells | |
BR112020022148A2 (en) | CANCER TREATMENT METHODS | |
WO2015142867A1 (en) | Synergistic enhancement of 5-fluorouracil cytotoxicity by deoxyuridine analogs in cancer cells | |
JP2023080357A (en) | Methods for treating lymphoid malignancies | |
CN110996960A (en) | Therapeutic combinations of third generation EGFR tyrosine kinase inhibitors and RAF inhibitors | |
US20060041013A1 (en) | Alanosine formulations and methods of use | |
US10328066B2 (en) | Pharmaceutical combination comprising the PI3K inhibitor alpelisib and the CDK4/6 inhibitor ribociclib, and the use thereof in the treatment/prevention of cancer | |
US11938143B2 (en) | Compositions comprising 2′-deoxycytidine analogs and use thereof for the treatment of sickle cell disease, thalassemia, and cancers | |
WO2023201338A1 (en) | Combination therapy comprising a mat2a inhibitor and a parp inhibitor | |
US20230019186A1 (en) | Dosing regimens for use in treating myelofibrosis and mpn-related disorders with navitoclax | |
US20180318275A1 (en) | Combination therapy using pi3k inhibitor and mdm2 inhibitor | |
TW202045155A (en) | Combination therapies for use in treating cancer | |
WO2023177894A1 (en) | Combination therapy comprising a mat2a inhibitor and an antimetabolite agent | |
KR20160101027A (en) | Pharmaceutical combinations | |
US10238679B2 (en) | Antitumor activity of multi-kinase inhibitors in colorectal cancer | |
WO2022221586A1 (en) | Combination therapy comprising a pkc inhibitor and a mek inhibitor | |
WO2023107894A1 (en) | Combination therapy comprising a pkc inhibitor and a c-met inhibitor | |
US20230277524A1 (en) | Combination therapy for treatment of viral infections | |
WO2023049731A2 (en) | Methods of treating myelodysplastic syndromes with decitabine and cedazuridine |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 23723784 Country of ref document: EP Kind code of ref document: A1 |